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The contamination of agricultural commodities with Fusarium mycotoxins is a global issue in food 
safety, with fumonisin B1 (FB1) being the most prevalent contaminant. FB1 is not only phytotoxic, but 
it induces a wide range of toxic effects in animals and humans and is associated with carcinogenesis in 
animals and humans. Intense research has uncovered several mechanisms by which FB1 induces 
toxicity. Recent evidence suggests that epigenetic mechanisms may also contribute to the toxic effects 
of FB1. Epigenetic modifications including DNA methylation, histone methylation, N-6-
methyladenosine (m6A) RNA methylation, and non-coding RNAs such as microRNAs (miRNA) and 
long non-coding RNA (lncRNA) are central mediators of cellular function and cellular stress responses 
and disruption may be pertinent in FB1-induced toxicities. This study aimed to determine the epigenetic 
mechanisms of FB1-induced hepatotoxicity by specifically investigating changes in DNA methylation, 
histone 3 lysine 4 trimethylation (H3K4me3), m6A RNA modification, and noncoding RNA in human 
hepatoma (HepG2) cells. The effect of these FB1-induced epigenetic modifications on stress responses 
was further investigated.  
FB1 impairs DNA repair processes via epigenetic mechanism. FB1 reduced the expression of histone 
demethylase, KDM5B, which subsequently increased the total H3K4me3 and the enrichment of 
H3K4me3 at the PTEN promoter region; this led to an increase in PTEN transcript levels. However, 
miR-30c inhibited PTEN translation. Thus, PI3K/AKT signaling was activated, inhibiting CHK1 
activity via phosphorylation of its serine 280 residue. This hampered the repair of oxidative DNA 
damage that occurred as a result of FB1 exposure.   
Exposure to FB1 not only induced oxidative DNA damage but elevated levels of intracellular ROS 
triggering cell injury. In response to oxidative injury, cells induce Keap1/Nrf2 signaling which is 
regulated by epigenetic mechanisms. FB1 elevated global m6A RNA levels which were accompanied 
by an increase in m6A “writers”: METTL3 and METTL14, and “readers”: YTHDF1, YTHDF2, YTHDF3 
and YTHDC2 and a decrease in m6A “erasers”: ALKBH5 and FTO. Hypermethylation occurred at the 
Keap1 promoter, resulting in a reduction of Keap1 transcripts. The hypomethylation of Nrf2 promoters 
and decrease in miR-27b expression led to an increase in Nrf2 mRNA expression. m6A-Keap1 and 
m6A-Nrf2 levels were both elevated; however, protein expression of Keap1 was reduced whereas Nrf2 
was increased. Collectively, these epigenetic modifications (promoter methylation, miRNA-27b and 
m6A RNA) activated antioxidant signaling by reducing Keap1 expression and increasing Nrf2 
expression.  
If cells are unable to cope with stress, p53-mediated apoptosis is activated. Crosstalk between the 
lncRNA, HOXA11-AS, miR-124 and DNA methylation can influence p53 expression and apoptosis. 
FB1 upregulated HOXA11-AS leading to the subsequent decrease in miR-124 and increase in SP1 and 




methylation and hypermethylation of p53 promoters, thereby reducing p53 expression and caspase 
activity. Taken together, the data suggests that FB1 inhibits p53-dependent apoptosis via HOXA11-
AS/miR-124/DNMT axis. 
Collectively, this study provides novel insights into additional mechanisms of FB1-induced toxicities 





CHAPTER 1  2 
INTRODUCTION 3 
One of the United Nations sustainable development goals is achieving food safety and security in 4 
developing countries. However, almost 30% of global agricultural crops are contaminated by toxic 5 
fungal secondary metabolites referred to as mycotoxins (Nesic, Ivanovic et al. 2014, Gbashi, Madala et 6 
al. 2018). Annually, over one billion tons of crops are lost due to mycotoxin contamination and it 7 
reduces the quality of an already limited food supply (Gbashi, Madala et al. 2018). Contamination 8 
frequently occurs in dietary staples that rural and developing communities heavily rely on. These staples 9 
include cereal grains such as maize, rice, wheat, oats and sorghum as well as ground nuts, fruit, and 10 
their byproducts (Fernández-Cruz, Mansilla et al. 2010, Tolosa, Font et al. 2013, Ferrigo, Raiola et al. 11 
2016, Lee and Ryu 2017). Moreover, the eminent reality of climate change further exasperates the 12 
situation as fungal growth and mycotoxin production thrive during weather extremes and plant stress 13 
(Magan, Medina et al. 2011). The ingestion of mycotoxin contaminated crops has enormous public 14 
health significance because these toxins are usually nephrotoxic, hepatotoxic, immunotoxic, teratogenic 15 
and mutagenic (Zain 2011). Over 300 chemically distinct mycotoxins with diverse biological activities 16 
have been identified (Nesic, Ivanovic et al. 2014). Among them, fumonisin B1 (FB1) is one of the most 17 
important in terms of prevalence, contamination levels and toxic effects (Rheeder, Marasas et al. 2002). 18 
FB1 is a diester that arises from the condensation of two molecules of propane-1,2,3-tricarboxylic acid 19 
and 2-amino-12,16-dimethylicosane-3,5,10,14,15-pentol (Alexander, Proctor et al. 2009). Fusarium 20 
verticillioides and Fusarium proliferatum are major FB1 producers with contamination occurring 21 
globally (Rheeder, Marasas et al. 2002).  FB1 is found in abundance in maize, wheat, rice, oats, barley, 22 
and millets and has been reported to contaminate numerous food products including vine fruit, 23 
asparagus, cornflakes, beers, beef, egg, and milk and canned foods (Gazzotti, Lugoboni et al. 2009, Lee 24 
and Ryu 2017, Farhadi, Nowrozi et al. 2019). FB1 contamination occurs at various points in the food 25 
chain including storage and is resistant to many food processing techniques making it difficult to control 26 
contamination of foods and feeds as well as human and animal exposure (Kamle, Mahato et al. 2019). 27 
Currently, several countries employ strict regulations to keep levels of FB1 low in food.  Acceptable 28 
limits of FB1 in maize intended for human consumption range from 1 to 2 parts per million (ppm).  The 29 
Scientific Committee on Food (SCF) and the joint Food and Agriculture Organization (FAO)/ World 30 
Health Organisation (WHO) Expert Committee for Food Additives (JECFA) independently established 31 
a provisional maximum tolerable daily intake (TDI) of 2 µg/kg body weight/day for FB1, which was 32 
later expanded to include FB1 alone or in combination with FB2 and FB3. This was based on a no-33 
observable-adverse-effects level (NOAEL) in the liver and kidney of rodent models (SCF/EC 2000, 34 




often masks their presence during analysis, the European Food Safety Authority (EFSA) established a 36 
TDI of 1.0 µg/kg bw per day of FB1 alone or in combination with FB2, FB3, and FB4 (EFSA 2018). 37 
Food that does not reach regulatory limits for human consumption are either used as animal feed or 38 
discarded completely. This leads to large annual losses in the agricultural industry (Gbashi, Madala et 39 
al. 2018). In many developing countries with a high-cereal consumption, regulation is either lacking or 40 
not enforced (Gbashi, Madala et al. 2018). Furthermore, FB1 contamination and exposure is higher in 41 
low income countries, where rural subsistence farming communities are common (Mngqawa, Shephard 42 
et al. 2016, Alberts, Rheeder et al. 2019). Young children weaned on maize-based food are also 43 
vulnerable to FB1 exposure that exceed the TDI (Shirima, Kimanya et al. 2013, Chen, Riley et al. 2018).  44 
FB1 is responsible for several pathological states in humans and animals.  It is known to induce 45 
leukoencephalomalacia in equine, oedema in porcine and liver and renal toxicities in equine, porcine 46 
and rodents (Klarić and Pepeljnjak 2001, Voss, Smith et al. 2007, EFSA 2018). The International 47 
Agency for Research on Cancer (IARC) has classified FB1 as a group 2 carcinogen as it is known to 48 
initiate and promote the development of renal, hepatocellular and cholangiocarcinoma in rodents, and 49 
is associated with the development of human esophageal (and in one case hepatocellular) carcinomas 50 
in regions that have a high maize consumption (Sydenham, Thiel et al. 1990, Dragan, Bidlack et al. 51 
2001, IARC 2002, Sun, Wang et al. 2007, Alizadeh, Roshandel et al. 2012). Due to its structural 52 
similarity to sphingoid bases, the primary mechanism by which FB1 induces its toxicity is through the 53 
disruption of sphingolipid metabolism. This inhibitory action interferes with signal transduction, cell 54 
cycle regulation and the functioning of lipid containing molecules such as cell membranes (Wang, 55 
Norred et al. 1991). FB1 is known to trigger a host of other toxic responses such as oxidative stress, 56 
endoplasmic reticulum (ER) stress, disrupts cell cycle and alterations in immune responses 57 
(Chuturgoon, Phulukdaree et al. 2015, Yin, Guo et al. 2016, Arumugam, Pillay et al. 2019, Arumugam, 58 
Ghazi et al. 2020, Liu, Zhang et al. 2020). It also disrupts anti-oxidant signaling and cell death 59 
mechanisms (Chuturgoon, Phulukdaree et al. 2015, Arumugam, Pillay et al. 2019). 60 
It has become increasingly clear that epigenetic mechanisms may also be exacerbate FB1 induced 61 
toxicities. Epigenetics involves phenotypic variations that are brought about by regulating gene 62 
expression rather than altering DNA sequences (Bollati and Baccarelli 2010). Epigenetic modifications 63 
are essential for the normal cellular processes and maintenance of gene expression patterns; however, 64 
aberrant modifications can affect genome stability or have toxic and carcinogenic effects (Ho, Johnson 65 
et al. 2012, Shamsi, Firoz et al. 2017). Epigenetic modifications include changes in DNA methylation, 66 
RNA methylation [such as N6-Methyladenosine (m6A)], histone modifications and non-coding RNAs 67 
(ncRNA) such as microRNA (miRNA) and long-noncoding RNA (lncRNA) (Bannister and Kouzarides 68 
2011, Moore, Le et al. 2013, Zaccara, Ries et al. 2019, Yang, Liu et al. 2020).  69 
Several studies have investigated the impact of FB1 on DNA methylation and histone modifications; 70 




glioma cells and human Caco-2 cells; however, hypomethylation was observed in HepG2 cells and no 72 
significant changes occurred in rat liver (Clone 9 cells) and kidney epithelial cells (NRK-52E) (Mobio, 73 
Anane et al. 2000, Kouadio, Dano et al. 2007, Chuturgoon, Phulukdaree et al. 2014, Demirel, 74 
Alpertunga et al. 2015). Furthermore, FB1 induced methylation of CpG islands found on the promoter 75 
regions of tumor suppressor genes (Demirel, Alpertunga et al. 2015). With regards to histone 76 
modification, FB1 induced H3K9me3 and repressed H4K20me3 (Pellanda, Forges et al. 2012, Sancak 77 
and Ozden 2015). FB1 had little effect on H4K16 and H3K18 acetylation; however, promoted 78 
acetylation of H2NK12, H3K9 and H3K23 (Pellanda, Forges et al. 2012, Gardner, Riley et al. 2016). 79 
Only one study has evaluated changes in miRNA profiles upon FB1 exposure (Chuturgoon, Phulukdaree 80 
et al. 2014). Thus far, no study has evaluated the impact of FB1 on m6A modifications and lncRNAs 81 
and little is known on the downstream implications of these epigenetic changes. In this study, the impact 82 
of FB1 on DNA methylation, histone methylation (H3K4), m6A RNA methylation, miRNAs and 83 
lncRNAs were evaluated. The effect of these changes on response mechanisms to cellular stress were 84 
further investigated.  85 
It was previously shown that FB1 enhanced ROS production, resulting in oxidative stress in HepG2 86 
cells (Arumugam, Pillay et al. 2019). Oxidative stress induced by FB1 has also been observed in several 87 
other in vivo and in vitro models [extensively reviewed by Arumugam, Ghazi et al. (2020)]. A major 88 
consequence of excessive ROS level is oxidative injury to DNA which results in modification to 89 
nitrogenous bases and single- and double-stranded DNA breaks.  The lesions incurred on DNA are often 90 
deleterious or have mutagenic effects (Loft, Høgh Danielsen et al. 2008).  Cells are safe guarded by a 91 
complex network of DNA damage responses (DDR) with the tumor suppressor, PTEN and checkpoint 92 
signaling at the forefront (Dai and Grant 2010). Checkpoint kinase 1 (CHK1), a key transducer in this 93 
signaling networking, halts the cell cycle allowing for repair of damaged DNA to occur (Dai and Grant 94 
2010, Patil, Pabla et al. 2013).  Loss of the tumor suppressor PTEN generates DNA damage and prevents 95 
DNA repair via the inappropriate inactivation of CHK1 (Puc, Keniry et al. 2005, Puc and Parsons 2005). 96 
It is possible that PTEN expression is affected by epigenetic changes such as histone modifications and 97 
miRNA. Tri-methylation of the fourth lysine residue of histone 3 (H3K4me3) found on the promoter 98 
region of PTEN activates its transcription, whereas demethylation has the opposing effect (Shen, Cheng 99 
et al. 2018). Furthermore, miRNA, such as microRNA-30c (miR-30c), binds to the 3’ untranslated 100 
region (3’UTR) of PTEN mRNA and inhibits its translation (Hu, Duan et al. 2019). FB1 in known to 101 
affect both miR-30c and H3K4me regulation and may therefore affect DNA damage checkpoint 102 
regulation by epigenetically modulating PTEN (Chuturgoon, Phulukdaree et al. 2014, Chuturgoon, 103 
Phulukdaree et al. 2014, Sancak and Ozden 2015). 104 
Oxidative stress not only induces oxidative lesions in DNA but it may also induce chemical 105 
modifications in RNA (Li, Li et al. 2017, Zhao, Li et al. 2019, Wu, Gan et al. 2020). Over a hundred 106 




the methylation of the sixth nitrogen of adenosine (m6A) residues found on mRNA and lncRNA 108 
(Cantara, Crain et al. 2011, Machnicka, Milanowska et al. 2013, Yue, Liu et al. 2015). m6A marks are 109 
installed by “writers” (methyltransferases: METTL3 and METTL14), removed by “erasers” 110 
(demethylases: FTO and ALKBH5) and recognized by “readers” [YT521-B homology (YTH) domain 111 
family proteins: YTHDF1, YTHDF2, YTHDF3, YTHDC1 and YTHDC2]. M6A “readers” control the 112 
fate of m6A modified transcripts by regulating its export, degradation, splicing, and protein translation 113 
(Zaccara, Ries et al. 2019). M6A modifications are also influenced by cellular stress and can influence 114 
stress responses (Dominissini, Moshitch-Moshkovitz et al. 2012, Engel, Eggert et al. 2018). Global 115 
m6A levels are increased in response to oxidative stress; however, m6A modifications to certain 116 
transcripts have been shown to influence oxidative stress responses (Li, Li et al. 2017, Zhao, Li et al. 117 
2019, Wu, Gan et al. 2020, Zhao, Wang et al. 2020). For instance, oxidative stress that occurred due to 118 
colistin exposure altered m6A levels; however, colistin-induced oxidative stress was diminished by 119 
m6A modifications on pri-miR-873. This promoted the generation of mature miR-873-5p and 120 
subsequently inhibited Keap1 expression and promoted Nrf2 antioxidant responses (Wang, Ishfaq et al. 121 
2019). It was previously shown that Keap1/Nrf2 signaling is activated in response to FB1-mediated 122 
oxidative stress (Arumugam, Pillay et al. 2019). The activation of Keap1/Nrf2 signaling promotes the 123 
transcription of anti-oxidants and other detoxifying enzymes to combat excess ROS (Ray, Huang et al. 124 
2012). It is possible that FB1-mediated oxidative stress affects global m6A levels and that m6A 125 
modifications are a potential factor contributing to Keap1/Nrf2 activation. Furthermore, Keap1 and 126 
Nrf2 are also regulated by promoter methylation and microRNA-27b (miR-27b).  127 
When cells are unable to overcome genotoxic and oxidative stress, they initiate p53 mediated apoptosis. 128 
While p53 is considered the most mutated gene in cancer, its expression may also be influenced by 129 
epigenetic factors such as lncRNA, miRNA and DNA methylation (Saldaña-Meyer and Recillas-Targa 130 
2011, Chmelarova, Krepinska et al. 2013, Anbarasan and Bourdon 2019). Epigenetic modifications 131 
may also work in concert to regulate gene expression. For instance, the lncRNA, homeobox A11 132 
antisense (HOXA11-AS) functions as circulating endogenous RNA (ceRNA) and molecular scaffold 133 
to alter DNA methylation patterns (Sun, Nie et al. 2016, Yu, Peng et al. 2017). As a ceRNA, HOXA11-134 
AS binds to miRNAs and inhibits the regulatory interaction between the miRNA and its target mRNA 135 
(Khandelwal, Bacolla et al. 2015). By acting as a molecular scaffold, HOXA11-AS modulates the 136 
transcription of target genes by recruiting proteins including DNA methyltransferases (DNMTs) to the 137 
promoter regions of genes (Wang and Chang 2011).  HOXA11-AS sequesters miR-124, which in turn 138 
upregulates DNMT3B and SP1, a DNMT1 transcription factor (Chen, Liu et al. 2015). HOXA11-AS 139 
may also act as a scaffold for DNMT1 (Sun, Nie et al. 2016). DNMTs are responsible for the 140 
methylation of gene promoters and thus inhibition of gene expression (Lyko 2018).  It was previously 141 




(Demirel, Alpertunga et al. 2015). It is possible that p53 expression may be downregulated by 143 
methylation of its promoter via the HOXA11-AS/miR-124/DNMT axis.  144 
In this study, the human hepatoma (HepG2) cell line was used to identify epigenetic mechanisms that 145 
may contribute to FB1 induced hepatoxicity. The liver is the initial site for the metabolism and 146 
detoxification of food contaminants and is one of the primary organs in which FB1 accumulates and 147 
exerts toxicity (Martinez-Larranaga, Anadon et al. 1999, Kammerer and Küpper 2018). The use of 148 
primary hepatocyte cell lines as a toxicity model has many limitations. When primary hepatocytes are 149 
cultured they undergo morphological, phenotypic and functional changes in a process known as de-150 
differentiation. Furthermore, liver specific functions such as cytochrome P450 metabolism also declines 151 
(Soldatow, Lecluyse et al. 2013). It is for these reasons that the HepG2 cell line was used instead. 152 
HepG2 cells have similar physiological functions to primary hepatocytes; however, it retains its 153 
functions and morphology in culture. It also displays a metabolic capacity and epigenetic profile similar 154 
to intact hepatocytes (Ruoß, Damm et al. 2019). Moreover, no mutations have been found in the PTEN 155 
or p53 gene of the HepG2 cell line, making it a reliable model for testing epigenetic changes as a result 156 
of FB1 exposure (Ma, Xu et al. 2005, Lee and Park 2015). 157 
1.1. Aim 158 
The aim of this study was to determine the epigenetic effects of FB1 and the downstream implications 159 
of these epigenetic alterations to stress response pathways in human liver (HepG2) cells.  160 
 161 
1.2. Hypothesis 162 
FB1 modifies the epigenome of HepG2 cells and alters cellular responses to stress which further 163 
contributes to its’ toxicity.  164 
 165 
1.3. Objectives 166 
The objectives of this study were to determine the effects of FB1 in HepG2 cells by assessing:  167 
- genome integrity, epigenetic regulation of PTEN by miR-30c and H3K4me3 and CHK1. 168 
- ROS levels, global m6A levels and the epigenetic regulation of Keap1/Nrf2 via m6A RNA 169 
methylation, miR-27b and promoter methylation. 170 
- epigenetic regulation of p53 via the HOXA11-AS/miR-124/DNMT axis and its effect on 171 
apoptosis. 172 
Ethical approval for this study was obtained from the University of Kwazulu-Natal Biomedical 173 
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CHAPTER 2 399 
LITERATURE REVIEW 400 
2.1. Fusarium Mycotoxins 401 
Among numerous fungal genera, those belonging to Fusarium are considered the most significant.  402 
Fusarium species invade important agricultural crops such as small grain cereals and maize (Escrivá et 403 
al., 2015). Under optimal conditions, many of these fungi produce an array of structurally diverse and 404 
toxic secondary metabolites. These metabolites are known as mycotoxins and the quantity and type 405 
produced is dependent upon factors such as moisture, temperature and insect stress (Nesic et al., 2014, 406 
Bakker et al., 2018). Mycotoxins are related to the development of plant diseases resulting in the 407 
reduction of global crops by almost 30% (Nesic et al., 2014). Of significant concern is the acute and 408 
chronic implications of the consumption of Fusarium contaminated commodities on human and animal 409 
health (Escrivá et al., 2015). Some Fusarium mycotoxins co-contaminate crops and elicit a broad 410 
variety of toxic and carcinogenic effects in both humans and animals. Co-exposure to multiple 411 
Fusarium mycotoxins results in possibly synergistic or additive toxic effects (Grenier and Oswald, 412 
2011). The most relevant Fusarium mycotoxins in terms of toxicology and distribution include 413 
fumonisins, trichothecenes and zearalenone (Figure 1) (Bakker et al., 2018). 414 
Trichothecenes consist of metabolites containing an epoxide moiety (Figure 2.1A). They are produced 415 
by a wide variety of Fusarium species, including F. sporotrichioides, F. poae, F. equiseti, and F. 416 
acumninatum (Chain, 2011). More than 150 trichothecenes have been identified and classified into 4 417 
types (A-D) based on substitutions on the core structure of 12,13-epoxytrichothec-9-ene (Escrivá et al., 418 
2015). Toxicologically relevant trichothecenes consist of T-2 toxin, HT-2 toxin, nivalenol (NIV) and 419 
deoxynivalenol (DON). Trichothecenes are potent inhibitors of DNA, RNA and protein synthesis and 420 
have been associated with damage to the gastrointestinal system, dermatitis, immune suppression and 421 
hematologic disorders (Chain, 2011, Nesic et al., 2014). 422 
Zearalenones (Figure 2.1B) are predominantly produced by F. graminearum, and F. cerealis, in 423 
temperate climates with cool temperatures and high humidity (EFSA, 2011). Zearalenones are classified 424 
as myco-oestrogens as they bind to cytosolic oestrogen receptors in the uterus, hypothalamus, mammary 425 
and pituitary glands resulting in strong hyper-oestrogenic effects (Abbès et al., 2006). Therefore, 426 
zearalenones exert their toxicity on the reproductive system by inducing morphological changes to the 427 
reproductive tract such as vaginal swelling, testicular atrophy and enlargement of mammary glands; as 428 
well as decreased fertility, higher embryo lethal resorptions and precocious puberty (EFSA, 2011, 429 
Escrivá et al., 2015). In addition, zearalenone also induces hepatotoxic, immunotoxic, and carcinogenic 430 
effects (EFSA, 2011, Escrivá et al., 2015).  431 
Fumonisins are polyketide derived mycotoxins predominantly produced by F. verticillioides and F. 432 




and renal toxicities (EFSA, 2018). Currently, 28 fumonisins have been identified and categorized into 434 
four groups (A, B, C and P). Among these analogues, fumonisin B1 (FB1; Figure 2.1C) is regarded as 435 
the most relevant due to its wide spread distribution and potent toxicity (Rheeder et al., 2002).  436 
 437 
Figure 2.1. Chemical structure of the main Fusarium mycotoxins. (A) Trichothecenes; (B) 438 
Zearalenone; (C) Fumonisins; OAc = acetyl group; OIsoval = isovalerate group (Ferrigo et al., 2016). 439 
    2.1.1. Fumonisin B1 440 
Approximately 61% of global cereal grains are contaminated with fumonisins (Lee and Ryu, 2017). 441 
FB1 accounts for 70-80% of total fumonisins that naturally infect food and feed samples, making it the 442 
most relevant fumonisin analogue (Rheeder et al., 2002). Due to their wide geographical distribution 443 
and frequent occurrence on maize, F. verticillioides and F. proliferatum are considered the most 444 
important FB1 producers (Rheeder et al., 2002). Furthermore, F. verticillioides and F. proliferatum 445 
produce the highest levels of FB1 reaching levels as high as 17,900 and 31,000 mg/kg of FB1. 13 446 
additional Fusariums have been found to produce FB1, however, to a much lower extent (7-7,200 447 
mg/kg) (Rheeder et al., 2002). 448 
The production of FB1 occurs preharvest and during storage and is heavily dependent on agroclimatic 449 
conditions. Production is favoured in temperate regions where temperatures are warm and humidity is 450 
high. Heat stress, insect damage and drought stress also influence FB1 production (Ferrigo et al., 2016). 451 
It is found in abundance in maize and maize-based products such as corn flakes, flour and oil as well as 452 
in small cereal grains such as wheat, rice and oats (Lee and Ryu, 2017). Maize and cereals are dietary 453 
staples and developing countries are heavily reliant on them. Moreover, FB1 production is prominent in 454 




implement the same agronomic practices seen in commercial settings. Poor agronomic practices 456 
exacerbate the incidence of Fusarium infection and FB1 production (Shephard et al., 2019). Due to the 457 
high incidence of FB1 in crops and its resistance to food processing, several countries and organisations 458 
have set regulations to limit FB1 contamination in food and feed. The Joint FAO-WHO Expert 459 
Committee (JECFA) have also declared the provisional maximum tolerable intake of FB1 alone or in 460 
combination with FB2 and FB3 should be 2 μg/kg bw/day (FOA/WHO, 2002); however, FB1 intake is 461 
exceeded in many developing countries that rely heavily on cereal grains (Sun et al., 2007, Torres et 462 
al., 2007).  463 
    2.1.1.1. Structure and Biosynthesis 464 
The structure of FB1 (C34H59NO15), consists of linear 20 carbon (C) aminopentol backbone which is 465 
substituted with an amine, three hydroxyl, two methyl, and two tricarboxylic acid groups at various 466 
positions (Alexander et al., 2009). Genes involved in the biosynthesis of fumonisin have been mapped 467 
to one locus in the genome of F. verticillioides and F. proliferatum. This region is regarded as the FUM 468 
cluster and consists of 17 genes (Khaldi and Wolfe, 2011). Genes belonging to the FUM cluster are co-469 
regulated and its expression is influenced by abiotic factors such as water availability and temperature 470 
which in turn influence fumonisin production (Medina et al., 2013). 471 
The biosynthesis of FB1 is initiated by the condensation of nine acetate and two methyl groups to form 472 
a linear 18-C long polyketide. This reaction is catalysed by polyketide synthase (FUM 1) (Du et al., 473 
2008, Alexander et al., 2009). Thereafter, the aminotransferase, FUM 8, mediates the condensation of 474 
the polyketide to alanine, resulting in a 20-C long backbone with an amine group at C-2, carbonyl group 475 
at C-3 and methyl groups at C-12 and C-16 (Du et al., 2008). The resulting polyketide amino acid 476 
undergoes hydroxylation at C-14 and C-15 by FUM 6. Thereafter, the carbonyl group is removed at C-477 
3, C-10 is hydroxylated and two tricarboxylic acids are esterified to C-14 and C-15. These three 478 
reactions are catalysed by FUM 13, FUM 2 and FUM 10/14, respectively (Alexander et al., 2009).  The 479 
addition of a hydroxyl group at C-5 by the dioxygenase FUM 3 is responsible for the final step of FB1 480 





Figure 2.2. FUM mediated biosynthesis of FB1 (prepared by author). 483 
 2.1.1.2. Primary mechanism of toxicity 484 
The primary mechanism by which FB1 exerts its toxicity is via the disruption of sphingolipid 485 
metabolism (Riley and Merrill, 2019). Ceramide synthase (CS) plays a central role in sphingolipid 486 
metabolism by catalysing the N-acylation of sphinganine (Sa) during sphingolipid synthesis and the N-487 
acylation of sphingosine (So) during sphingolipid turnover (Futerman and Riezman, 2005). The 488 
aminopentol backbone of FB1 bares close structural resemblance to the sphingoid bases: Sa and So, 489 
thus, FB1 competes with sphingoid bases for CS binding. CS recognizes and binds both the amino group 490 
and the tricarboxylic acid side chains of FB1, thereby inhibiting both de novo synthesis and degradation 491 
pathways of sphingolipid metabolism (Wang et al., 1991). This results in the reduction in the formation 492 
of complex sphingolipids such as sphingomyelin and glycosphingolipids. The toxic effects of FB1 are 493 
only partially due to the reduction of complex sphingolipids. The rapid accumulation of sphingoid bases 494 
and their phosphorylated counter parts can also trigger cell injury and membrane degradation (Wang et 495 
al., 1991, Riley and Merrill, 2019). Reduction of ceramide and the accumulation of 496 
phosphosphingolipids disrupt signalling pathways and in turn trigger several toxicologically relevant 497 
perturbations such endoplasmic reticulum (ER) stress, accumulation of reactive oxygen species (ROS), 498 
altered mitochondrial and immune functioning, and disruption to developmental regulation (Riley and 499 
Merrill, 2019). Furthermore, FB1-induced fluctuations in the levels of sphingoid bases alter rates of cell 500 
death and regeneration, which may play a major role in FB1-mediated tumorigenesis (Wang et al., 1991, 501 
Soriano et al., 2005). For a detailed discussion on the impact of FB1 on disruption of sphingolipid 502 
metabolism and the molecular implications, see chapter 3:  Molecular and Epigenetic Mechanisms of 503 
FB1 Mediated Toxicity and Carcinogenesis and Detoxification Strategies, pages 74-86. 504 




2.1.1.3. Impact of FB1 on human and animal health 506 
The 1970 field outbreak of equine leukoencephalomalcia (ELEM) in South Africa prompted the 507 
discovery and characterization of fumonisins. The disease was associated with the consumption of 508 
maize contaminated with F. verticillioides (formally F. moniliforme); later it was discovered that FB1 509 
was the main aetiological agent in the outbreak (Marasas, 2001). ELEM affects the central nervous 510 
system and is characterized by liquefactive lesions in the subcortical white matter of the cerebrum. 511 
Lesions may also develop in the brain stem, spinal cord and cerebellum (Klarić and Pepeljnjak, 2001). 512 
This leads to depression, pharyngeal paralysis, lethargy, blind staggering and seizures in affected horses 513 
(EFSA, 2018). Death can occur within a week after consuming of contaminated feed and can occur 514 
without prior signs (Klarić and Pepeljnjak, 2001). Moreover, hepatic and renal lesions and cardiac 515 
defects may develop independently or concurrently with ELEM (Klarić and Pepeljnjak, 2001, EFSA, 516 
2018). 517 
Along with horses, swine are considered the most sensitive domestic animals to FB1. Swine exposed to 518 
FB1 develop a syndrome termed porcine pulmonary oedema (Haschek et al., 2001). Within 4 to 7 days 519 
of exposure, swine present with respiratory distress, cyanosis, hydrothorax and pulmonary oedema. 520 
Death occurs rapidly within hours of respiratory distress; however, long term exposure to low doses of 521 
FB1 results in non-lethal oedema (Voss et al., 2007). Pulmonary oedema induced by FB1 may result 522 
from acute left-side heart failure due to changes in So/Sa concentrations which regulate L-type calcium 523 
channels. As a result, decreased heart rate, cardiac output and contractility also occur (Haschek et al., 524 
2001). Aside from the pulmonary and cardiac effects, acute liver injury, pancreatic necrosis, formation 525 
of oesophageal plaques and depressed immune responses have also been observed (Voss et al., 2007).  526 
The pathological effects of FB1 have been well established in experimental rodent models. FB1 527 
predominantly targets the liver and kidney of rat and mouse models however the extent of toxicity is 528 
dependent on the species and sex of the animals as well as the dose of FB1 received (Klarić and 529 
Pepeljnjak, 2001). Hepatoxicity is minimal in Sprague Dawley and Fischer 344 rats, whereas the liver 530 
is a major target in BD IX rats. However, male rats are more sensitive to the nephrotoxic effects of FB1 531 
than female rats; while mice are less sensitive to nephrotoxicity than rats (Voss et al., 2007). FB1-532 
induced hepatotoxicity consisted of necrosis accompanied by changes in the lipid ratios, distortion of 533 
liver lobules, and the development of hyperplastic nodules. Nephrotoxicity was characterised by 534 
hyperplasia, necrosis of tubules, fatty changes and pyknosis (Klarić and Pepeljnjak, 2001). Impairment 535 
of development and congenital malformations in the embryo and foetus are common in dams exposed 536 
to FB1. FB1 further retards growth and induces developmental abnormalities in these offspring 537 
(Lumsangkul et al., 2019).  FB1 has been implicated in the initiation and promotion of carcinogenesis. 538 
Cholangiocarcinomas, hepatocellular carcinomas and renal tubular tumours have been observed in male 539 
rats; while female mice present with hepatocellular carcinomas and adenomas (Dragan et al., 2001). 540 




conjunction with compensatory cell proliferation and apoptosis are the proposed mechanisms by which 542 
FB1 exerts its carcinogenic effects (Dragan et al., 2001, Demirel et al., 2015). 543 
 While the carcinogenicity of FB1 in experimental animals have been well established, evidence of FB1-544 
carcinogenicity in humans are limited. Therefore, the International Agency for Research on Cancer 545 
(IARC) has classified FB1 as a class 2B carcinogen (IARC, 2002). Epidemiological studies have shown 546 
an association between the high incidence of oesophageal cancer and, in one instance, hepatocellular 547 
carcinomas in regions with high consumption of FB1 contaminated maize. Regions of major concern 548 
include South Africa, Iran and China (Sydenham et al., 1990, Sun et al., 2007, Alizadeh et al., 2012). 549 
Epidemiological studies have also linked the high incidence of neural tube defects along the Mexican-550 
Texan border to the maternal consumption of maize based products contaminated with FB1 (Missmer 551 
et al., 2006). The inhibition of sphingolipid synthesis disturbs cellular membranes and receptors. FB1 552 
inhibits folate uptake, leading to neural tube defects such as spinal bifida and anencephaly with 553 
extremely high exposure leading to foetal death (Marasas et al., 2004). Furthermore, evidence linking 554 
fumonisin exposure to the stunting of growth in Sub-Saharan infants and children that consume maize‐555 
based weaning foods has been increasing (Shirima et al., 2013, Chen et al., 2018). Finally, only one 556 
outbreak of acute mycotoxicosis caused by the consumption of FB1-contaminated sorghum and corn 557 
has been recorded. The outbreak occurred in South India after 2 cyclonic storms which promoted growth 558 
of mould. The outbreak affected 27 villages and 1,412 people. Affected individuals reported transient 559 
abdominal pain, borborygmus and diarrhoea (Reddy and Raghavender, 2008). 560 
While the disruption of sphingolipid metabolism by FB1 has been ruled as the primary mechanism for 561 
its adverse effects; several emerging evidences suggests that mycotoxins induce epigenetic changes that 562 
play a key role in their toxicity. It is plausible to assume that epigenetic changes may also contribute to 563 
FB1-mediated toxicities and pathologies. 564 
2.2. Epigenetics  565 
Although virtually all cells in an organism contain identical DNA sequence, not all cell types share the 566 
same phenotype at the same time (Moore et al., 2013). Conard Waddington found that environmental 567 
changes during development could induce an alternative phenotype despite their identical sequence. He 568 
further observed that these environmentally induced changes could be inherited.  He termed this 569 
phenomenon as “epigenetics” (Waddington, 1956, Holliday, 2006). Epigenetics encompasses heritable 570 
modifications that regulate gene expression and are not associated with changes in DNA sequence 571 
(Bollati and Baccarelli, 2010). The complete description of all epigenetic modifications of a cell at any 572 
given time is termed the epigenome. Interactions between the epigenome, genome and environment 573 
play a critical role in shaping the development and health of an individual (Marczylo et al., 2016). 574 
Several types of epigenetic modifications have been identified. These modifications include: DNA 575 




2.3). DNA methylation and histone modifications influence transcription by altering chromatin 577 
structure and accessibility of transcriptional machinery to nucleotide sequences (Bannister and 578 
Kouzarides, 2011, Moore et al., 2013). On the other hand, RNA methylation targets posttranscriptional 579 
regulation; whereas, ncRNA influence transcriptional and posttranscriptional regulation of genes 580 
(Zaccara et al., 2019, Yang et al., 2020). 581 
 582 
Figure 2.3. The complex epigenetic landscape involves: (A) DNA methylation, (B) histone 583 
modifications, (C) ncRNA such as miRNA and lncRNA and (D) RNA modifications such as RNA 584 
methylation (Aristizabal et al., 2020) 585 
While the epigenome is stable, it is dynamic and can be influenced by a number of environmental factors 586 
(Marczylo et al., 2016). Aberrant changes to the epigenome can induce abnormalities in gene expression 587 
and disrupt cellular processes (Kanherkar et al., 2014). Therefore, aberrations in the epigenome have 588 
been identified to precede various diseases such as metabolic disorders, autoimmune diseases, 589 
neurological disorders and cancers (Shamsi et al., 2017). However, unlike genetic defects, epigenetic 590 
deviations are reversible and are thus potential therapeutic targets (Kelly et al., 2010).  591 
     2.2.1. DNA Methylation 592 
DNA methylation is the most studied epigenetic mark that involves the covalent transfer of methyl 593 
groups from S-adenosylmethionine (SAM) to the fifth carbon in the nitrogenous base of cytosine (5mC) 594 
in DNA (Robertson, 2005). It usually occurs on cytosine bases adjacent to guanine bases (CpG site) 595 
(Robertson, 2005). Approximately 70% of CpG sites in mammalian DNA are methylated (Cooper and 596 
Krawczak, 1989); however, the distribution of CpG sites are not random. Multiple repeats of CpG sites, 597 
known as CpG islands, are usually found on gene promoters (Saxonov et al., 2006).  CpG islands found 598 




1986, Antequera, 2003, Saxonov et al., 2006). In contrast, methylation of promoter associated CpG 600 
islands results in the silencing of gene expression (Figure 2.4) (Mohn et al., 2008, Payer and Lee, 2008). 601 
Methylation can also occur on intergenic regions, where it prevents the expression of potentially 602 
harmful genetic elements (Moore et al., 2013), as well as within the gene body, where a positive 603 
correlation with gene expression occurs (Hellman and Chess, 2007, Aran et al., 2011, Jjingo et al., 604 
2012).   605 
 606 
 607 
Figure 2.4. Regulation of gene expression via DNA methylation. (A) Genes are actively transcribed 608 
when CpG islands are unmethylated; however, (B) methylation of CpG islands on the gene promoter 609 
inhibits transcription (prepared by author). 610 
It is clear that DNA methylation is strongly involved in the physiological control of gene expression 611 
(Moore et al., 2013). It plays a key role in normal development (Li et al., 1992), compaction of 612 
chromatin (Geiman et al., 2004), genomic imprinting (Li et al., 1993), X chromosome inactivation 613 
(Csankovszki et al., 2001) and the bulk silencing of viral and transposable elements (Schulz et al., 614 
2006). However, aberrant methylation patterns are associated with a multitude of diseases especially, 615 
cancer (Laird and Jaenisch, 1996, Ehrlich, 2002, Robertson, 2005, Jin and Liu, 2018, Kader et al., 2018). 616 
For example, CpG sites especially, those found in the promoter region of tumour suppressor genes are 617 
hot spots for somatic mutations (Rideout et al., 1990, Greenblatt et al., 1994). DNA methylation can 618 
promote increases in mutation rates and forms part of Knudson’s two-hit model for tumour formation 619 
by causing the heritable silencing of growth regulating genes (Jones, 1996, Moore et al., 2013, Zhou et 620 
al., 2020). Furthermore, global hypomethylation accompanied with hypermethylation of tumour 621 
suppressor genes are considered a hallmark of cancer and have been observed in several types of cancers 622 
(Lin et al., 2001, Yang et al., 2003, Saito et al., 2010, Wu et al., 2010, Hon et al., 2012, Pfeifer, 2018).  623 
2.2.1.1. Regulation of DNA Methylation  624 
DNA methylation is dynamic and involves enzymes that install (methyltransferases), recognize 625 
(readers) and remove (demethylases) methyl marks on DNA. DNA methylation is established by the 626 




DNMT3L (Cheng and Blumenthal, 2008). The DNMT family are structurally similar with large 628 
regulatory N-terminal domains and catalytic C-terminal domains; however, they vary in functionality 629 
(Lyko, 2018).  630 
DNMT1 is known as the maintenance DNMT as it maintains methylation patterns in a cell lineage 631 
(Moore et al., 2013). A unique feature of its N-terminal is the replication foci targeting sequence which 632 
allows DNMT1 to localize to the replication fork during DNA synthesis (Leonhardt et al., 1992). Here, 633 
DNMT1 copies methylation patterns to hemi-methylated daughter strands to precisely mimic the 634 
methylation pattern of the parent strand (Hermann et al., 2004). Moreover, DNMT1 accumulates at 635 
DNA repair sites and is associated with mismatch repair and DNA damage response machinery 636 
(Mortusewicz et al., 2005, Eades et al., 2011, Loughery et al., 2011). Silencing of DNMT1 leads to the 637 
significant reduction in DNA methylation, aberrant imprinting and embryonic lethality suggesting that 638 
it plays a critical role in dividing cells and cellular differentiation (Li et al., 1992, Li et al., 1993). While 639 
DNMT1 maintains methylation patterns, DNMT3A and DNMT3B are responsible for the de novo 640 
methylation of DNA (Figure 2.5) (Okano et al., 1998). DNMT3A and DNMT3B bare close structural 641 
resemblance with the key difference being their expression pattern. DNMT3A is ubiquitously expressed 642 
while DNMT3B is poorly expressed in most differentiated tissue (Xie et al., 1999). Furthermore, 643 
DNMT3B is essential for early development as knockout of DNMT3B results in embryonic lethality in 644 
mice, whereas growth is stunted when DNMT3A is silenced (Okano et al., 1998). The final member of 645 
the DNMT3 family, DNMT3L, lacks catalytic activity however it supports de novo DNMTs by 646 
enhancing their ability to bind to SAM and by stimulating their activity (Kareta et al., 2006). DNMT3L 647 
is mainly present during early development where it is required for imprinting, compaction of the X 648 
chromosome and methylation of retrotransposons (Bourc'his et al., 2001, Hata et al., 2002, Bourc'his 649 
and Bestor, 2004, Zamudio et al., 2011). The exact mechanism by which de novo methyltransferases 650 
target specific gene sequences is unknown; however, two hypotheses exist. The first suggests that RNA 651 
interference directs DNMTs to specific sequences. While this mechanism occurs in plants, the evidence 652 
observed in the mammalian genome is insufficient (Morris et al., 2004). The second suggests that 653 
transcription factors regulate DNA methylation by either recruiting or blocking DNMTs to specific 654 
DNA sequences (Brenner et al., 2005, Straussman et al., 2009). Binding of transcription factors seems 655 
to primarily protect CpG islands from methylation and deletion or mutations to transcription factor 656 
binding sites results in the de novo methylation of CpG islands (Brandeis et al., 1994, Macleod et al., 657 
1994). 658 
While DNA methylation prevents the binding of transcription factors and thus switched off 659 
transcription, DNA methylation “readers” are able to recognize and bind to 5mC bases, further 660 
inhibiting transcription factor binding (Moore et al., 2013). Three classes of DNA methylation readers 661 
exist: methyl-CpG-binding domain (MBD), ubiquitin-like containing PHD and RING-finger domain 662 




MBD1, MBD2, MBD3, and MBD4. (Fatemi and Wade, 2006). MeCP2, MBD1 and MBD2 contain a 664 
transcriptional repression domain that allows them to recruit corepressor complexes such as histone 665 
deacetylases to methylated DNA to further silence gene transcription (Nan et al., 1998, Ng et al., 1999, 666 
Villa et al., 2006). MeCP2 also plays a role in methylation maintenance by recruiting DNMT1 to hemi-667 
methylated DNA (Kimura and Shiota, 2003). MBD4 has DNA N-glycosylase enzymatic activity and is 668 
able to recognize and repair guanine : thymine, uracil, or 5-fluorouracil mismatches that occur due to 669 
5mC demethylation processes (Hendrich et al., 1999). Zinc finger proteins (Kaiso, ZBTB4, and 670 
ZBTB38) are able to bind to 5mC and act in a similar way to the MBD family by repressing transcription 671 
in a DNA methylation-dependent manner (Prokhortchouk et al., 2001, Filion et al., 2006). UHRF 672 
promotes DNMT1-targeted methylation of hemi-methylated DNA during DNA synthesis by tethering 673 
DNMT1 to chromatin (Bostick et al., 2007). 674 
DNA demethylation is the process of removing methyl marks from 5mC residues in either a passive or 675 
active manner. Passive demethylation is the loss of DNA methylation patterns during successive rounds 676 
of replication (Kohli and Zhang, 2013). It usually occurs due to loss of DNA methylation maintenance 677 
in actively dividing cells (von Meyenn et al., 2016). Active demethylation occurs in both dividing and 678 
non-dividing cells and is dependent on three enzyme families (Bhutani et al., 2011, Kohli and Zhang, 679 
2013): (i) ten-eleven translocation (TET) family which can either hydroxylate 5mC to 5-680 
hydroxymethylcytosine (5hmC) or further oxidize it to 5-formylcytosine (5fC) and 5-carboxylcytosine 681 
(5caC) (Tahiliani et al., 2009, Ito et al., 2011), (ii) Activation-induced cytidine 682 
deaminase/apolipoprotein B mRNA-editing catalytic polypeptides (AID/APOBEC) family which is 683 
responsible for the deamination of 5mC to thymine or 5hmC to 5-hydroxymethyluracil (5hmU) 684 
(Morgan et al., 2004, Guo et al., 2011) and (iii) base excision repair glycosylases such as thymine DNA 685 
glycosylase (TDG) which cleaves the products of TET and AID/APOBEC demethylation (5fC, 5caC, 686 
thymine, and 5hmU) from the DNA backbone and replaces it with an unmethylated cytosine (Figure 687 





Figure 2.5. Regulation of DNA methylation. DNMT1 maintains DNA methylation patterns via 690 
methylation, while DNMT3A and DNMT3B are required for de novo methylation by catalysing the 691 
transfer of a methyl group from SAM to cytosine forming 5mC. TET plays a central role in DNA 692 
demethylation by oxidizing 5mC to hmC and further to 5fC and 5caC. 5caC is excised by TDG and 693 
replaced with an unmethylated cytosine (prepared by author). 694 
    2.2.2. Histone Modifications 695 
The eukaryotic genome is tightly packaged into chromatin whose functional and structural unit is 696 
referred to as the nucleosome. Each nucleosome consists of four core histone proteins (H2A, H2B, H3 697 
and H4) arranged as an octamer around which approximately 200 base pairs of DNA is wrapped (Luger 698 
et al., 1997). The tight packaging of DNA by the nucleosome imposes a barrier to protein machinery 699 
required for its replication, repair and transcription (Ehrenhofer-Murray, 2004, Eaton et al., 2010, 700 
Chambers and Downs, 2012, Voss and Hager, 2014, Li and Zhu, 2015). Like DNA, histones can be 701 
modified by the addition or removal of chemical groups to control gene expression; however, histone 702 
modifications are not limited to methylation (Bannister and Kouzarides, 2011, Jambhekar et al., 2019).  703 
The N-terminal of histone tails can be subjected to several post-translational modifications. Such 704 
modifications include the methylation of arginine (R) and lysine (K), phosphorylation of serine and 705 
threonine and acetylation, ribosylation, sumoylation or ubiquitination of K (Figure 2.6). These covalent 706 
modifications, alter chromatin state, affect nucleosome positioning and influence accessibility to 707 





Figure 2.6. Schematic representation of some of the modifications found on histone tails of core 710 
histones (H2A, H2B, H3, H4) (Ueda and Seki, 2020).  711 
The most common and well-studied histone marks are acetylation and methylation. Acetylation usually 712 
occurs on histone 3 (H3) and histone 4 (H4) and is a dynamic process regulated by histone 713 
acetyltransferases (HATs) and histone deacetylases (HDACs) (Verdone et al., 2006). The N-terminal 714 
tail of histones contain highly conserved positively charged K residues that have high affinity to the 715 
negatively charged DNA backbone, resulting in a condensed chromatin structure (Müller and Muir, 716 
2015). Acetylation of K residues neutralizes the positive charge; reducing the affinity between histone 717 
tail and DNA backbone. This leaves the DNA exposed and more accessible to transcription factors 718 
(Müller and Muir, 2015, Zhao and Shilatifard, 2019). Acetylation not only contributes to gene 719 
expression by influencing histone-DNA interactions but it is also recognized and bound by 720 
bromodomain containing enzymes that can influence transcription and other chromatin-templated 721 
processes (Zhao and Shilatifard, 2019). 722 
Histone methylation primarily occurs on K and R residues found on H3 and H4 and is more complex 723 
than acetylation (Jambhekar et al., 2019). Methylation does not alter the charge of histone tails, instead 724 
histone methylation generates motifs that recruit bromo-, chromo-, and PHD domains of protein 725 
containing complexes that regulate gene expression (Strahl and Allis, 2000, Jenuwein and Allis, 2001). 726 
The outcome of methylation on gene expression is dependent on the specific residue that is methylated, 727 
the degree of methylation and the location of the methylated nucleosome in the genome (Jambhekar et 728 
al., 2019). There are three major forms of methylated R: mono-methyl-R, symmetrical di-methyl-R, 729 
and asymmetric-di-methyl-R, which are regulated by protein arginine N-methyltransferases (PRMTs) 730 
and the demethylase – Jumonji Domain-Containing Protein 6 (JmjD6) (Chang et al., 2007, Guccione 731 
and Richard, 2019). Several methylation sites have been identified to alter gene expression. The 732 
following R modifications have been associated with active transcription: H4R3me2a, H3R2me2s, 733 
H3R17me2a, H3R26me2a; while H3R2me2a, H3R8me2a, H3R8me2s, whereas H4R3me2s marks 734 




mono-, di- or tri- methylated (Jenuwein and Allis, 2001). Di- or tri- methylation of H3K4 at promoters, 736 
H3K36 and K3K79 on gene body is typically associated with active transcription (Bernstein et al., 2002, 737 
Bannister et al., 2005, Steger et al., 2008), whereas methylation of H3K9, H3K27, and H4K20 is 738 
generally gene repressive (Karachentsev et al., 2005, Brykczynska et al., 2010, Ninova et al., 2019).  739 
In this study, the interest is focussed on histone 3 lysine 4 trimethylation (H3K4me3) due to its distinct 740 
presence at transcriptional start sites and promoters of actively transcribing genes as well as its possible 741 
susceptibility to alteration by genotoxic agents. 742 
     2.2.2.1. H3K4me3 743 
H3K4me3 is a highly conserved histone mark occurring in organisms as simple as protozoan to complex 744 
organisms such as humans (Woo and Li, 2012, Song et al., 2017). In mammals, H3K4 methylation is 745 
facilitated by histone lysine methyltransferase 2 family (KMT2) which consists of six members. Each 746 
member contains a catalytic Su(var)3-9, Enhancer-of-zester and Trithorax (SET) domain that is 747 
responsible for the transfer of methyl groups from SAM to the fourth lysine reside of H3 (Collins et al., 748 
2019). Each histone methyltransferase operates within a multiprotein complex that produces distinct 749 
enzymatic responses (Hyun et al., 2017). Histone methylation functions by recruiting effector proteins 750 
that function in chromatin remodelling and regulate gene expression. Interestingly, some H3K4 751 
effectors reside within the enzymatic writer complexes (Collins et al., 2019). For example, H3K4me3 752 
recruits bromodomain PHD finger transcription factor (BPTF), a subunit of the chromatin remodelling 753 
complex – nucleosome remodelling factor (NURF), through its PHD fingers. This promotes the 754 
accessibility of transcriptional machinery to the chromatin template (Mizuguchi et al., 1997). On the 755 
other hand, demethylation of H3K4 makes the chromatin template inaccessible to transcription factors 756 
and inhibits transcription (Hyun et al., 2017). This process is regulated by two families of histone lysine 757 
demethylases: KDM1 and KDM5. KDM1 family (KDM1A and KDM1B) removes methyl groups from 758 
H3K4me1 and H3K4me2 while the KDM5 family (KDM5A, KDM5B, KDM5C and KDM5D) removes 759 
methyl groups from H3K4me1, H3K4me2 and H3K4me3 (Collins et al., 2019).  760 
Aside from its role in transcriptional activation, H3K4me3 has been implicated in other nuclear 761 
processes, including pre-mRNA splicing (Davie et al., 2015), meiotic DNA recombination (Borde et 762 
al., 2009), and DNA repair (Pena et al., 2008, Faucher and Wellinger, 2010). H3K4me3 is essential for 763 
cell cycle regulation, development and differentiation (Cui et al., 2009, Grandy et al., 2016, Zhang et 764 
al., 2016, Huang et al., 2019b). Dysregulation of H3K4me3 has been associated with intellectual 765 
disabilities and developmental disorders (Singh et al., 2016, Zamurrad et al., 2018, Larizza and Finelli, 766 
2019). Moreover, aberrant H3K4me3 and mutations in H3K4 methyltransferases highly increases an 767 




    2.2.3. RNA methylation: N6-methyladenosine  769 
Chemical modifications are not limited to histones and DNA as over a hundred structurally distinct 770 
chemical modifications are known to occur on the various classes of RNA (Cantara et al., 2011, 771 
Machnicka et al., 2013). The most prevalent of these RNA modifications is the methylation of the sixth 772 
nitrogen of adenosine (m6A) residues found on mRNA as well as lncRNA (Yue et al., 2015). M6A 773 
modifications were first identified in the 1970s by researchers evaluating 5’ cap structure of mammalian 774 
mRNA (Desrosiers et al., 1974, Perry and Kelley, 1974). However, research in the field subsided shortly 775 
after due to the lack of methods for detecting m6A sites in RNA. With the establishment of high 776 
throughput sequencing methods, interest in the field has now resurfaced. These mapping approaches 777 
has revealed that m6A modifications are dynamic, widespread, conserved and occur primarily in 778 
DRACH (where D = A/G/U, R= A/G, H=A/C/U) sequence consensus motifs that are located near stop 779 
codons, long exonic regions and 3’ untranslated regions (3’ UTR) (Dominissini et al., 2012, Meyer et 780 
al., 2012, Ke et al., 2015). M6A modifications are conserved amongst eukaryotes (Dominissini et al., 781 
2012) but have also been identified in the mRNA of replicating viruses (Krug et al., 1976), and several 782 
classes of RNA in bacteria and archaea (Deng et al., 2015, Couturier and Lindås, 2018). The 783 
modification functions by affecting mRNA stability, translation, splicing and nuclear export, miRNA 784 
biogenesis and lncRNA metabolism (Wang et al., 2014a, Alarcón et al., 2015, Ma et al., 2019, Zaccara 785 
et al., 2019). 786 
The m6A epitranscriptome is shaped by m6A writers, readers and erasers (Figure 2.7) (Zaccara et al., 787 
2019). m6A marks are installed during transcription by a multicomponent methyltransferase complex 788 
which selectively methylates RNA substrates exhibiting the DRACH consensus (Bokar et al., 1997, Liu 789 
et al., 2014, Ping et al., 2014). The complex consists of methyltransferase like 3 (METTL3) (Bokar et 790 
al., 1997), methyltransferase like 14 (METTL14) (Liu et al., 2014) and Wilms' tumor 1-associating 791 
protein (WTAP) (Ping et al., 2014). METTL3 serves as the catalytic subunit and facilitates the transfer 792 
of methyl groups from SAM to adenosine (A) of RNA (Bokar et al., 1997) while METTL14 acts as a 793 
support for METTL3 by recognizing RNA substrates and allowing binding to RNA (Wang et al., 2016). 794 
Liu et al. (2014) have demonstrated that METTL14 may have catalytic activity as well. Studies have 795 
shown that knockdown of either METTL3 or METTL14 led to a concurrent decrease in m6A levels of 796 
polyadenylated RNA (Liu et al., 2014). Surprisingly, the knockdown of METTL14 led to a more 797 
pronounced decrease in global m6A transcript levels (Place et al., 2008); however, a combination of 798 
both methyltransferases drastically enhances methylation efficiency (Wang et al., 2014b). WTAP is the 799 
third crucial component; it does not possess catalytic methyltransferase activity, but coordinates the 800 
localization of the METTL3-METTL14 heterodimer into nuclear speckles (Liu et al., 2014, Ping et al., 801 
2014). WTAP may also interact with other components such as RNA binding motif protein 15 (RBM15) 802 




methylate nearby DRACH motifs (Patil et al., 2016) and Zinc Finger CCCH-Type Containing 13 804 
(Zc3H13) which also plays a role in the nuclear localization (Wen et al., 2018). 805 
 806 
Figure 2.7: m6A modification machinery. The m6A methyltransferase complex (METTL13, 807 
METTL14 and WTAP) serves as an m6A “writer”, demethylases (e.g., FTO and ALKBH5) serve as 808 
m6A “erasers”, and a set of m6A “readers” (e.g., YTHDF1/2/3, YTHDC1/2) serve to determine the 809 
fate of target m6A-modified mRNA transcripts (prepared by author). 810 
Seeing that m6A modifications are dynamic, demethylation of m6A to adenosine (A) is catalysed by 811 
the m6A “erasers” (Jia et al., 2011).  Thus far, only two m6A demethylases have been identified, i.e., 812 
fat mass and obesity associated protein (FTO) and its homologue ALKBH5 (Jia et al., 2011, Zheng et 813 
al., 2013). Both proteins belong to the ALKB subfamily of Fe(II)/α-ketoglutarate-dependent 814 
dioxygenases which repair DNA alkylation damage by demethylating DNA and RNA nucleotides that 815 
have been alkylated (Fedeles et al., 2015). FTO has been shown to oxidatively demethylate m6A to A 816 
in a stepwise manner with N6-hydroxymethyladenosine (hm6A) and N6-formyladenosine (f6A) as 817 
intermediates (Fu et al., 2013). In contrast, ALKBH5 directly and oxidatively removes methyl marks 818 
with no detected intermediates (Zheng et al., 2013). FTO and ALKBH5 knockout and overexpression 819 
have been shown to increase and reduce m6A levels, respectively (Jia et al., 2011, Zheng et al., 2013). 820 
Both demethylases are tissue specific and have diverse intracellular localization, thus demethylation in 821 
some tissue may be facilitated solely by FTO or ALKBH5 (Zhang et al., 2019). 822 
 While writer and eraser proteins are responsible for installing and removing m6A marks, readers 823 
control the fate of m6A modified transcripts (Liao et al., 2018).  The m6A readers consist of the YT521-824 
B homology (YTH) domain family proteins: YTHDF1, YTHDF2, YTHDF3 and YHT domain 825 
containing proteins: YTHDC1 and YTHDC2, which preferentially recognize and bind to m6A sites and 826 




nuclear processes (Xiao et al., 2016) whereas cytoplasmic readers affect mRNA stability, translation 828 
and localization (Zaccara et al., 2019). The localization and function of all known YTH domain 829 
containing m6A readers are summarized in Table 2.1.  830 
Table 2.1: The localization and function of YTH domain containing m6A-readers 831 
m6A Reader Cellular Localization Effects of Binding to m6A RNA 
YTHDC1 Nucleus Affects splicing and export 
Preferably binds to ncRNA, may bind to mRNA 
YTHDC2 Nucleus and cytoplasm Implicated in mRNA degradation and initiation of 
translation 
YTHDF1 Cytoplasm Promotes translation 
YTHDF2 Cytoplasm Promotes degradation  
YTHDF3 Cytoplasm Promotes translation  
 832 
    2.2.4. NcRNA  833 
Although early studies have reported the occurrence of transcription in regions not coding for proteins, 834 
it is only recently that researchers have realized that while a vast majority of the genome is transcribed 835 
(62.1%); only 2-3% constitute of protein coding genes (Panzeri et al., 2016). Areas of the genome that 836 
do not encode for protein, are transcribed to ncRNA. Since ncRNA do not function in protein coding, 837 
it was long regarded that ncRNAs were “junk RNAs” or “transcriptional noise”. However, through the 838 
development of high-throughput technologies, this idea has been rejected as we now know that ncRNAs 839 
play a key role in regulating cellular events and gene expression (Kapranov et al., 2002, Kapranov et 840 
al., 2007). 841 
NcRNAs are classified based on their function into housekeeping ncRNAs and regulatory ncRNAs 842 
(Wei et al., 2017). Housekeeping ncRNAs include ribosomal RNAs (rRNAs), transfer RNAs (tRNAs), 843 
small nuclear RNAs (snRNAs) and small nucleolar RNAs (snoRNAs). They are usually short (~20-200 844 
nucleotides; nt), constitutively expressed and necessary for the maintenance of normal cellular functions 845 
and are involved in protein translation, splice regulation, RNA modifications as well as the transport 846 
and insertion of proteins into membranes (Morey and Avner, 2004). On the other hand, regulatory 847 
ncRNA consists of both short and long (22 nt to ∼100 kilobases) ncRNAs that are involved in regulating 848 
gene expression through various mechanisms (Table 2.2). Transcriptional silencing by ncRNA has been 849 
implicated in several diseases including cancer predisposition or status. Among the ever-increasing 850 
types of ncRNAs being deciphered, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are 851 




Table 2.2: Characteristics and functioning of regulatory ncRNAs. 853 
Type Symbol Source Size (nt) Function 




siRNA Long double 
stranded RNA 












lncRNA Multiple ˃200 Transcriptional activation 
Post-transcriptional regulation 
X chromosome inactivation 
Regulation of chromatin remodelling, 
imprinting, miRNA, methylation and 
RNA binding proteins 
 854 
    2.2.4.1. MiRNAs 855 
The discovery of miRNAs has revolutionized the field of molecular biology. In 1993, Lee and 856 
Whiteman identified the first miRNA, lin-4 in Caenorhabditis elegans (Lee et al., 1993, Wightman et 857 
al., 1993). Although miRNAs were identified in the early 1990s, it took almost 10 years until their 858 
fundamental roles in gene regulation were recognized (Lagos-Quintana et al., 2001). The field of 859 
miRNA research has since grown with over 17,000 miRNAs discovered to date in 142 species (Dwivedi 860 
et al., 2019). Today, we know that these small regulatory RNAs, play key roles in developmental and 861 
physiological processes in most eukaryotes and are even encoded by some viruses (Pfeffer et al., 2004, 862 
Vidigal and Ventura, 2015). However, aberrant expression of miRNAs is associated with many human 863 
diseases. Aberrant miRNA profiles have been observed in numerous cancers where they act as either 864 
tumour suppressors or oncogenes depending on their mRNA targets (Cui et al., 2019). Therefore, the 865 
evaluation of extracellular miRNAs profiles are used as potential biomarkers for a variety of diseases 866 






    2.2.4.1.1. Biogenesis  870 
The biogenesis of miRNAs begins with its transcription from the host gene (intragenic miRNAs) or 871 
independently of the host gene with the use of their own promoter (intergenic miRNAs). miRNAs can 872 
be transcribed individually as monocistronic transcripts or as one long transcript (polycistronic 873 
transcripts) called clusters which are later processed to individual mature miRNAs. The biogenesis of 874 
miRNAs can occur via the canonical or noncanonical pathways (O'Brien et al., 2018). 875 
Processing of miRNAs usually occurs via the canonical biogenesis pathway which involves two ordered 876 
endonucleolytic cleavages by RNAse III enzymes (Figure 2.8) (Davis and Hata, 2009). Most miRNAs 877 
are transcribed from DNA sequences by RNA polymerase II (RNAP II) as capped and polyadenylated 878 
primary miRNAs (pri-miRNA), which undergo processing by the microprocessor complex to form a 879 
single hairpin structure termed precursor miRNA (pre-miRNA) (Treiber et al., 2019). The 880 
microprocessor complex consists of DiGerorge Syndrome Critical Region 8 (DGCR8), an RNA binding 881 
protein that recognizes an N6-methyladenylated GGAC motif within the pri-miRNA and RNase III 882 
enzyme Drosha, which cleaves the pri-miRNA duplex.  Once pre-miRNA is generated, exportin-5 and 883 
Ran-GTP exports it to the cytoplasm where it undergoes cleavage by the RNase III enzyme, Dicer 884 
(O'Brien et al., 2018). Processing by Dicer removes the terminal loop giving rise to a double stranded 885 
22 nt product consisting of the mature miRNA guide strand and passenger strand. The double stranded 886 
miRNA product is transferred onto RNA binding proteins known as Argonaute (AGO) protein. The 887 
passenger strand is usually discarded whereas the guide strand is incorporated into the RNA-induced 888 
silencing complex (miRISC) and mediates mRNA degradation or translational inhibition. (Treiber et 889 
al., 2019).  890 
 891 




Biogenesis of miRNAs can also occur via several non-canonical pathways. Non-canonical pathways 893 
are generally classified into Drosha/DGCR8-independent pathway and Dicer-independent pathways. 894 
One class of Drosha/DGCR8-independent miRNAs are known as mitrons which originate from spliced 895 
introns and function as pre-miRNAs that do not require cleavage by Drosha/DGCR8 complex. They 896 
are immediately exported to the cytoplasm for Dicer processing (Treiber et al., 2019). On the other 897 
hand, Dicer-independent miRNAs are relatively rare. They are processed by Drosha from endogenous 898 
short hairpin RNA (shRNA) transcripts and are directly recognized by Ago proteins. Therefore, they 899 
are produced independently of Dicer (Dai et al., 2019). 900 
     2.2.4.1.2. Regulation of gene expression  901 
Generally, miRNAs guide miRISC to recognize a specific complementary seed sequence in the 3’UTR 902 
region of the target mRNA and downregulates gene expression by either translational repression or 903 
mRNA degradation (Wahid et al., 2010). miRNA binding sites have also been detected in other mRNA 904 
regions. miRNA binding to 5’ UTR and coding sequences have been reported to have silencing effects 905 
whereas binding within promoter regions induces transcription (Place et al., 2008). The mechanism of 906 
gene silencing by miRISC depends on the degree of complementarity between the miRNA and a 907 
specific sequence on the target mRNA known as the miRNA response element (MRE). A high degree 908 
of sequence complementarity enables AGO degradation of target mRNA (Jo et al., 2015). Other 909 
mechanisms such as deadenylation, decapping, and exonucleolytic digestion of mRNA are also 910 
involved in mRNA degradation (Wahid et al., 2010). However, most miRNA-MRE interactions are not 911 
entirely complementary and result in translational repression. The exact mechanism is not well 912 
understood but miRNAs are involved in either the inhibition of initiation or elongation stages of 913 
translation (Kong et al., 2008). 914 
    2.2.4.2. LncRNAs 915 
The first lncRNA, H19, was discovered in the late 1980s during studies investigating genomic 916 
imprinting (Jarroux et al., 2017). Since then tens of thousands of lncRNAs have been identified; 917 
however, less than 1% of loci identified lncRNA have been experimentally validated (Kopp and 918 
Mendell, 2018). lncRNAs share several characteristics with mRNA such as poly-adenylation, 5’-919 
capping and exon-intron splicing. Despite these similarities, lncRNAs tend to have fewer exons and 920 
lack open reading frames which prevent its translation (Wang et al., 2017a, DiStefano, 2018).  Although 921 
lncRNA lack protein coding abilities, they have a broad functional repertoire which include regulation 922 
of gene expression, embryonic development, imprinting, chromosomal dynamics, telomere biology, 923 
and immune responses (Amaral and Mattick, 2008, Ouyang et al., 2016, Liu et al., 2017, Oliva-Rico 924 
and Herrera, 2017). Due to its diverse role in regulating molecular pathways, dysregulation of lncRNA 925 




DiStefano, 2018). Therefore, significant research endeavours are being exercised to study the role of 927 
lncRNAs in biological processes, and to apply lncRNAs as biomarkers or therapeutic targets.  928 
 2.2.4.2.1. Biogenesis 929 
The synthesis of most lncRNA, like mRNA and miRNA, begins with its transcription by RNAP II. 930 
They can be transcribed from several different genomic loci and are classified accordingly (Figure 2.9 931 
and Table 2.3) (Khandelwal et al., 2015). Similar to protein coding regions, lncRNA promoters are 932 
enriched for active histone modifications (Quinn and Chang, 2016). Many lncRNA transcripts are not 933 
end products. To reach their mature forms, they undergo extensive co- and post-transcriptional 934 
processing which include 5’capping, 3’-polyadenylation, splicing and RNA editing (Dhanoa et al., 935 
2018). Some lncRNAs undergo alternative processing to distinguish them from other transcripts. For 936 
example, back-splicing of linear transcripts produces stable circular RNAs (circRNAs) consisting of 937 
non-sequential exon–exon junctions (Lasda and Parker, 2014).  938 
 939 
Figure 2.9. Classification of lncRNA based on the location in the genome (Choudhari et al., 2020). 940 
Table 2.3: Classification of lncRNA 941 
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the opposite strands of the 
pseudogene) 












     2.2.4.2.2. Functions 943 
Unlike miRNAs, the functioning of lncRNA cannot be inferred from its sequence or structure. The exact 944 
functioning and mechanism of these RNA molecules calls for extensive research; however, we do know 945 
that the dynamic functional repertoire of lncRNA includes gene silencing, cell cycle regulation, 946 
splicing, chromatin modifications, and differentiation and that lncRNA implement these functions by 947 
serving as signalling molecules, molecular decoys, guides or scaffolds (Wang and Chang, 2011, Dhanoa 948 
et al., 2018). 949 
The belief that some lncRNA act as signalling molecules stems from the finding that their transcription 950 
is tightly controlled and fluctuates in a cell specific manner and is dependent on diverse stimuli and 951 
biological events (Figure 2.9A). Signalling lncRNA serve as molecular indicators that reversibly 952 
regulate transcriptional and post-transcriptional processes in response to various stimuli (Wang and 953 
Chang, 2011). lincRNA-p21 promotes p21 transcription, thereby signalling the repression of p53-954 




molecular signal to regulate transcription in response to various stimuli. Thus, its production and 956 
presence can serve as an indicator of transcriptional activity (Huarte et al., 2010). 957 
Recent evidence suggests that like proteins, lncRNA are major players involved in various scaffolding 958 
complexes. lncRNAs can also serve as platforms upon which relevant molecular components may be 959 
assembled. lncRNA that act as scaffolds are complex and possess different domains that bind to multiple 960 
effectors concurrently to regulate gene expression. These effectors can achieve either transcriptional 961 
activation or repression in a time and space restricted manner (Figure 2.9B) (Wang and Chang, 2011). 962 
For example, the 5’-end of the lncRNA, HOX transcript antisense RNA (HOTAIR) binds to polycomb 963 
repressive complex 2 (PRC2) which methylate H3K27 while its 3’-end binds to LSD1 which results in 964 
H3K4 demethylation and subsequently gene repression (Tsai et al., 2010).  965 
lncRNA that act as decoys can regulate transcription in a positive and negative manner. Decoy lncRNAs 966 
mimic the target binding site of effector molecules on DNA. This prevents the effectors such as 967 
transcription factors and chromatin modifiers from gaining access to DNA (Figure 2.9C) (Khandelwal 968 
et al., 2015). The lncRNA, p21-associated ncRNA DNA damage activated (PANDA) binds and 969 
sequesters the transcription factor NF-YA to limit the expression of pro-apoptotic genes and promote 970 
cell survival in response to low levels of DNA damage (Hung et al., 2011).  971 
As molecular guides, lncRNAs bind to proteins and chaperones them to specific targets (Figure 2.9D). 972 
This activity can cause changes in gene expression either in cis (on neighbouring genes) or in trans 973 
(distantly located genes). For example, the lncRNA, Air recruits the histone methyltransferase, G9a and 974 






Figure 2.10. General mechanism by which lncRNA function. lncRNAs can act as (A) molecular 978 
signals, (B) dynamic scaffolds, (C) decoys and (D) guides (prepared by author).  979 
    2.2.4.3. Regulation of miRNA by lncRNAs 980 
As previously discussed, miRNAs sequester their target mRNA through binding of MRE to inhibit 981 
translation. lncRNA are able to compete with MRE for miRNA binding. These lncRNA are known as 982 
competing endogenous RNAs (ceRNAs) (Wang and Chang, 2011, Tay et al., 2014). They are able to 983 
mimic miRNA targets which results in the sequestering of miRNAs at their 3’ UTR. This reduces 984 
miRNA availability within cells and promotes the translation of their target mRNA (Figure 2.10) 985 
(Khandelwal et al., 2015). An example of a lncRNA that functions as a ceRNA is HOXA 11 antisense 986 
RNA (HOXA11‑AS). HOXA11-AS ceRNA abilities have been observed in various cancers. In non-987 
small-cell lung cancer, HOXA11-AS sequester miR-124 and miR-454, which promotes SP1 and 988 
STAT3 expression, respectively (Yu et al., 2017, Zhao et al., 2018). This, in turn, promotes 989 
proliferation, invasion and migration of cancer cells. In addition, HOXA11-AS targets miR-125a-5p, 990 
miR-130a, miR-140-5p, miR-146-5p, miR-214-3p, miR-215a-5p, miR-241-3p, miR-1297 in various 991 
cancers such as hepatocellular, gastric, renal, colorectal cancers and glioma (Wei et al., 2020). 992 
Furthermore, HOXA11-AS-miR-124 interactions are involved in fracture healing by inhibiting 993 
osteoblast proliferation and enhancing apoptosis (Wang et al., 2017b). 994 
 995 
Figure 2.11. Interaction between ncRNA and mRNA. (A) miRNA prevents translation by binding to 996 
mRNA. (B) lncRNA sequesters miRNA which allows translation to occur (prepared by author).  997 
    2.2.5. The role of epigenetics in Fusarium mycotoxin induced toxicities 998 
The molecular mechanisms by which Fusarium mycotoxins induces toxicity have been well 999 




modifications play an important role in Fusarium-induced toxicities (Huang et al., 2019a, Ghazi et al., 1001 
2020a).  1002 
It has been suggested that epigenetic modifications may be responsible for Zearalenone’s oestrogenic 1003 
effects. Zearalenone induces the expression of DNMTs and increases global levels of DNA methylation, 1004 
H3K4me3, H3K9me3 and H3K27me3. These changes have been associated with the disruption of 1005 
oocyte maturation and early embryonic development associated with zearalenone exposure (Han et al., 1006 
2015). Moreover, zearalenone induces CpG methylation of the LIM Homeobox 8 (LHX8) gene, 1007 
repressing its transcription. LXH8 is the transcription factor responsible for ovarian follicle formation, 1008 
therefore its downregulation disrupts primordial follicle formation (Zhang et al., 2017). Changes in 1009 
miRNA profiles have also been attributed to zearalenone’s effect on the reproductive system. 1010 
Zearalenone induces miR-7 expression via protein kinase C and p38. Zearalenone-induced 1011 
overexpression of miR-7 inhibits follicle stimulating hormone synthesis and secretion (He et al., 2018).  1012 
The trichothecenes, T-2 toxin and HT-2 have been shown to induce epigenetic modifications. HT-2 1013 
toxin-induced disruption of mouse oocyte maturation via increased global 5mC levels, and decreased 1014 
H3K9me2 and H3K27me3 levels (Zhu et al., 2016). T-2 toxin induces toxicity through proinflammatory 1015 
mechanisms. While T-2 toxin increased global DNA methylation, it demethylated the promoters of 1016 
proinflammatory cytokines which induced cytokine production which in turn induced hepatoxicity (Liu 1017 
et al., 2019). Furthermore T-2 toxin induces miR-155 expression which disrupts cytokine suppressors 1018 
(Guo et al., 2020).  1019 
Like zearalenone and trichothecenes, the effect of FB1 on DNA methylation and histone modifications 1020 
have been thoroughly researched while little research has focused on the role of miRNAs in FB1-1021 
induced toxicity. For instance, several studies have evaluated the effects of FB1 on DNA methylation. 1022 
Chuturgoon et al. (2014a) demonstrated that FB1 induces DNA hypomethylation in HepG2; however, 1023 
DNA hypermethylation occurred in rat C6 glioma cells and human Caco-2 cells (Mobio et al., 2000, 1024 
Kouadio et al., 2007). Furthermore, Demirel et al. (2015) found no significant changes in global DNA 1025 
methylation but hypermethylation occurred at the promoter regions of the tumor suppressors: c-myc, 1026 
p15, p16, and e-cadherin.  With regards to histone modification, FB1 induced H3K9me3 and acetylation 1027 
of H2NK12, H3K9 and H3K23 and repressed H4K20me3 (Pellanda et al., 2012, Sancak and Ozden, 1028 
2015, Gardner et al., 2016). The only study to investigate the effect of FB1 on miRNA found that FB1 1029 
downregulated miR-27b which subsequently increased cytochrome P450 1B1; which may play a role 1030 
in FB1-induced hepatic neoplastic transformation (Chuturgoon et al., 2014b). For a detailed discussion 1031 
on epigenetic mechanisms involved in FB1 toxicity, see Chapter 3: Molecular and Epigenetic 1032 
Mechanisms of FB1 Mediated Toxicity and Carcinogenesis and Detoxification Strategies; pages 86-89. 1033 
 Little is known on the relationship between Fusarium mycotoxins and lncRNA and RNA modifications 1034 




acid and DON alters the m6A transcriptome (Ghazi et al., 2020b, Zhengchang et al., 2020). While the 1036 
above-mentioned studies demonstrate that epigenetic modifications play an important role in 1037 
mycotoxin-induced toxicities, further research should be dedicated to ncRNA and RNA modifications. 1038 
Moreover, our understanding on the downstream effects of FB1-induced epigenetic changes is 1039 
insufficient. Further research should be done to assess the downstream effects of FB1-induced 1040 
epigenetic modifications. For instance, epigenetic mechanisms may exacerbate toxicity by 1041 
dysregulating response mechanism to the stress induced by FB1. Such stress response mechanisms 1042 
include DNA damage checkpoint signalling, Keap1/Nrf2 anti-oxidant responses and apoptosis as it well 1043 
established that FB1 induces DNA damage and oxidative stress.   1044 
     2.3. Cellular Response to stress 1045 
     2.3.1.The DNA damage response 1046 
The survival of organisms depends on the preservation of genetic information between cell lineages 1047 
during replication (Zhou and Elledge, 2000). However, DNA is highly susceptible to damage by 1048 
endogenous and exogenous agents and mistakes during replication can occur (Chatterjee and Walker, 1049 
2017). It is estimated that approximately 105 DNA lesions occur in each cell per day. These lesions 1050 
severely affect important genomic processes such as transcription and replication of damaged DNA 1051 
result in mutations that induce and propagate carcinogenesis (Giglia-Mari et al., 2011). The timely 1052 
clearance of genomic injuries is therefore, essential. Cells are equipped with a complex network of 1053 
DNA damage responses (DDR) which monitor the structure and integrity of the genome, co-ordinate 1054 
cell cycle arrest and initiate DNA repair (Zhou and Elledge, 2000).  1055 
DNA damage checkpoint signalling is a central orchestrator of the DDR network. Checkpoints stall cell 1056 
division so that effective DNA repair can occur (Dai and Grant, 2010). This signalling network consists 1057 
of sensors, transducers, mediators and effectors (Figure 2.11) (Zhou and Elledge, 2000). Sensors are 1058 
multiprotein complexes that detect aberrant DNA structures and initiate the signalling response. The 1059 
MRe11-Rad 50-Nbs1 (MRN) sensor complex detects double stranded DNA breaks and recruit’s ATM 1060 
to the DNA damage site, while Rad17 and Rad9-Rad1-Hus1/9-1-1 complex generally recognise single 1061 
strand breaks and localizes ATR to the lesion (Dai and Grant, 2010). ATR and ATM are proximal 1062 
transducers that have kinase activity. The activation of ATR and ATM phosphorylates and activates 1063 
mediators (such as 53BP1, MDC1, TopBP1, and claspin etc.) at DNA damage sites which in turn 1064 
activates the distal transducers: checkpoint kinase 1 (CHK1) and checkpoint kinase 2 (CHK2) (Dai and 1065 
Grant, 2010). Ultimately, ATR transduces signals to CHK1 whereas ATM transduces signals to CHK2. 1066 
Activated “distal transducers” phosphorylate, degrade or sequester “effectors” Cdc25s (e.g., Cdc25A, 1067 
B, and C), which in turn inhibit cyclin-dependent kinases (e.g., Cdk1/cdc2 and Cdk2) that are 1068 




This process prevents S-phase entry (G1/S-phase checkpoint), delay S-phase progression (S-phase 1070 
checkpoint), or halts mitotic entry (G2/M-phase checkpoint) (Dai and Grant, 2010). DNA repair is now 1071 
able to occur and the type of repair is dependent on the type of DNA damage that occurred (Chatterjee 1072 
and Walker, 2017). If the damage is irreversible CHK1 and CHK2 trigger p53-dependent or -1073 
independent apoptosis (Dai and Grant, 2010). 1074 
 1075 
Figure 2.12. DNA damage response network (prepared by author). 1076 
     2.3.1.1. CHK1 1077 
As a central regulator in DNA damage checkpoint signalling, the role of CHK1 is not limited to the 1078 
interphase of the cell cycle.  CHK1 enables spindle checkpoint which delays anaphase onset in cells 1079 
with mitotic spindle defects (Dai and Grant, 2010). CHK1 facilitates DNA damage-induced 1080 
transcriptional repression via the phosphorylation of threonine residues on histone 3 and loss of histone 1081 
acetylation (Patil et al., 2013). In addition to its regulation of p53, CHK1 suppresses caspase-3-1082 
dependent apoptosis and blocks caspase-2-dependent apoptotic responses. Furthermore, CHK1 1083 
mediates DNA repair by targeting repair kinases (e.g., DNA-PK) important for the repair double 1084 
stranded DNA breaks, homologous repair and Fanconi Anemia(FA)/BRCA-mediated DNA repair 1085 
pathway (Patil et al., 2013). 1086 
Diminished activity or expression of CHK1 abrogates its essential function and therefore it should be 1087 
tightly regulated. As discussed previously, CHK1 is activated via mediators in response to DNA damage 1088 
(Dai and Grant, 2010). Activation occurs via the phosphorylation of two conserved sites, serine-317 1089 




et al., 2013). One model suggests that the C-terminal domain of CHK1 interacts with its kinase domain 1091 
to mask the active site, and that the phosphorylation at serine-317 and serine-345 dissociates these two 1092 
domains leading to CHK1 activation (Chen et al., 2000). Phosphorylation of CHK1 can also have 1093 
inhibitory effects. Downregulation of the tumour suppressor, phosphatase and tensin homolog (PTEN), 1094 
inactivates CHK1 activity and promotes the accumulation of DNA damage due to its loss of control 1095 
over phosphatidylinositol 3‑kinase (PI3K)/protein kinase B (AKT) signalling. PI3K/AKT signalling 1096 
induces phosphorylation of the serine-280 residue of CHK1 which subsequently impairs CHK1 1097 
activation by DNA damage and promotes genomic instability (King et al., 2004, Puc et al., 2005). 1098 
     2.3.2. Keap1/Nrf2 anti-oxidant signalling 1099 
ROS are produced during normal physiological reactions and are involved in a number of signalling 1100 
pathways (Finkel, 2011). The rapid accumulation of ROS by dysfunctional endogenous or exogenous 1101 
sources overwhelms the antioxidant system of cells and oxidative stress ensues (Thannickal and 1102 
Fanburg, 2000). This results in cellular injury in the form of lipid peroxidation, protein carbonylation 1103 
and DNA damage and eventually, the development of cancer, neurodegeneration, and diabetes. It is, 1104 
therefore, necessary that cellular redox signalling is tightly controlled (Thannickal and Fanburg, 2000, 1105 
Finkel, 2011).  1106 
The Kelch-like ECH-associated protein 1 (Keap1)/ Nuclear factor erythroid 2-related factor 2 (Nrf2) 1107 
signalling pathway is the master regulator of cytoprotective responses to oxidative and electrophilic 1108 
stress. The key players are the redox sensitive transcription factor, Nrf2 and the cysteine rich repressor 1109 
protein Keap1 (Kansanen et al., 2013). In a redox balanced environment Keap1 interacts with the cullin-1110 
3 E3-ubiquitin ligase (Cul3) which serves as a platform for the ubiquitination and proteasomal 1111 
degradation of Nrf2 by 26S. (Baird and Yamamoto, 2020). On exposure to oxidative or xenobiotic 1112 
stress, excess ROS interacts with the redox sensitive cysteine residues on Keap1 resulting in 1113 
conformational changes to Keap1. The binding affinity between Nrf2 and Keap1 is reduced and the 1114 
ubiquitination system of Nrf2‐Cul3 is disrupted (Kansanen et al., 2013). The stabilized Nrf2 translocates 1115 
to the nucleus where it dimerizes with small maf proteins and subsequently binds to the anti-oxidant 1116 
response element (ARE) found on genes involved phase II and III detoxification, cellular regeneration, 1117 
xenobiotic metabolism, and ROS detoxification (antioxidants) (Figure 2.12) (Ray et al., 2012).  On 1118 
recovery of the redox balance, Nrf2 is dissociated from the ARE sequence. Keap1 enters into the 1119 





Figure 2.13. (A) Nrf2 promotes the transcription of antioxidants as well as phase II and III detoxifying 1122 
enzymes. (B) Oxidative stress triggers Nrf2 dissociation from Keap1 and induces transcription of ARE 1123 
genes (Arumugam et al., 2020). 1124 
Although the cytoprotective effects offered by Nrf2 is essential in cancer prevention, the constitutive 1125 
activation of Nrf2 promotes the development and chemoresistance of various cancers. Nrf2 1126 
hyperactivity incites new characteristics to cancer cells such as avoidance of apoptosis, excessive 1127 
proliferation and chemoresistance. There are several mechanisms by which Nrf2 signalling is activated 1128 
in cancer cells: i) somatic mutations in Keap1, Cul3 or Nrf2 disrupting Keap1/Nrf2 interactions, (ii) 1129 
Nrf2 transcription facilitated by the oncogenes Myc, K‐Ras, and B‐Raf mutation via mitogen‐activated 1130 
protein kinases (MAPKs), (iii) Keap1 competing proteins that disrupt Keap1/Nrf2 interactions and (iv) 1131 
epigenetic changes that amplify Nrf2 levels and reduce Keap1 (Wu et al., 2019). 1132 
    2.3.2.1. Epigenetic regulation of Keap1/Nrf2 1133 
Research into Epigenetic modifications involved in Keap1/Nrf2 regulation have only recently become 1134 
wide spread. Interest in the field was initiated by Guo et al. (2012) who observed that hypermethylation 1135 
of Keap1 promoters in lung cancer prevented SP1 binding and thus Keap1 transcription. Since then, 1136 
several studies have evaluated the effect of DNA methylation, histone modifications, and ncRNA on 1137 
Keap1 and Nrf2 (Cheng et al., 2016, Bhattacharjee and Dashwood, 2020). Table 2.4 summarizes the 1138 








Table 2.4: Epigenetic regulation of Keap-1 and Nrf2 1144 
Target Epigenetic 
modification 
Effect on target 
 
Reference 
Nrf2 DNA methylation Gene silencing (Khor et al., 2014) 
DNA demethylation Transcriptional activation (Kang et al., 2014) 
H3k27me3 Gene silencing (Li et al., 2014) 
miR-27a, 34, 93 153, 
142-5p, 144 




Promotes Nrf2 translation by 




Keap1 DNA methylation Gene silencing (Guo et al., 2012) 
DNA demethylation Transcriptional activation (Palsamy et al., 2012) 
H3K4me3 Transcriptional activation (Mishra et al., 2014) 
miR-7, 141, 200, 432, 
455, 873 
Degrades Keap1 mRNA (Bhattacharjee and 
Dashwood, 2020) 
lncRNA: MALAT Downregulates Keap1 (Bhattacharjee et al., 
2020) 
 1145 
The role of m6A modifications in Keap1/Nrf2 regulation have also been investigated but not as 1146 
thoroughly as other epigenetic modifications. One study showed that colistin-induced oxidative stress 1147 
was attenuated by the accumulation of m6A modifications on pri-miR-873. This promoted the 1148 
generation of mature miR-873-5p which in turn inhibited Keap1 expression and promoted Nrf2 1149 
antioxidant responses (Wang et al., 2019). Oxidative stress was also shown to elevate m6A-Nrf2 levels 1150 
in di-(2-ethylhexyl) phthalate (DEHP) exposed rats; however, the authors hypothesized that m6A-Nrf2 1151 
inhibits Nrf2 signalling (Zhao et al., 2020). 1152 
    2.3.3. Apoptosis 1153 
Apoptosis is a form of cell death that involves the controlled dismantling of intracellular components 1154 
while avoiding inflammation and damage to neighbouring tissue (McIlwain et al., 2013). It is a 1155 
homeostatic process that secures normal development and aging and controls cell populations by 1156 




mechanism that responds to various noxious stimuli and stresses such as DNA damage, cell cycle 1158 
dysfunctions and oncogene activation (Shen and White, 2001, Elmore, 2007). Considering that 1159 
apoptosis responds to both physiological and pathophysiological stimuli, aberrant regulation of 1160 
apoptosis can result in Alzheimer’s disease, rheumatoid arthritis, defects in embryonic development 1161 
and cancer.  1162 
Various morphological changes occur during apoptosis (Figure 2.13). The onset apoptosis is 1163 
characterized by cell shrinkage followed by pyknosis – chromatin condensation and nuclear shrinkage; 1164 
while the latter stages are typified by membrane blebbing, karyorrhexis (nuclear and DNA 1165 
fragmentation) and the containment of cell fragments into apoptotic bodies (Saraste and Pulkki, 2000, 1166 
Elmore, 2007). The apoptotic bodies are tightly packed with intact organelles and nuclear fragments of 1167 
the apoptotic cells. These bodies are subsequently engulfed by phagocytes such as macrophages and 1168 
parenchyma (Saraste and Pulkki, 2000). Degradation occurs within phagolysosomes; however, if 1169 
phagocytosis does not occur cells will undergo degradation which resembles necrosis (cell death via 1170 
rapid swelling and rupturing of cells) in a process called secondary necrosis (Saraste and Pulkki, 2000) 1171 
The containment of apoptotic cells in apoptotic bodies and rapid engulfment by phagocytes prevents 1172 
apoptotic cells from releasing their cellular content into the neighbouring tissue. This prevents the 1173 
occurrence of inflammation and necrosis to the surrounding tissue (Elmore, 2007).  1174 
 1175 
Figure 2.14. Morphological changes that occur during apoptosis (prepared by author).  1176 
These morphological hallmarks of apoptosis are dependent on highly complex and sophisticated 1177 
molecular and biochemical events necessary for the proper execution of apoptosis (Shen and White, 1178 




death receptor pathway (Elmore, 2007). Both pathways rely on the activation of a family of endo-1180 
proteases known as caspases (McIlwain et al., 2013).  1181 
     2.3.3.1. Caspase 1182 
Caspases are a family of evolutionary conserved cysteinyl aspartate proteinases that are responsible for 1183 
the morphological changes that occur during apoptosis. Presently, 14 caspases have been identified and 1184 
have been broadly classified according to their functions in apoptosis and inflammation (McIlwain et 1185 
al., 2013). All caspases consist of an active site cysteine and can cleave substrates after an aspartic acid 1186 
residue. Caspases are initially expressed as inert monomeric proenzymes or procaspases (McIlwain et 1187 
al., 2013). Procaspases consist of an N-terminal prodomain, p10 and p20 domains and activation of 1188 
caspases can occur via three general mechanisms: induced proximity, formation of a holoenzyme or 1189 
processing by an upstream caspase (Hengartner, 2000).  1190 
Induced proximity involves the aggregation of multiple procaspases resulting in their cross-activation; 1191 
while activation by holoenzyme is mediated by conformational changes rather than proteolytic 1192 
cleavage. These two mechanisms are involved in the activation of short domain initiator caspase-8 and 1193 
caspase-9, respectively (Hengartner, 2000). The activation of procaspase by an upstream caspase is 1194 
responsible for the activation of most caspases and is the most effective method for executioner caspase 1195 
(caspase-3, -6, and -7) activation. Initiator caspases cleave executioner procaspases at the aspartate 1196 
residue between the N-terminal prodomain and p20 and between p20 and p10 domains. These 1197 
executioner caspases are workhorses of the caspase family. Once activated, an executioner caspase can 1198 
activate other executioner procaspases (McIlwain et al., 2013). The activation of procaspases by mature 1199 
caspases is known as the caspase cascade and is an effective method of amplifying apoptotic signalling 1200 
resulting in rapid cell death (Elmore, 2007).  1201 
    2.3.3.2.. Pathways of apoptosis 1202 
Various pathways exist to execute apoptotic cell death. They are easily distinguished by their adaptors 1203 
and initiator caspases. However, there are two distinct yet converging pathways that play a key role in 1204 
the apoptotic program of mammals. These pathways are referred to as the intrinsic and extrinsic 1205 
pathways and both pathways rely on the activation of the caspase cascade to execute apoptosis.  1206 
    2.3.3.2.1. Intrinsic apoptotic program 1207 
The intrinsic pathway of apoptosis is also known as the mitochondrial pathway as it depends on factors 1208 
released from the mitochondria. It is activated by an array of cellular stresses such as toxins, free 1209 
radicals, radiation and viral factors or via developmental signals such as the absence of growth factors 1210 
or hormones that usually suppress death programs (Elmore, 2007). 1211 
These stimuli trigger the activation of the proapoptotic protein, Bim. Bim sequesters the antiapoptotic 1212 




mitochondria (Nakajima and Kuranaga, 2017). This results in the opening of the mitochondrial 1214 
permeability transition pore and the release of cytochrome c from the mitochondria (Elmore, 2007). 1215 
The release of cytochrome c into the cytosol promotes the formation of the signalling platform known 1216 
as the apoptosome (Nakajima and Kuranaga, 2017). The binding of cytochrome c and subsequent 1217 
binding of deoxyATP to apoptotic protease activating factor-1 (Apaf-1) induces conformational 1218 
changes that activate Apaf-1 (McIlwain et al., 2013). Seven activated Apaf-1 monomers oligomerize 1219 
and recruit procaspase-9. This complex is known as the apoptosome and its formation induces 1220 
conformational changes required for the activation of procaspase-9, which consequently activates 1221 
executioner caspases, resulting in apoptotic cell death (Figure 2.14) (McIlwain et al., 2013). 1222 
    2.3.3.2.2. Extrinsic Apoptotic program 1223 
The extrinsic pathway or death receptor pathway is triggered by extracellular signals in the form of 1224 
ligands binding to death receptors. Death receptors involved in apoptosis include tumor necrosis factor 1225 
(TNF) receptor 1 (TNFR1), TNF-related apoptosis inducing ligand receptor 1 (TRAILR1), TRAILR2, 1226 
Fas receptor (FasR) and death receptor 3 (DR3) (McIlwain et al., 2013). The binding of ligands to their 1227 
respective death receptors triggers the multimerization of death receptors and recruitment of adapter 1228 
proteins [TNFR-associated death domain (TRADD) and Fas-associated death domain (FADD)] via 1229 
their death domains, forming an intracellular death-inducing signalling complex known as DISC (Li 1230 
and Yuan, 2008). The N-terminal of procaspase-8 also contains a death domain, thus DISC can recruit 1231 
procaspase-8 to the complex. An accumulation of procaspase-8 results in its dimerization and activation 1232 
(McIlwain et al., 2013). Depending on the cell type, caspase-8 can directly cleave and activate 1233 
executioner caspases (type I cells) or activate intrinsic apoptosis (type II cells). To activate intrinsic 1234 
apoptosis, caspase-8 cleaves and activates the proapoptotic protein bid to tBid. tBid localizes to the 1235 





Figure 2.15. Intrinsic and extrinsic signalling of apoptosis (Glowacki et al., 2013). 1238 
    2.3.3.2.3. Execution of apoptosis 1239 
Both intrinsic and extrinsic apoptosis terminate with the activation of executioner caspases (Caspases-1240 
3, -6 and -7) (McIlwain et al., 2013). Executioner caspases execute apoptosis via the cleavage and 1241 
subsequent activation of substrates such as cytoplasmic endonucleases and proteases, which degrade 1242 
nuclear material and cytoskeletal proteins respectively (Elmore, 2007). The cleavage of various 1243 
substrates results in the morphological changes that occur in apoptotic cells. For example, caspase-1244 
activated deoxyribonuclease (CAD) is responsible for chromatin condensation and degradation of 1245 
chromosomal DNA during apoptosis. In proliferating cells, CAD is inactivated as it is complexed to the 1246 
inhibitor, ICAD. Caspase-3 cleaves ICAD thereby activating CAD and chromatin condensation (Enari 1247 
et al., 1998). 1248 
    2.3.3.3. p53 1249 
The tumour suppressor, p53 is widely regarded as the guardian of the genome and is the master regulator 1250 
of cellular stress responses (Anbarasan and Bourdon, 2019). p53 is responsible for maintaining tissue 1251 
homeostasis and responds to a variety of stress signals (such as DNA damage, nutrient deprivation and 1252 
oncogenic activation) by mediating surveillance of genome integrity, cell cycle checkpoint regulation, 1253 
DNA repair and apoptosis (Figure 2.15). Loss of p53 expression or function promotes checkpoint 1254 




2003). Unfortunately, almost 50% of cancers have been reported to contain a mutated or inactive p53 1256 
(Anbarasan and Bourdon, 2019). On the other hand, chronic activation of p53 is associated with 1257 
degenerative disorders such as arthritis and sclerosis. It is, therefore, imperative that expression and 1258 
activity of p53 should be tightly regulated (Fierabracci and Pellegrino, 2016). 1259 
 1260 
Figure 2.16. p53 responds to a plethora of stress signals and regulates diverse responses (Bieging and 1261 
Attardi, 2012). 1262 
As the central player in stress response, p53 needs to be tightly regulated. During homeostatic 1263 
conditions, p53 is maintained in an inactive state via proteasomal degradation by Mouse double minute 1264 
2 homolog (MDM2). Cellular stress signals inhibit MDM2 degradation of p53 or induce 1265 
posttranslational modifications (such as acetylation, proliferation) to p53. These changes allow for the 1266 
accumulation and activation of p53 (Aubrey et al., 2018). 1267 
p53 is also regulated via epigenetic mechanisms such as promoter methylation. At the transcriptional 1268 
level, hypermethylation of the p53 gene promoter prevents the binding of transcriptional machinery and 1269 
reduces p53 transcription. However, hypomethylation of the p53 promoter, enables the binding of 1270 
transcriptional machinery, and promotes p53 expression (Chmelarova et al., 2013). In vitro studies 1271 
using reporter gene constructs found that DNA methylation reduced p53 gene expression by 90% in 1272 
mice and by 85% in rats (Saldaña-Meyer and Recillas-Targa, 2011). In cancer cells tumour suppressor 1273 
genes are frequently silenced via epigenetic mechanisms Hypermethylation of the p53 gene promoter 1274 
and subsequent loss of p53 function was observed in the majority of patients with hepatocellular 1275 
carcinomas, 51.5% of patients with ovarian cancer, 40% of patients with chronic lymphocytic 1276 
leukaemia and 30% of patients with acute lymphoblastic leukaemia (Saldaña-Meyer and Recillas-1277 
Targa, 2011, Chmelarova et al., 2013). At the post-transcriptional level, p53 is regulated by a variety of 1278 
miRNAs. miRNAs such as miR-125a, miR-125b, miR-504, miRNA-25 are responsible for the 1279 




    2.3.3.3.1. p53-mediated apoptosis 1281 
p53 is a transcription factor that has the ability to transactivate genes involved in promoting apoptosis 1282 
(Aubrey et al., 2018). The Bcl2 family are important players in regulating apoptosis. The Bcl2 family 1283 
consists of both pro-apoptotic (Bax, Bak, Bim, Bid, Noxa, Puma and Bcl-xs) and anti-apoptotic (Bcl-2 1284 
and Bcl-xL) members that interact with one another to control apoptosis especially intrinsic apoptosis 1285 
(Shen and White, 2001). Such interaction includes the binding and inactivation of anti-apoptotic Bcl2 1286 
by proapoptotic Bim (Nakajima and Kuranaga, 2017). Genes encoding for several pro-apoptotic Bcl2 1287 
members (Bax, Bid, Puma, and Noxa) harbour consensus p53 response elements which allows for p53 1288 
binding. p53 binding to these sequences promotes the transcription of these apoptotic genes (Figure 1289 
2.16) (Fridman and Lowe, 2003).  1290 
Furthermore, p53 is also involved in the transactivation of apoptotic machinery involved in the extrinsic 1291 
pathway (DR5, FasR, Fas ligand) and the intrinsic pathway (Apaf-1) and executioner caspase-6. While 1292 
most studies focus on p53 transactivation function, p53 also suppresses transcription. The inhibitor of 1293 
apoptosis, survivin is one of the targets of p53-transrepression (Fridman and Lowe, 2003).   1294 
p53 can drive the expression of several other genes to inhibit survival pathways. For example, the 1295 
PI3K/AKT pathway is involved in the phosphorylation and subsequent activation of proteins that 1296 
promote survival. p53 induces PTEN expression which in turn negatively regulates PI3K/AKT and 1297 
survival signals (Fridman and Lowe, 2003). p53 induces miR-34 expression, which in turn represses 1298 
proapoptotic Bcl2 translation (Aubrey et al., 2018).  p53 may also regulate apoptosis via transcription-1299 
independent mechanisms, however it is not as established as transcriptional-dependent mechanisms. 1300 
p53 accumulates in the mitochondria in response to DNA damage and this redistribution may play a 1301 
role in cytochrome c release and caspase activation (Fridman and Lowe, 2003). p53 plays an essential; 1302 
role in co-ordinating apoptosis. While it may not induce apoptosis directly; it sensitizes cells so that 1303 
apoptosis can be triggered more easily in response to stimuli that activates cell death (Aubrey et al., 1304 





Figure 2.17. Mechanisms of p53-mediated apoptosis via Bcl2-regulated pathway (Aubrey et al., 2018). 1307 
Recently, changes to the epigenome have been associated with exposure to FB1. However current 1308 
research on the association between FB1 and epigenetic modifications are often conflicting. 1309 
Furthermore, the downstream effects of these FB1-induced epigenetic changes have not been adequately 1310 
assessed. It is well established that FB1 induces oxidative stress and DNA damage. FB1-induced 1311 
epigenetic changes may dysregulate responses (checkpoint signalling, Keap1/Nrf2 and apoptosis) to 1312 
oxidative stress and/or DNA damage. This may further exacerbate toxicity induced by FB1. Therefore, 1313 
this study aimed to determine the epigenetic effects of FB1 and the downstream implications of these 1314 
epigenetic alterations to stress response in human liver (HepG2) cells. 1315 
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Fumonisin B1 (FB1) is a natural contaminant of agricultural commodities that has displayed a myriad 2035 
of toxicities in animals and humans. Moreover, it is known to be a hepatorenal carcinogen in rodents 2036 
and may be associated with oesophageal and hepatocellular carcinomas in humans. The most well 2037 
elucidated mode of FB1-mediated toxicity is its disruption of sphingolipid metabolism; however, 2038 
enhanced oxidative stress, endoplasmic reticulum stress, autophagy and alterations in immune response 2039 
may also play a role in its toxicity and carcinogenicity. Alterations to the host epigenome may impact 2040 
on the toxic and carcinogenic response to FB1. Seeing that the contamination of FB1 in food poses a 2041 
considerable risk to human and animal health, a great deal of research has focused on new methods to 2042 
prevent and attenuate FB1-induced toxic consequences. The focus of the present review is on the 2043 
molecular and epigenetic interactions of FB1 as well as recent research involving FB1 detoxification.  2044 
Key Words 2045 
Fusarium, Mycotoxins, Fumonisin B1, Toxicity, Oxidative Stress, ER Stress, Immunotoxicity, 2046 
Epigenetics, Mycotoxin Detoxification 2047 
Introduction 2048 
Fumonisins are a ubiquitous group of secondary fungal metabolites (mycotoxins) which are produced 2049 
by the Fusarium genus, particularly F. verticillioides and F. Proliferatum (Rheeder et al., 2002). The 2050 
discovery of fumonisins were prompted by a field outbreak of equine leukoencephalomalacia (ELEM) 2051 
in 1970, South Africa. After extensive research it was concluded that the causative agent of this neurotic 2052 
disease was associated with mouldy maize that was predominately contaminated with F. verticillioides 2053 
(formally, F. moniliforme) (Kellerman et al., 1972). Almost a decade later, F. verticillioides 2054 
contaminated maize was found to be linked with the high incidence of oesophageal cancer in South 2055 
Africa’s former Transkei region, where maize is a dietary staple (Marasas et al., 1981). Experimental 2056 
studies also showed that F. verticillioides induced ELEM in horses as well as pulmonary oedema in 2057 
swine (Kriek et al., 1981a).  In rats, the fungi were found to be hepatotoxic, cardiotoxic and induced 2058 
primary hepatocellular carcinomas and cholangiocarcinoma (Kriek et al., 1981b, Marasas, 2001). 2059 
Several mycotoxins were identified to be metabolites of F. verticillioides, but the causative agent of 2060 
these incidents remained elusive until fumonisins were finally isolated and characterized in 1988 2061 
(Gelderblom et al., 1988b). 2062 
Since then, at least 28 fumonisins have been identified and grouped into one of four classes (A, B, C 2063 
and P) of which fumonisin B1 (FB1) is regarded as the most abundant and toxicologically relevant 2064 
homologue (Rheeder et al., 2002). FB1 persistently contaminates the food supply of both animals and 2065 
humans across the world. Maize and maize-based products are one of the most common foods infected 2066 
by FB1 (Lee and Ryu, 2017). It is also found in abundance in other cereals such as wheat, rice, oats, 2067 




including vine fruit (Varga et al., 2010), asparagus (Waskiewicz et al., 2010), beers (Piacentini et al., 2069 
2017), and milk (Gazzotti et al., 2009). FB1 contamination of crops can occur pre- and/or post-harvest, 2070 
making it difficult to control contamination. Factors favouring Fusarium growth and FB1 production 2071 
include heat stress, insect damage, and high humidity (Ferrigo et al., 2016). Furthermore, improper 2072 
storage conditions that are not moisture and temperature-controlled account for a large amount of FB1 2073 
contamination (Phokane et al., 2019). Due to regional climatic variations, the Americas have the highest 2074 
incidence of FB1 contamination (96%), followed by Africa and Asia (62%) (Lee and Ryu, 2017). 2075 
Moreover, the rise in average temperatures and humidity due to climate change may potentially give 2076 
rise to increased levels of FB1 in agricultural products. It is expected that additional regions may begin 2077 
to experience issues with FB1 contamination while countries with existing FB1 contamination may 2078 
expect higher levels in their crops (Magan et al., 2011). 2079 
Developed countries have set federal regulations to limit FB1 contamination of foods and feeds. For 2080 
example, the United States Food and Drug Administration set the maximum tolerable limit for FB1 in 2081 
maize products at 2 ppm while the European Union regulation of FB1 levels in maize is 1 ppm (Wild 2082 
and Gong, 2010). In 2000, the Scientific Committee on Food established a maximum daily intake of 2083 
0.2 mg/kg body weight (bw) based on no observed adverse effects in the liver and kidneys of rodents. 2084 
Later, the limit was expanded to include FB2 and FB3. The Joint FAO-WHO Expert Committee 2085 
(JECFA) has also declared that the provisional maximum tolerable intake of FB1 alone or in 2086 
combination with FB2 and FB3 should be 2 μg/kg bw/day (FOA/WHO, 2002), however, in developing 2087 
countries where maize is a dietary staple, intake far exceeds the recommended maximum daily limits. 2088 
FB1 intake can range from 2.87–8.14 µg/kg bw/day in Eastern Cape, South Africa (van der Westhuizen 2089 
et al., 2011); 3.5-15.6 µg/kg bw/day in Guatemala (Torres et al., 2007); 0.1-26 µg/kg bw/day in 2090 
Tanzanian children (Kimanya et al., 2009); and can reach as high as 10,541.6 µg/kg bw/day in Fusui, 2091 
China (Sun et al., 2011).  2092 
FB1 contamination is especially prominent in rural areas where subsistence farming is common 2093 
(Shephard et al., 2019). Most subsistence farmers do not have the resources to implement the same 2094 
agronomic practices seen in commercial settings. Lack of pest control and crop rotation, use of untreated 2095 
seeds from previous seasons, maize monoculture, poor sorting and inadequate storage conditions, and 2096 
general lack of mycotoxin awareness can exacerbate the incidence of fungal infection and FB1 2097 
production in crops (Mboya and Kolanisi, 2014, Alberts et al., 2019, Phokane et al., 2019). FB1-related 2098 
adverse health conditions are especially common in rural areas that depend on “homegrown” crops. 2099 
Areas along the Mexican-American borders have reported that maternal consumption of maize and 2100 
maize products contaminated with FB1 during gestation was related to an increased risk of their 2101 
offspring developing neural tube defects (NTD) such as spinal bifida and anencephaly with extremely 2102 
high exposure leading to foetal death (Hendricks, 1999, Missmer et al., 2006). In rural Tanzania, 2103 




et al., 2015, Chen et al., 2018). Outbreaks of acute toxicosis presenting with transient abdominal pain, 2105 
borborygmus, and diarrhoea were reported in South India after the consumption of bread made from 2106 
FB1-contaminated sorghum and corn (Reddy and Raghavender, 2008). In addition to the 1981 cohort, 2107 
several other epidemiological studies have demonstrated a close link between the high incidence of 2108 
oesophageal carcinomas and FB1 (Sydenham et al., 1990, Yoshizawa et al., 1994, Wang et al., 2000, 2109 
Qiu et al., 2001, Sun et al., 2007, Alizadeh et al., 2012). A Chinese cohort also found that FB1 may be 2110 
linked with a high incidence of hepatocellular carcinomas (Sun et al., 2007). While FB1 exposure is a 2111 
suspected contributing factor for carcinogenesis in humans; FB1 has both cancer initiating and 2112 
promoting effects in animal models (Table 3.1). The type of tumour present in these models are both 2113 
sex and species dependent. After evaluating published epidemiological studies and experimental models 2114 
that demonstrated a link between FB1 consumption and cancer occurrence, the International Agency for 2115 
Research on Cancer (IARC) concluded that there was enough evidence to classify FB1 as a class 2B 2116 
carcinogen (IARC, 2002).  2117 
The carcinogenic character of fumonisins is not fully understood; however, it has been hypothesized 2118 
that tumour development could be a result of FB1 mimicking genotoxic carcinogens by inducing toxicity 2119 
resulting in compensatory proliferation and survival (Ramljak et al., 2000). The primary mode in which 2120 
FB1 induces toxicity is through the disruption of sphingolipid metabolism which can trigger or 2121 
potentiate a host of toxic responses such as oxidative stress, endoplasmic reticulum (ER) stress, 2122 
autophagy, and alterations in immune responses. Furthermore, FB1 can mediate changes in the 2123 
epigenome, altering the expression of cancer-related genes (Chuturgoon et al., 2014b, Demirel et al., 2124 
2015). Therefore, this review focuses on the molecular and epigenetic modes of action involved in FB1 2125 
toxicity and carcinogenicity with emphasis on recent findings. Furthermore, we discuss new strategies 2126 
related to the detoxification of this harmful mycotoxin.  2127 
Table 3.1: Studies evaluating the development of neoplastic lesions in in vivo models exposed to 2128 
F. verticillioides and/or FB1 2129 
Model Target 
organ 




Liver In a life-long feeding experiment, BDIX rats were fed diets 
containing 4% culture of F. moniliforme. 80% of rats fed 
diets containing culture material developed hepatocellular 
carcinomas; while 63% developed ductular carcinomas. The 
incidence of both carcinomas increased with increased 
exposure time and the two distinctive tumours often 









Liver F344 rats were fed maize naturally contaminated with F. 
moniliforme (MRC 826) for 123 to 176 days. Three distinct 
lesions: neoplastic nodules, adenofibrosis and 
cholangiocarcinomas were observed in the liver of all rats in 






Liver The cancer-promoting activity of FB1 isolated from F. 
moniliforme (MRC 826) was evaluated. FB1 (0.1%) was 
incorporated into the diet of male rats where cancer was 
initiated with DEN or not for 4-weeks. There was a marked 
increase in the formation of GGT+ foci in both DEN-initiated 
and non-initiated groups. After 33 days, proliferation and 
fibrosis of bile ducts were also observed. 
(Gelderblom 




Liver Progression of lesions were assessed at 6, 12 and 24 months 
in male BD IX rats fed a corn-based diet containing 50 mg/kg 
of purified FB1 isolated from F. moniliforme (MRC 826). All 
FB1-fed rats developed regenerative nodules which 
manifested characteristics of preneoplastic nodules with 
93.3% developing cholangiofibrosis. All rats that survived to 
the terminal end of the study developed cirrhosis and 
hepatocellular carcinomas. Neoplasms metastasized in the 
heart and lung in 2 of the rats and in the kidney for one of 
them. 
(Gelderblom 




Liver Varying concentrations of FB1-containing diets (0-500 mg 
FB1/kg) were fed to DEN-initiated rats for 21 days. The 
number of GGT+ foci were increased in livers of rats fed 100 
mg/kg FB1 and greater. Marked increases in number and size 
of GSTP+ foci were present in livers fed 50 mg/kg and higher. 
The cancer-promoting activity of FB1 was associated with an 
inhibitory effect on PH-induced regenerative hepatocyte 
proliferation. 
(Gelderblom 









Doses of FB1 were administered to male (0-150 mg/kg diet) 
and female (0-80 mg/kg diet) mice as well as male (0-150 







Mice: Significant tumour incidence was only detected in 
female mice. At 50 ppm FB1, 40.4% of the mice had either 
adenomas or carcinomas, while at 80 ppm FB1, 86.7% of the 
mice had either adenomas or carcinomas. 
Rats: There was no significant FB1 tumour development in 
female F344 rats.  4.2% and 14.6% of male F344 fed 50 ppm 
and 150 ppm developed renal tubule adenomas while 10.4% 
and 20.8% fed 50 ppm and 150 ppm developed renal tubule 
carcinomas. Increased renal tubule apoptosis and hyperplasia 








Doses of FB1 were administered to male (0-150 ppm) and 
female (0-80 ppm) mice and male (0-150 ppm) and female 
(0-100 ppm) rats for 104 weeks.  
Mice: Hepatocellular adenomas were present in 36.3% (50 
ppm FB1) and 73.7% (80 ppm FB1) of female B6C3F1 mice. 
Hepatocellular carcinomas were also present in 22.5% (50 
ppm FB1) and 23% (80 ppm FB1) of female mice. Adenomas 
and carcinomas were also evident in the lower concentration 
but were not statistically significant. FB1 did not affect the 
incidence of neoplasia in male mice.  
Rats: There was no significant FB1 tumour development in 
female F344 rats, while their male counterparts groups dosed 
with higher concentrations of FB1 developed renal tubule 
carcinomas, with 38.1% of rats dosed with 150 ppm 










Male and female F344 rats and B6C3F1 mice were fed diets 
containing 0–150 ppm FB1 for 104 weeks.  
Mice: FB1 increased the incidence of hepatocellular 
adenomas and carcinomas with 88% of female mice fed 80 
ppm FB1 developing either lesion. Carcinomas were locally 
invasive and metastatic.  
Rats: Tumour incidence in female rats was unaffected by 
FB1; however, there was a dose-dependent rise in the 
incidence of renal tumours in males. Renal tubule adenomas 





or carcinomas were present in 26% and 38% of male rats fed 




Kidney A 2-year carcinogenicity bioassay was conducted on male 
and female F344 rats fed 0-150 ppm and 0-100 ppm FB1, 
respectively. Nephrotoxicity manifested in a dose-dependent 
manner. FB1 induced proximal tubule loss and sustained 
regeneration which is a risk factor for tumour development. 
In males, renal tubule tumours were observed at 100 (21%) 
and 150 (33%) ppm. Atypical tubule hyperplasia, a 
preneoplastic lesion were found in 8% and 19% of these 2 
groups. Tumour development in female rats was statistically 
insignificant. Furthermore, there was a correlation between 
proliferative lesions and nephrotoxicity. 





Liver The separate and combined effects of FB1 and AFB1 on the 
cancer initiation and promotion in hepatocarcinogenesis were 
evaluated in rats. There was a significant increase in the 
number of large GSTP+ lesions in AFB1 and FB1-treated rats 
subjected to PH promoting treatment. The induction of 
GSTP+ lesions was also significantly enhanced in rats treated 
either with AFB1 or FB1 without the 2-AAF/PH promoting 
stimuli. The underlying mechanism that resulted in the 
significant increase in the size of GSTP+ foci and nodules 
during the successive AFB1/FB1 treatment regimen could be 
ascribed to the potent cancer promoting potential of FB1. 
(Gelderblom 
et al., 2002) 
F344 
Rats 
Liver Male F344 mice were fed diets of AFB1 (150 µg/kg), FB1 
(250 mg/kg) or AFB1 and FB1 sequentially. GSTP+ 
preneoplastic hepatic foci were evaluated after 8 weeks. The 
number and mean size of GSTP+ foci were higher in the 
AFB1-only group than that of the FB1-only treated group. 
Sequential treatment markedly and significantly increased 
the number and size of GSTP+ foci by approximately 7-fold 
and 12-fold as compared to the AFB1 or FB1 only treatment 
groups, respectively. This indicates that there is a synergistic 





effect by sequential treatment on preneoplastic foci 
induction. 
DEN: Diethylnitrosamine; GGT+: gamma-glutamyl-transpeptidase-positive; GSTP+: glutathione-S-transferase-2130 
positive; PH: partial hepatectomy; AFB1: aflatoxin B1; 2-AAF/PH: 2-acetylaminofluorene/partial hepatecomy 2131 
Overview of literature search 2132 
We performed a systematic search of published research studies pertaining to the molecular and 2133 
epigenetic modes of FB1-induced toxicity and carcinogenicity. We further identified recent studies that 2134 
assessed strategies to reduce and detoxify FB1 contaminated foods and feeds. To identify eligible studies 2135 
for this review, the following academic databases and search engines were used: Pubmed, Google 2136 
scholar and Europe PMC. Keywords searched included a combination of fumonisin b1, toxicity, cancer, 2137 
sphingolipid metabolism, oxidative stress, endoplasmic reticulum stress, autophagy, immunotoxicity, 2138 
epigenetics, DNA methylation, histone modifications, microRNA, and detoxification. Moreover, we 2139 
used the bibliography of papers obtained using the above-mentioned database to identify additional 2140 
studies. Articles eligible for inclusion in this review included original research studies and review 2141 
papers that reported an association between FB1 exposure and negative health outcomes in animal 2142 
models as well as negative effects on cultures cells of human and animal origin. Additionally, we 2143 
included papers that assessed, developed or improved on methods (physical, chemical or biological) 2144 
that may possibly reduce FB1 contamination of food and feeds or attenuate the effects of FB1 exposure. 2145 
Only full text articles published in English in scientific journals with high peer-reviewing standards 2146 
were included. Following sourcing suitable literature, we assessed the quality of research based on the 2147 
scientific approach. This included assessing details of methods, validity and reliability of results and 2148 
accuracy of statistical analysis. The results from the relevant studies are included under the appropriate 2149 
sections which summarizes and analyses findings on the molecular and epigenetic aspects of FB1 2150 
toxicity and as well as recent methods used to detoxify FB1 contaminated foods and feed.  2151 
Disruption of Sphingolipid Metabolism 2152 
The disruption of sphingolipid metabolism has been identified as a key molecular mode of FB1 toxicity. 2153 
Sphingolipids are abundant in all eukaryotic cells as they form major components of membranes, 2154 
lipoproteins, and other lipid-rich structures. They are critical in maintaining the fluidity and structure 2155 
of membranes and modulating the activity of receptors (Merrill, Schmelz et al. 1997). Bio-active 2156 
sphingolipids [ceramide, sphinganine (Sa), sphingosine (So) and their phosphorylated counterparts] 2157 
also mediate vital signalling pathways such as differentiation, cell cycle progression, proliferation, and 2158 
apoptosis (Merrill, Sullards et al. 2001). Thus, disruptions in sphingolipid metabolism can trigger a 2159 
chain of events leading to FB1-altered cell growth, differentiation, and cell injury. 2160 
The initiation of de novo sphingolipid synthesis occurs in the ER where, serine palmitoyltransferase 2161 




ketosphinganine; which is subsequently reduced to Sa (Futerman and Riezman, 2005). Sa is either 2163 
phosphorylated by sphingosine kinase to form sphinganine-1-phosphate (Sa1p) or acylated to form 2164 
dihydroceramide by ceramide synthase (CS). Dihydroceramide is desaturated to ceramide, which can 2165 
then be converted to complex sphingolipids such as glycosphingolipids and sphingomyelin (Futerman 2166 
and Riezman, 2005). CS is also responsible for reacylation of So to ceramide via the sphingolipid 2167 
salvage pathway (Kitatani et al., 2008).  2168 
FB1 and its hydrolysed form (HFB1) bare close structural resemblance to the aminopentol backbone of 2169 
sphingoid bases (Figure 3.1). Due to this similarity, CS recognizes the amino group of FB1 and HFB1 2170 
as a substrate and allows it to compete with sphingoid bases for the same binding site (Wang et al., 2171 
1991). CS is also able to recognize the tricarboxylic acid side chain of FB1 as an analogue of fatty acyl 2172 
CoA and can thus obstruct the fatty acyl-CoA binding site of CS (Wang et al., 1991). In vitro assessment 2173 
showed that FB1 blocks the incorporation of serine into the So backbone, completely inhibits the 2174 
formation of sphingolipids and depletes the total mass of cellular sphingolipids (Wang et al., 1991, Yoo 2175 
et al., 1992, Merrill et al., 1993). Accumulation of free sphingoid bases and their phosphorylated 2176 
counterparts are evident in affected tissues, serum, and urine of animals exposed to contaminated feed 2177 
[summarised by Riley et al. (2001)].  2178 
 2179 
Figure 3.1. The molecular structure of FB1, HFB1 and the sphingoid bases, Sa and So. The aminopentol 2180 
backbone of FB1 and HFB1 bare close structural resemblance to that of Sa and So. 2181 
HFB1 is considered a weak disruptor of sphingolipid metabolism and is not as toxic in comparison to 2182 
FB1. The lack of tricarboxylic acid side chains reduces the potency of HFB1 as a ceramide synthase 2183 
inhibitor by almost 10-fold (Howard et al., 2002, Collins et al., 2006, Hahn et al., 2015, Harrer et al., 2184 
2015). Rats fed hydrolysed Fusarium culture material containing hydrolysed fumonisins but not FB1 2185 




et al., 1993, Voss et al., 1996). In contrast, studies on pregnant rats have found no evidence of tissue 2187 
lesions or changes in sphingoid bases (Collins et al., 2006); while studies in female mice fed HFB1 2188 
found no signs of hepatic lesions but altered sphingolipid metabolism was observed (Howard et al., 2189 
2002).  A recent study found that exposure to HFB1 or partially hydrolysed FB1 (PHFB1) did not affect 2190 
Sa/So ratios and slightly increased the number of lesions observed in the kidney of exposed rats; while 2191 
a significant increase in Sa/So ratios and number of lesions were observed in FB1 exposed rats (Hahn 2192 
et al., 2015). Regardless, HFB1 can undergo acylation by CS to form cytotoxic N-acylated HFB1 2193 
metabolites (Cn-HFB1). The type of metabolite produced is dependent on the isoform of CS and the acyl 2194 
CoA chain used (Seiferlein et al., 2007). Humpf et al. (1998) found that the N-acyl derivative, N-2195 
palmitoyl-HFB1 (C16-HFB1) was only half as effective as FB1 in inhibiting CS but caused significantly 2196 
greater accumulation of Sa and toxicity in human colonic (HT-29) cells.  Seiferlein et al. (2007) also 2197 
investigated the impact N-acyl-HFB1 derivatives; incubation of rat liver microsomes with HFB1 and 2198 
either nervonoyl-CoA or palmitoyl-CoA resulted in the formation of N-nervonoyl-HFB1 (C24:1-HFB1) 2199 
and N-palmitoyl-HFB1 (C16-HFB1), respectively. In vivo assessment of these derivatives in HT-29 cells 2200 
were undertaken to determine toxicity and its ability to inhibit CS. There was a 50% reduction in cell 2201 
viability after a 24-hour treatment with 25 µM of C24:1-HFB1 and C16-HFB1. These results suggest 2202 
that the N-acylated metabolites are more potent than FB1 and HFB1 in HT-29 cells (Schmelz et al., 2203 
1998, Seiferlein et al., 2007). Furthermore, just 1 µM of C24:1-HFB1 and C16-HFB1 inhibited CS 2204 
activity by 30%, while up to 80% inhibition was observed at 10 µM (Seiferlein et al., 2007). An in vitro 2205 
assessment showed that the most prevalent metabolites were the HFB1-acyl compounds containing 2206 
long-chain fatty acids (C24, C24:1, C22 and C20) in rats dosed with HFB1 (52, 115 and 230 µg/day for 2207 
5 days); however, gross and microscopic examinations of the liver and kidneys of these animals found 2208 
no treatment-related alterations (Seiferlein et al., 2007). It has long been regarded that FB1 is unable to 2209 
undergo N-acylation due to its tricarboxylic acid side chains; however, N-acyl-FB1 metabolites were 2210 
recently discovered. Human fibroblasts, hepatoma (Hep3B), and embryonic kidney (HEK293) cells 2211 
were treated with 20 µM of either FB1 or HFB1 for 24 hours; subsequently FB1 metabolites were then 2212 
quantified by HPLC-ESI-MS/MS. Similar to HFB1, the N-acylation of FB1 corresponded to the acyl 2213 
chain specificity of each of the CS isoforms and the N-acyl-FB1 metabolites were significantly more 2214 
cytotoxic than FB1 in cell culture (Harrer et al., 2013). The in vivo formation of N-acyl-FB1 were tissue 2215 
specific and depended on the dominant CS isoform. C16 derivatives were dominant in the kidney and 2216 
C24 derivatives were more prevalent in the liver (Harrer et al., 2015). However, further investigation on 2217 
N-acyl-FB1 toxicity in vivo should be undertaken.  2218 
Computational modelling has revealed that FB1 disruption of sphingolipids goes beyond inhibition of 2219 
CS. While ceramide synthesis occurs in the ER, the formation of the complex sphingolipid - 2220 
sphingomyelin occurs in the Golgi apparatus (Futerman and Riezman, 2005). Ceramide transport 2221 




steroidogenic acute regulatory protein-related lipid transfer (START) domain (Hanada et al., 2003). 2223 
Through docking simulations, Dellafiora et al. (2018) demonstrated that N-acyl derivatives of HFB1 2224 
might fit the START binding site depending on the fatty acid chain length. N-capryl- and N-palmitoyl-2225 
HFB1 might compete with ceramides for CERT-dependent ER-to-Golgi transport, although 2226 
polar/hydrophobic mismatch may limit binding into the START pocket. Nevertheless, disruptions to 2227 
CERT mediated ceramide transport may be a contributing factor in reduced sphingomyelin synthesis 2228 
that is observed post FB1 exposure (He et al., 2006). Dellafiora et al. (2018) also demonstrated that 2229 
HFB1 was able to fit the enzyme pocket of sphingosine kinase 1 (SPK1), the enzyme responsible for 2230 
the conversion of So to sphingosine-1-phosphate (So1P) (Maceyka et al., 2002). The calculated fit of 2231 
HFB1 was similar to that calculated for known SPK1 inhibitors. This stimulation contradicted work 2232 
done by He et al. (2006) and collaborators who observed an increase in SPK1 activity, and several other 2233 
studies have demonstrated the accumulation of So1p and Sa1p during FB1 exposure (Gelineau-van 2234 
Waes et al., 2012, Riley et al., 2015a, Riley et al., 2015b, Gardner et al., 2016).  2235 
FB1 not only induces the accumulation of Sa, So and its phosphorylated counterparts, but also results 2236 
in the accumulation of 1-deoxysphinganine (1-deoxySa). 1-deoxySa is formed when SPT utilizes 2237 
alanine instead of serine in the initial steps of sphingolipid synthesis. In vivo and in vitro exposure to 2238 
FB1 results in the accumulation of this atypical sphingoid base. In vitro experimentation also revealed 2239 
that the cytotoxicity of 1-deoxySa was greater than or equal to Sa (Zitomer et al., 2009). 1-DeoxySa 2240 
can also undergo acylation by CS; however, these acylated derivates are unable to produce complex 2241 
sphingolipids and function as membrane disruptors (Jiménez-Rojo et al., 2014). In summary, the 2242 
inhibition of CS by FB1 and HFB1 results in: 1. reduced levels of dihydroceramide, ceramide, and 2243 
complex sphingolipids; 2. accumulation of sphingoid bases and phosphorylated sphingoid bases; 3. 2244 
elevation in 1-deoxySa bases; and 4. the accumulation of cytotoxic N-acylated HFB1/FB1 metabolites 2245 
(Figure 3.2). These changes result in several toxicologically relevant perturbations such as ER stress, 2246 
accumulation of ROS, altered mitochondrial and immune functioning, and disruption to developmental 2247 
regulation (Riley and Merrill, 2019). Furthermore, FB1-induced alterations in sphingolipid signalling 2248 
pathways will lead to altered rates of cell death and regeneration, which may play a major role in FB1-2249 
mediated tumorigenesis via continuous compensatory regeneration of cells as a response to the 2250 





Figure 3.2. An overview of the effect of FB1 and its metabolites on sphingolipid metabolism. A) 2253 
Sphingolipid biosynthesis begins in the ER, where serine and palmitoyl-CoA are incorporated into 3-2254 
ketosphinganine before sphinganine (Sa), followed by acylation to dihydroceramides by ceramide 2255 
synthase (CS). Likewise, 1-deoxysphinganine (1-deoxy-Sa) is made from alanine (not shown). 2256 
Dihydroceramide is desaturated to ceramide and subsequently incorporated into complex sphingolipids. 2257 
The formation of some complex sphingolipids such as sphingomyelin occurs in the golgi apparatus and 2258 
requires ceramide transport protein (CERT) mediated trafficking of ceramide. Sphingolipid degradation 2259 
occurs to release Sphingosine (So) and is recycled via CS phosphorylated by sphingosine kinase (SPK1) 2260 
to sphingosine-1-phosphate (So1p). SPK1 can also phosphorylate Sa to sphinganine-1-phosphate 2261 
(Sa1p). FB1 and/or its metabolites disrupts sphingolipid metabolism by inhibiting CS and CERT, 2262 
altering levels of sphingolipid metabolites. The metabolites with the blue arrow are generally elevated 2263 
when CS is inhibited by FB1 while the metabolites with the red arrow are reduced. B) FB1, HFB1 and 2264 
deoxy-1Sa act as substrates for CS, releasing cytotoxic N-acylated metabolites.  2265 
Oxidative Stress 2266 
Reactive oxygen species (ROS) are radical and nonradical derivatives of oxygen; formed predominantly 2267 
during normal aerobic respiration (Andreyev et al., 2005). Low basal levels of ROS mediate several 2268 
biological processes such as cell proliferation, apoptosis, cell cycle, phosphorylation of proteins, 2269 
activation of transcription factors and immune regulation (Pizzino et al., 2017). Contrarily, excessive 2270 
ROS levels and a diminished capacity of cells to detoxify excess ROS results in oxidative stress 2271 
(Phaniendra et al., 2015). This disturbance in redox homeostasis inflicts damage to macromolecules and 2272 
can trigger the onset or progression of diseases such as cancer, diabetes, metabolic disorders, 2273 




Mitochondria metabolize carbohydrates and fatty acids via the electron transport chain (ETC) to 2275 
produce ATP. During this process, unpaired electrons leak into the mitochondrial matrix, where it 2276 
reduces oxygen to form ROS (Ma, 2013). Unwarranted production of ROS from the ETC can be 2277 
stimulated by several factors, such as the inhibition of complexes of the ETC (Bratic and Larsson, 2278 
2013). Domijan and Abramov (2011) have reported that FB1 inhibits complex I of the ETC. FB1 2279 
inhibited state 4 respiration in the presence of substrates for complex I. This resulted in the enhanced 2280 
generation of mitochondrial ROS and subsequent mitochondrial depolarization. The activation of 2281 
cytochrome P450 (CYP450) enzymes by FB1 may also be a driving force in ROS production as seen in 2282 
spleen mononuclear cells of Wistar rats and colonic tissue of ICR mice (Mary et al., 2012, Kim et al., 2283 
2018). Several other studies reported elevated levels of ROS after FB1 exposure in rodent GT1-7 2284 
hypothalamic cells, C6 glioblastoma, and spleen mononuclear cells as well as in human fibroblast, U-2285 
118MG glioblastoma, and HepG2 hepatocellular carcinoma cells (Galvano et al., 2002, Stockmann-2286 
Juvala et al., 2004a, Mary et al., 2012, Arumugam et al., 2019); with only one study showing that low 2287 
doses of FB1 had the opposite effect on ROS levels in human oesophageal carcinoma cells (SNO) (Khan 2288 
et al., 2018).  2289 
A major consequence of ROS overproduction is oxidative injury to macromolecules and organelles 2290 
(Phaniendra et al., 2015). Besides disrupting sphingolipid metabolism, FB1 can indirectly disrupt lipid 2291 
homeostasis through the oxidative degradation of lipids. Lipid peroxidation results in the formation of 2292 
lipid peroxyl radicals that can accelerate the peroxidation of other unsaturated fatty acid moieties, 2293 
disrupt membrane receptor signalling as well as membrane permeability (Ayala et al., 2014). 2294 
Malondialdehyde (MDA), is a cytotoxic and tumorigenic by-product of lipid peroxidation that is often 2295 
used as a biomarker in determining oxidative stress (Ayala et al., 2014). Varying concentrations and 2296 
treatment periods showed that FB1 is a potent inducer of lipid peroxidation and elevates MDA levels 2297 
(Abado-Becognee et al., 1998, Mobio et al., 2003, Stockmann-Juvala et al., 2004b, Stockmann-Juvala 2298 
et al., 2004a, Kouadio et al., 2005, Domijan et al., 2007a, Domijan et al., 2008, Theumer et al., 2010, 2299 
Domijan and Abramov, 2011, Mary et al., 2012, Minervini et al., 2014, Hassan et al., 2015, Arumugam 2300 
et al., 2019). Interestingly, SNO cells were more resistant to lipid peroxidation when exposed to low 2301 
doses of FB1 (Khan et al., 2018). 2302 
A strong correlation between elevated ROS levels and structural damage to proteins in the form of 2303 
protein carbonyls have also been made in the presence of FB1 (Domijan et al., 2007a, Domijan et al., 2304 
2007b, Mary et al., 2012, Arumugam et al., 2019). HepG2 cells were extremely sensitive to FB1 as 2305 
indicated by the 11.9-fold increase in protein carbonyls (Arumugam et al., 2019). The carbonylation of 2306 
proteins alters polypeptide confirmation which can impair protein functioning. This may have various 2307 
downstream consequences such as disrupting signalling pathways, modifying enzyme activity, and 2308 
impairing other protein functions including binding of transcription factors to DNA (Gonos et al., 2018). 2309 




carbonylated proteins. Thus, protein carbonylation can result in cellular dysfunction and eventually 2311 
contribute to the aetiology and progression of disease states (Dalle-Donne et al., 2006). 2312 
The threat of oxidative damage is particularly significant to nucleic acids. Elevated levels of ROS can 2313 
induce strand breaks, protein-DNA crosslinking and has mutagenic potential (Loft et al., 2008).  Several 2314 
studies have demonstrated the genotoxic potential of FB1 in humans and animals. With the use of the 2315 
micronuclei test, Ehrlich et al. (2002), Theumer et al. (2010) and Karuna and Rao (2013) assessed 2316 
genotoxic potential of FB1. Micronuclei are formed when there are breakages in chromosomes or when 2317 
spindle assembly is disturbed. A dose-dependent formation of micronuclei occurred in FB1-exposed 2318 
HepG2 cells (Ehrlich et al., 2002) and Wistar rats (Theumer et al., 2010). Conversely, FB1 failed to 2319 
induce micronuclei in BALB/C mice (Karuna and Rao, 2013). DNA strand breaks and fragmentation 2320 
were studied in vivo and in vitro. These studies found that DNA fragmentation and strand breaks 2321 
occurred as a consequence of FB1-induced oxidative stress (Atroshi et al., 1999, Mobio et al., 2003, 2322 
Stockmann-Juvala et al., 2004b, Theumer et al., 2010, Hassan et al., 2015). 8-hydroxy-deoxyguanosine 2323 
(8-OHdG) is a predominant oxidative DNA lesion, and thus widely used as a critical biomarker for 2324 
oxidative stress and carcinogenesis (Valavanidis et al., 2009). FB1-mediated the oxidation of guanine 2325 
in both in vivo and in vitro studies (Mobio et al., 2003, Mary et al., 2012, Arumugam et al., 2020). Only 2326 
one study found that DNA damage occurred independent of ROS levels (Galvano et al., 2002) 2327 
The detoxification capacity of cells is also affected by FB1-induced ROS. Kelch-like ECH-associated 2328 
protein 1 (Keap1)/Nuclear factor erythroid 2-related factor 2 (Nrf2) signalling pathway is activated in 2329 
response to excess ROS production. Antioxidant defence depends on the disassociation of the 2330 
antioxidant transcription factor, Nrf2, from Keap1 degradation. Surplus ROS alters Keap1 conformation 2331 
and activates phosphorylation pathways which in turn phosphorylate Nrf2. These changes trigger the 2332 
dissociation of Nrf2 from Keap1 degradation and promotes anti-oxidant transcription (Huang et al., 2333 
2002, Nguyen et al., 2009).  In response to FB1-induced ROS, HepG2 cells significantly upregulate 2334 
phosphorylation of Nrf2 leading to the transcription of major antioxidants: superoxide dismutase 2 2335 
(SOD2), catalase (CAT), and glutathione peroxidase (GPx) (Arumugam et al., 2019). Nrf2 was also 2336 
activated in SNO cells but antioxidant expression did not correspond (Khan et al., 2018). Furthermore, 2337 
FB1 reduced antioxidant status in BALB/C mice, Wistar rats and bovine peripheral blood mononuclear 2338 
cells (PBMC) exposed to FB1 (Domijan et al., 2007a, Bernabucci et al., 2011, Abbès et al., 2016). 2339 
However, subchronic exposure of Wistar rats with FB1 boosted SOD2 and CAT activity (Theumer et 2340 
al., 2010). The use of antioxidants is being investigated as a method to reduce FB1 toxicity. Antioxidants 2341 
such as N-acetylcysteine, coenzyme Q10, L-carnitine, vitamin E (α-tocopherol) and selenium were 2342 
shown to attenuate FB1-mediated oxidative stress and toxicity (Abel and Gelderblom, 1998, Atroshi et 2343 
al., 1999, Zhang et al., 2018). In summary, FB1 promotes ROS generation and alters antioxidant status, 2344 
which results in oxidative injury to cells (Figure 3.3). The use of antioxidants may be a promising 2345 





Figure 3.3. FB1 disrupts redox homeostasis. High levels of ROS are generated through the activation 2348 
of cytochrome P450 enzymes and inhibition of the electron transport chain (ETC) by FB1. Reduced 2349 
capacity of intracellular antioxidants to detoxify ROS leads to oxidative injury to lipids, protein and 2350 
DNA. The use of dietary antioxidants may normalize ROS levels. 2351 
Endoplasmic Reticulum Stress and Autophagy 2352 
The role of the ER is not exclusive to sphingolipid synthesis. It is a highly dynamic organelle 2353 
responsible for protein folding, free calcium storage, carbohydrate metabolism, synthesis of other lipids 2354 
and assembly of lipid bilayers (Koch, 1990, Stevens and Argon, 1999, Hebert and Molinari, 2007, Bravo 2355 
et al., 2013, Schwarz and Blower, 2016, Jacquemyn et al., 2017). The ER also has tissue-specific 2356 
functioning; liver ER contain cytochrome P450 enzymes that can metabolize and detoxify hydrophobic 2357 
drugs and carcinogens (Kwon et al., 2020); whereas in the muscle, specialized ER (sarcoplasmic 2358 
reticulum) regulate calcium flux to execute muscle contraction and relaxation (Guerrero-Hernandez et 2359 
al., 2010). Despite its dynamic role, the ER is sensitive to a multitude of intracellular and 2360 
microenvironmental changes. Cellular stressors such as imbalances in redox and calcium homeostasis 2361 
or defects in lipid metabolism or protein folding can cause unfolded or misfolded proteins to accumulate 2362 
in the ER. This phenomenon is known as ER stress (Senft and Ronai, 2015). The accumulation of 2363 
damaged proteins in the ER can lead to irreversible damage to cellular functioning and pose a threat to 2364 
cell survival. Fortunately, eukaryotes have developed several signalling mechanisms to sense and 2365 
ameliorate the effects of ER stress and restore ER homeostasis and functioning (Bravo et al., 2013). 2366 
Principal pathways involved in this response include the unfolded protein response (UPR), ER-2367 




pathways work in concert to determine whether cells re-establish ER homeostasis or activate cell death 2369 
mechanisms (Senft and Ronai, 2015). 2370 
In unstressed conditions, the master regulator – binding immunoglobin protein (GRP78) sequesters and 2371 
maintains UPR sensors in an inactive state. During UPR, the ER lumen binds to GRP78, releasing UPR 2372 
sensors. Together, these sensors [protein kinase RNA-like endoplasmic reticulum kinase (PERK), 2373 
activating transcription factor 6 (ATF6) and inositol-requiring protein 1 (IRE1α)] and their respective 2374 
transducers [activating transcription factor 4 (ATF4), cleaved ATF6, and X-Box Binding Protein 1 2375 
(XBP1)] suppress protein translation and folding, facilitate ERAD to degrade misfolded proteins and 2376 
mediate cell death and survival (Chakrabarti et al., 2011, Senft and Ronai, 2015). ER stress is also a 2377 
potent trigger for autophagy, a self-degradative process that has both pro-survival and pro-apoptotic 2378 
functioning (Yorimitsu et al., 2006, Glick et al., 2010). Both UPR signalling and autophagy are 2379 
interconnected with the 3 canonical arms of UPR regulating autophagy during ER stress (Kouroku et 2380 
al., 2007, Margariti et al., 2013, Li et al., 2014, Kabir et al., 2018).  2381 
Several in vivo and in vitro investigations have revealed that FB1 induces ER stress through the 2382 
disruption of sphingolipid metabolism and subsequent accumulation of sphingoid bases and 2383 
intracellular ROS (Yin et al., 2016, Singh and Chul, 2017, Kim et al., 2018, Liu et al., 2020, Yu et al., 2384 
2020). Autophagy was also observed in these studies; however, the activation and role of autophagy 2385 
differed. FB1-induced autophagy was first observed in MARC145 green monkey kidney cells. Yin et 2386 
al. (2016) showed a dose-dependent increase in the phosphorylation and activation of ER stress markers 2387 
[IRE1α, eIF2AK2 and eIF2S1] after exposure to FB1 for 48 hours. IRE1α mediated mitogen-activated 2388 
protein kinase 8/9/10 (MAPK8/9/10) autophagy in response to ER stress as numerous autophagic 2389 
vacuoles and increased LC3 I/LC3 II conversion was observed. Inhibition of IRE1α via RNA 2390 
interference or chemical inhibition attenuated MAPK activity, LC3 conversion as well as autophagy 2391 
confirming the role of IRE1α/MAPK8/9/10 in FB1-mediated autophagy (Yin et al., 2016). 2392 
In colon tissue of male mice, both IRE1α and PERK levels were upregulated after exposure to 2.5 mg/kg 2393 
bw FB1 for 24 to 96 hours. Rather than MAPK8//9/10 activation, IRE1α activated JNK, which led to 2394 
the subsequent elevation in autophagy markers (beclin, ATG5, ATG7) and LC3 I conversion in all FB1 2395 
treated mice (Kim et al., 2018). Most recently, Yu et al. (2020) found that human gastro-intestinal 2396 
epithelial (GES-1) cells were also sensitive to FB1-mediated ER stress autophagy via the PERK/CHOP 2397 
pathway. All 3 of these studies reported that pro-death mediated autophagy and apoptosis occurred in 2398 
response to FB1 (Yin et al., 2016, Kim et al., 2018, Yu et al., 2020). With the use of the SPT inhibitor, 2399 
myriocin in the presence of FB1, levels of free sphingoid bases diminished which in turn reduced ER 2400 
stress biomarkers and abolished FB1-mediated autophagy apoptosis (Yin et al., 2016, Yu et al., 2020). 2401 
This data strongly suggests that disruptions in sphingolipid metabolism is an essential event for FB1 to 2402 




However, in vitro and in vivo assessment by Singh and Chul (2017) and Liu et al. (2020) proved that 2404 
FB1 mediated autophagy is a pro-survival mechanism in the liver. ER stress activated PKC, PERK and 2405 
JNK, which lead to the activation of autophagy related gene 5 (ATG5), ATG7, and LC3 conversion. 2406 
Mammalian target of rapamycin (mTOR) signalling was suppressed resulting in the dissociation of pro-2407 
autophagic Beclin from B-cell lymphoma 2 (Bcl2). Both research groups found that FB1 mediated ER 2408 
stress activated PERK and IRE1α but concluded the main mechanism of autophagy was facilitated via 2409 
the IRE1α/JNK pathway. The pre-treatment of HepG2 cells with the autophagy inhibitor 3-2410 
methyladenine (3-MA) followed by FB1 significantly reduced cell viability with respect to the control 2411 
and individual treatment with 3-MA and FB1. Only 20% loss in viability was observed after 24 hours, 2412 
with proliferation occurring after 12 hours. The inhibition of autophagy using RNA interference led to 2413 
increased cell death  in mouse liver cells, while the autophagy inducer rapamycin protected the liver 2414 
cells from FB1-induced cell death. (Liu et al., 2020) Taken together, these results suggest that FB1-2415 
mediated autophagy protects cells from hepatic injury (Singh and Chul, 2017, Liu et al., 2020).  2416 
The difference in the role of autophagy can be explained by the type of cell (cancerous versus non-2417 
cancerous), duration of FB1 exposure (acute versus prolonged), and the duration and extent of 2418 
autophagy (Sun et al., 2013, Linder and Kögel, 2019). The extent and duration of autophagy may have 2419 
been greater in kidney, gastric, and colon tissue. This could be due to the prolonged exposure to FB1 in 2420 
these cells in comparison to the acute exposure received by the liver. Furthermore, the HepG2 cell line 2421 
is cancerous and FB1 is known to induce cancer in hepatic tissues in mice. Autophagy is used as a pro-2422 
survival mechanism in the latter stages of tumorigenesis to cope with metabolic stress, hypoxia, nutrient 2423 
deprivation, and ER stress (Sun et al., 2013, Linder and Kögel, 2019). As previously mentioned, FB1 2424 
has been shown to upregulate sphingosine kinase activity. Recently, sphingosine kinases were shown 2425 
to play a role in ER stress mediated through the inhibition of mTOR signalling via Sa1P. This is a pro-2426 
survival phenomenon used by cancer cells and should be further investigated in relation to FB1 (Lépine 2427 
et al., 2011). But what we do know is that FB1-induced ER stress mediates autophagy through either 2428 
the IRE1α/MAPK8/9/10, IRE1α/JNK or PERK/CHOP pathway (Figure 3.4). The outcome of 2429 





Figure 3.4. FB1-induced ER stress mediates autophagy. The accumulation of sphingolipids and ROS 2432 
in the ER after exposure to FB1 triggers ER stress. Cells cope with stress by activating UPR signalling 2433 
and autophagy via IRE1α/MAPK8/9/10, IRE1α/JNK, or PERK/CHOP pathways. FB1-induced 2434 
autophagy can be either pro-death or pro-survival depending on several factors. 2435 
Immunotoxicity  2436 
The immune system is a major defence mechanism in animals and humans, protecting them from 2437 
invading micro-organisms and foreign chemicals and its’ effectiveness is an important determinant of 2438 
animal and human health (Surai and Mezes, 2005). Mycotoxins are major immuno-suppressive agents 2439 
and FB1-induced immunotoxicity is an area of active research (Surai and Mezes, 2005). Current studies 2440 
have observed diverse immunomodulatory effects of FB1, which include altered inflammatory, cellular, 2441 
and humoral responses (Oswald et al., 2005). 2442 
Inflammation is a non-specific response that acts by removing harmful stimuli and initiating repair 2443 
through the activation of phagocytes. The activated phagocytes secrete cytokines that act as chemical 2444 
messengers between other immune cells (Oswald et al., 2005). They stimulate or inhibit the growth and 2445 
activity of various immune cells, which mediate and regulate immunity and inflammation. 2446 
Proinflammatory cytokines mediate inflammation via receptor activation, which can trigger 2447 
intracellular signalling pathways such as MAPK, nuclear factor kappa B (NFκB), and Janus 2448 
kinase/Signal transducer and activator of transcription (JAK/STAT). While inflammation plays an 2449 
important role in immune response, excessive production of inflammatory cytokines can lead to 2450 
cytotoxicity and tissue damage (Chen et al., 2017).   2451 
Alterations in proinflammatory cytokine profiles have been shown to be one of the factors that influence 2452 




interferon gamma (INF-γ) and interleukin-12 (IL-12) are involved in FB1-induced hepatotoxicity in 2454 
mice (Bhandari et al., 2002). Knockout of TNFα and IFN-γ or their receptors greatly reduced toxicity 2455 
in the liver of mice (Sharma et al., 2000, Sharma et al., 2001, Sharma et al., 2003). The differential 2456 
hepatotoxic response to FB1 in male and female mice can also be attributed to the difference in 2457 
proinflammatory cytokine profiles (Bhandari et al., 2001). Several studies have investigated the 2458 
immunomodulatory effect of FB1 in porcine intestinal systems as the intestine is the first physical barrier 2459 
to protect against ingested FB1. Furthermore, the results obtained from these studies may be valid for 2460 
humans due to the similarities between the porcine and human intestinal system. In porcine intestinal 2461 
epithelial (IPEC-J2) cells, both non-cytotoxic (20 µM) and cytotoxic (40 µM) concentrations of FB1 2462 
significantly increased the expression of inflammatory cytokines [ monocyte chemoattractant protein 2463 
(MCP-1), TNF-α, IL-1β, IL-6, and IL-8]; however, 40 µM had no significant effect on IL-1α (Wan et 2464 
al., 2013). Gu et al. (2019) investigated the effects of FB1 and HFB1 in a co-culture of IPEC-J2 and 2465 
porcine PBMCs that had been stimulated with lipopolysaccharide (LPS) and Deoxynivalenol (DON). 2466 
FB1 significantly increased intestinal permeability and reduced barrier integrity. This may be due to 2467 
disruptions in sphingolipid metabolism and depletion of glycosphingolipids which act as a structural 2468 
component of tight junctions. FB1 exacerbated proinflammatory responses through the upregulation of 2469 
IL-8, MCP-1 and C-C Motif Chemokine Ligand 20 (CCL20) in the presence of LPS/DON compared to 2470 
only LPS/DON treatments. The use of HFB1 leads to decreased cytokine expression; however, the effect 2471 
of HFB1 on IPEC-J2 cell viability and barrier integrity was comparable to that of FB1. Thus, FB1 2472 
degradation could be an effective strategy to reduce intestinal inflammation. Moreover, FB1 but not 2473 
HFB1 provoked PBMC cell death in the presence of LPS/DON. In another study, FB1 reduced IL-2 2474 
expression and inhibited porcine PBMC proliferation via blockage of G0/G1 transition of CD2+, CD4+, 2475 
CD8+ and immunoglobulin+ (Ig+) lymphocyte subsets (Marin et al., 2007).  2476 
In humans, cytokine profiles were investigated in lymphocytes, gastric adenocarcinoma (AGS) and 2477 
colon cancer (SW742) cells. FB1 stimulated the synthesis of TNF-α, IL-1β, inhibited IL-8 expression, 2478 
and reduced cell viability in a dose-dependent manner in all 3 cell lines. The changes in cytokine profiles 2479 
were more evident in SW742 cells than AGS cells; this higher sensitivity of colon cells might be due to 2480 
FB1 having a greater inhibitory effect on CS in the colon compared to the stomach (Mahmoodi et al., 2481 
2012). FB1 was found to be immunosuppressive in human cancer patients. Lymphocytes and 2482 
neutrophils, harvested from the circulation of healthy subjects and patients with breast or oesophageal 2483 
cancer, were dosed with 20 µg/ml to 100 µg/ml for 0 to 24 hours. Ultrastructure visualization of exposed 2484 
lymphocytes and neutrophils showed cell membrane disruption, damage to cytoplasmic organelles and 2485 
loss of nuclear integrity. The extensive cellular damage observed in all 3 populations correlated with 2486 
enhanced apoptosis in exposed cells (Odhav and Bhoola, 2008). In some cancer therapies, cytokines 2487 
are used to activate the immune system of cancer patients (Conlon et al., 2019). FB1 downregulated 2488 




Furthermore, FB1 increased expression of IL-1 and decreased IL-10 in lymphocytes of breast cancer 2490 
patients and decreased IL-6 in oesophageal cancer patients (Odhav and Bhoola, 2008). Taken together, 2491 
this data suggests FB1 suppresses immune functioning in a population that is already 2492 
immunocompromised.  Not only does FB1 diminish immune response to cancer but also raises 2493 
susceptibility to infectious diseases. Pig weanlings were given 0.5 mg/kg bw FB1 for 6 weeks before 2494 
being orally inoculated with a septicaemic Escherichia coli (E. coli) strain.  FB1 facilitated intestinal 2495 
colonization of septicaemic E. coli and its translocation. Bacterial translocation was prominent in 2496 
mesenteric lymph nodes and lungs and to a lesser extent in the liver and spleen (Oswald et al., 2003). 2497 
FB1 also prolonged intestinal infection of enterotoxigenic E. coli in pigs. This was achieved through the 2498 
impairment of antigen-presenting cells maturation by downregulating IL-12p40 and major 2499 
histocompatibility complex class II molecules (MHC-II) (Devriendt et al., 2009).  Antigen processing 2500 
and presentation was also affected in human gastric epithelium (GES-1) cells. FB1 reduced expression 2501 
of antigen processing complexes: transporter associated with antigen processing 1 (TAP1) and low 2502 
molecular weight peptide (LMP2), which contributed to reduced expression of human leukocyte antigen 2503 
(HLA)-class I expression. This may also lead to CD8+ T cells resistance (Yao et al., 2010). 2504 
Finally, FB1 can affect humoral immune response by diminishing the specific antibody response built 2505 
during vaccination. IL-4 plays a key role in the development of the humoral immune response and 2506 
antibody production (Yang et al., 2017). Prolonged exposure (8 mg FB1/kg; 28 days) to FB1 2507 
significantly decreased the expression of IL-4 in porcine lymphocytes, which in turn diminished 2508 
antibody response after vaccination against Mycoplasma agalactiae (Taranu et al., 2005). A decrease 2509 
in the specific antibody production was also observed in rodents immunized with sheep red blood cells 2510 
(Martinova and Merrill, 1995, Tryphonas et al., 1997). However, exposure of piglets for up to 4 months 2511 
to FB1-contaminated feed had no significant effect on antibody production against Aujeszky's disease 2512 
(Tornyos et al., 2003). In summary, exposure to FB1 activates proinflammatory networks, impairs 2513 
maturation of antigen-presenting cells and affects immune cell viability and responses. These 2514 
immunosuppressive effects increase susceptibility to infectious diseases, affects the treatment of 2515 
diseases such as cancer, and diminishes vaccine efficacy. 2516 
FB1-mediated changes to the epigenome 2517 
Exogenous stimuli such as mycotoxins are prominent disrupters to the epigenome (Huang et al., 2019). 2518 
They can induce phenotypic changes by differentially regulating gene expression rather than altering 2519 
DNA sequences. Epigenetic modifications are essential for the normal cellular processes and 2520 
maintenance of gene expression patterns. In contrast, aberrant alterations to the epigenome can affect 2521 
genome stability and may activate transcription of various genes, such as oncogenes, or silence the 2522 
expression of tumour suppressor genes (Sharma et al., 2010, Ho et al., 2012, Peschansky and 2523 
Wahlestedt, 2014). Epigenetic mechanisms include DNA methylation, histone modifications and the 2524 




(Lennartsson and Ekwall, 2009, Smith and Meissner, 2013, Peschansky and Wahlestedt, 2014). These 2526 
modifications play an important role in the toxicity and sometimes carcinogenicity of mycotoxins. 2527 
Epigenetic alterations in response to FB1 have been investigated in vivo and in vitro (Mobio et al., 2000, 2528 
Kouadio et al., 2007, Pellanda et al., 2012, Chuturgoon et al., 2014a, Chuturgoon et al., 2014b, Demirel 2529 
et al., 2015, Sancak and Ozden, 2015, Arumugam et al., 2020). 2530 
DNA methylation 2531 
DNA methylation is the most widely studied epigenetic modification. It is facilitated by DNA 2532 
methyltransferases (DNMTs), which catalyses the transfer of methyl groups to selective cytosine and 2533 
to a lesser extent adenine of mammalian DNA (Lyko, 2018). DNA methylation usually occurs in CpG 2534 
islands of gene promoters although non-CpG methylation can also occur. Hypermethylation of CpG 2535 
islands in gene promoter regions inhibit the binding of transcription factors and suppress gene 2536 
transcription (Moore et al., 2013). FB1 (9 and 18 µM) induced significant DNA hypermethylation in rat 2537 
C6 glioma cells after 24 hours; however, failed to induce hypermethylation at higher concentrations (27 2538 
and 54 µM). It was suggested that the lack of DNA methylation in higher concentrations could be due 2539 
to higher toxicity and DNA damage inflicted by FB1 (Mobio et al., 2000). Hypermethylation is known 2540 
to play a role in the regulation of DNA replication and gene expression in cell division and 2541 
differentiation processes (Moore et al., 2013). Hypermethylation observed at 9-18 µM may have 2542 
resulted in the hypermethylation of gene promoters involved in protein synthesis, DNA synthesis and 2543 
cell cycle regulation which may explain the impairment of G0/G1 transition, DNA and protein synthesis 2544 
and the low percentage of cells observed in the S phase of the cell cycle (Mobio et al., 2000). In human 2545 
intestinal Caco-2 cells, FB1 (10, 20, 40 µM for 24 hours) was also shown to significantly increase DNA 2546 
methylation from 4.5% in control cells to 9%, 9.5% and 8% at concentrations of 10, 20 and 40 µM of 2547 
FB1, respectively (Kouadio et al., 2007).  Moreover, Demirel et al. (2015) evaluated the effect of FB1 2548 
on both global DNA methylation and candidate gene methylation. While no significant changes to 2549 
global DNA methylation occurred in rat liver (Clone 9 cells) and kidney epithelial cells (NRK-52E); 2550 
CpG promoter methylation occurred in selective tumour suppressor genes. CpG islands of VHL and e-2551 
cadherin promoters were methylated in both cell lines. In addition, c-Myc was found methylated 2552 
exclusively in Clone 9 cells and methylation of p16 gene occurred in NRK-52E cells (Demirel et al., 2553 
2015). Hypermethylation of tumour suppressor genes inhibits the transcription of these genes aiding 2554 
carcinogenesis (Sharma et al., 2010). Global DNA hypomethylation is also characteristic of cancer cells 2555 
and is found in early carcinogenesis and during tumour progression (Sheaffer et al., 2016). In HepG2 2556 
cells, FB1 (200 µM; 24 hours) induced significant global DNA hypomethylation which was 2557 
accompanied by decreased expression of DNA methyltransferases (DNMT1, DNMT3a, and DNMT3b) 2558 
and increased expression of DNA demethylase, MBD2 (Chuturgoon et al., 2014a). A major 2559 
consequence of global DNA hypomethylation is the lack of sufficient ability to maintain genomic 2560 




hypomethylation by FB1 leads to the loss of genomic integrity which was observed by the increased 2562 
comet tail lengths induced by FB1 (Chuturgoon et al., 2014a).  The inconsistencies in global methylation 2563 
across these 4 studies maybe due to a number of factors: i) heterogeneity of the cells used – DNA 2564 
methylation regulates gene expression in a cell and tissue specific manner; ii) doses of FB1 used – low 2565 
doses seemed to favour hypermethylation; whereas high dose favoured hypomethylation. 2566 
Hypermethylation of tumour suppressor genes observed by Demirel et al. (2015) in combination with 2567 
a gross loss of global DNA methylation witnessed by Chuturgoon et al. (2014a) may be one of the 2568 
mechanisms responsible for FB1-related carcinogenesis.   2569 
Histone Modifications 2570 
Modifications to histones are another means in which FB1 can affect chromatin architecture and gene 2571 
expression. Histone modifications are covalent post-translational modifications that can influence 2572 
chromatin structure and subsequently the transcriptional status of genes. Histone modifications include 2573 
the methylation, acetylation, phosphorylation, sumoylation and ubiquitination of specific amino acid 2574 
residues (Cosgrove et al., 2004). In FB1-treated NRK-52E cells (25, 50 and 100 µM), a global increase 2575 
in di- and tri- methylation of lysine 9 on histone 3 (H3K9me2/3) was accompanied by an increase in 2576 
H3K9 histone methyltransferase (HMT). However, high doses (50 and 100 µM, 24 hours) and 2577 
prolonged exposure (25 µM, 27 and 96 hours) to FB1 significantly reduced methylation of lysine 20 of 2578 
histone 4 (H4K20) (Sancak and Ozden, 2015). Similar results in H3K9me3 and H4K20me3 were 2579 
observed in the foetus of methyl deficient dams exposed to FB1 (Pellanda et al., 2012). Both H3K9me3 2580 
and H4K20me3 establishes a condensed and transcriptionally inert chromatin conformation that 2581 
contributes to the maintenance of genome stability (Saksouk et al., 2015). Loss of H4K20me3 provokes 2582 
genome instability and is considered a hallmark of cancer (Van Den Broeck et al., 2008); The rise in 2583 
H3K9me3 might be the defence mechanism promoting the cell to resist heterochromatin disorganization 2584 
by FB1 (Pellanda et al., 2012). These changes in H3K9 methylation are associated with closed chromatin 2585 
and inhibition of transcription, further pointing to the probability that FB1 silences genes especially, 2586 
tumour suppresser genes (Sharma et al., 2010). However, the study by Chuturgoon et al. (2014a) 2587 
indicated that FB1 significantly increased the expression of two histone demethylase genes KDM5B and 2588 
KDM5C, which may promote H3K4me3/me2 demethylation. But this was not the case in NRK-52E 2589 
cells and in a recent study which used HepG2 cells (Sancak and Ozden, 2015, Arumugam et al., 2020). 2590 
Regarding histone acetylation, FB1 had little effect on H4K16 and H3K18 acetylation (Pellanda et al., 2591 
2012, Gardner et al., 2016). A dose and time-dependent decrease was observed in the H3K9ac levels in 2592 
response to FB1, while histone acetyl transferase activity was only inhibited as a consequence of 2593 
prolonged exposure (96 hours) (Sancak and Ozden, 2015). In LM/Bc embryonic fibroblasts, the 2594 
elevation in Sa1P after FB1-mediated inhibition of CS, inhibited histone deacetylase activity, promoting 2595 
histone acetylation of H2NK12, H3K9 and H3K23 (Gardner et al., 2016) The results of this study along 2596 




observed in mice and humans following FB1 exposure. However, further in vitro studies should be 2598 
undertaken to confirm this hypothesis.  Histone phosphorylation also contributes to the toxicity of FB1. 2599 
Downregulation in the phosphorylation of γ-H2AX was observed upon FB1 (200 µM, 24 hours) 2600 
exposure in HepG2 cells (Chuturgoon et al., 2015). Poor phosphorylation of γ-H2AX provokes genome 2601 
instability and prevents appropriate responses to DNA damage leading to gene mutations and 2602 
tumorigenesis (Podhorecka et al., 2010).  2603 
MicroRNA profiles 2604 
Only two studies has investigated the effect of FB1 on miRNA profiles (Chuturgoon et al., 2014b, 2605 
Arumugam et al., 2020). MiRNAs are a class on small non-coding RNAs that target mRNAs to induce 2606 
mRNA degradation and translational repression (O'Brien et al., 2018). Quantitative polymerase chain 2607 
reaction array-based profiling of miRNA and hierarchical cluster analysis by Chuturgoon et al. (2014b) 2608 
found that miR-135b, miR-181d, miR-27a, miR-27b, and miR-30c were significantly downregulated. 2609 
They further investigated miR-27b and found a 10-fold decrease that correlated with increased 2610 
expression of cytochrome 1B1, which mediates the bioactivation of procarcinogens (Chuturgoon et al., 2611 
2014b). A recent study found that FB1 induced miR-30c expression which altered H3K4me as well as 2612 
inhibited the translation of the tumour suppressor, phosphatase and tensin homolog (PTEN) leading to 2613 
diminished response and repair of FB1-induced oxidative DNA lesions (Arumugam et al., 2020). By 2614 
evaluating all the previous data, it is evident that epigenetic modifications are involved in FB1 toxicity 2615 
and possibly the aetiology of diseases such as neural tube defects and cancer. Nevertheless, further 2616 
research should be undertaken to fully explore the effect of FB1 on the epigenome as a whole and to 2617 
elucidate the impact of gene-specific epigenetic modifications in relation to a particular toxicological 2618 
phenotype. 2619 
Current strategies in minimizing FB1 toxicity 2620 
Considering that FB1 contamination of agricultural staples is unavoidable and the negative impact it has 2621 
on human health, a great deal of research has focused on strategies to mitigate FB1 contamination and 2622 
toxicity. The implementation of good agricultural, storage and processing practices can reduce FB1 2623 
contamination and subsequent exposure to humans and animals (Okabe et al., 2015). Several new 2624 
approaches are being investigated to detoxify FB1 contaminated foods and feeds. These strategies 2625 
include the use of physical, chemical or biological means to remove FB1 or attenuate its effects. Below 2626 
we review some recent research investigating FB1 detoxification. 2627 
Physical methods 2628 
Although FB1 is relatively heat stable, the use of extrusion cooking (high temperature/high pressure) 2629 
has been shown to be an effective method of reducing FB1 levels in maize [reviewed by Jackson et al. 2630 
(2012)]. At the right temperature and pressure, extrusion cooking can reduce FB1 concentration by 64% 2631 




FB1 from this maize-based porridge. Furthermore, this cooking technique prevented the disruption of 2633 
sphingolipid metabolism and development of kidney lesions in male rats fed diets consisting of FB1 2634 
contaminated grits that have undergone extrusion and glucose supplementation (Voss et al., 2011). 2635 
Nixtamalization is an alternative cooking method of corn and other grains. This ancient cooking process 2636 
involves cooking and steeping grains in an alkaline solution (calcium hydroxide) to improve nutritional 2637 
value and possibly reduce toxin contamination (Voss et al., 2017). However, the fate of FB1 during 2638 
nixtamalization is not fully understood and potentially toxic reaction products, including matrix-2639 
associated “masked” FB1 might remain in nixtamalized corn (Voss et al., 2013). Nixtamalization 2640 
involves the removal of one or both tricarboxylic acid groups from FB1 yielding pHFB1 or HFB1, 2641 
respectively (Voss et al., 2017). De Girolamo et al. (2016) found that while cooking without an alkaline 2642 
solution did reduce the levels of FB1 and pHFB1; HFB1 levels remained the same. However, the use of 2643 
an alkaline solution reduced FB1 and pHFB1 by converting it to HFB1. This confirms the role of alkaline 2644 
in releasing matrix associated FB1. No evidence of “masked” FB1 was found in another study that 2645 
investigated the role of nixtamalization on FB1 detoxification. Moreover, nixtamalization not only 2646 
reduced FB1 levels in the feed of Sprague Dawley rats but also lowered Sa and So levels and reduced 2647 
the number of renal lesions in comparison to rats fed uncooked corn (Voss et al., 2013).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2648 
Chemical methods 2649 
Organic and inorganic compounds can be used to bind or adsorb mycotoxins from the gastrointestinal 2650 
tract preventing their entry into circulation. Calcium montmorillonite (NovaSil), a dioctahedral smectite 2651 
clay, is an affective aflatoxin binder and is considered safe in humans. Robinson et al. (2012) evaluated 2652 
the effectiveness of NovaSil with regards to FB1 in male F344 rats and humans. NovaSil reduced rat 2653 
urinary FB1 levels by 20% in the first 24 hours and 50% after 48 hours. In a clinical trial, 3 g/day 2654 
NovaSil eliminated 90% of FB1. The protonation of the amino group of FB1 in acidic conditions like 2655 
that of the stomach allows for its binding to the negatively charged surfaces of the clay. Nanosilicate 2656 
platelets exfoliated from montmorillonite have a large surface area and high density which may allow 2657 
for effective FB1 binding. Nanosilicate platelets lowered FB1 levels in circulation, reversed sphingolipid 2658 
perturbations and prevented abnormalities in mice dams fed FB1 contaminated diets. It also lowered the 2659 
incidence of neural tube defects in their offspring (Liao et al., 2014).  Two studies independently 2660 
evaluated the effects of novel nanocellulose compounds on FB1. Jebali et al. (2015) modified 2661 
nanocellulose with polylysine (NMPL); which has a high affinity to the carboxyl groups of FB1; while 2662 
Zadeh and Shahdadi (2015) coated nanocellulose with free fatty acids which bind to the hydrophobic 2663 
tail of FB1. Both studies found that the nanocellulose compounds effectively adsorbed FB1 and reduced 2664 
toxicity in mouse liver cells (Jebali et al., 2015, Zadeh and Shahdadi, 2015). However, NMPL is 2665 
sensitive to changes in pH (Jebali et al., 2015), and both compounds should be tested in vivo. Lastly, 2-2666 




Dawley rats; however, it did not fully avoid a significant accumulation of sphingolipids (Denli et al., 2668 
2015). 2669 
Biological Methods 2670 
Certain micro-organism form part of normal gut flora and its consumption is associated with a range of 2671 
health benefits, including improved immune function, antioxidant capacity and prevention of cancer 2672 
(Hullar et al., 2014). Consequently, the role of these micro-organisms as mycotoxin detoxification 2673 
agents are being investigated and inclusion of such microbes in the diet may decrease availability and 2674 
absorption of FB1 in the gastrointestinal tract. 12 Lactobacillus bacterial strains and 6 Saccharomyces 2675 
cerevisiae yeast strains significantly reduced FB1 levels by 62-77% and 67-74%, respectively (Chlebicz 2676 
and Śliżewska, 2020). FB1 binds to the micro-organism’s cell wall through weak noncovalent 2677 
interactions. The interactions need as little time as a minute, suggesting that neither FB1 cell entry nor 2678 
metabolism may occur. Further, they can absorb FB1 and aflatoxin simultaneously without changes in 2679 
their efficiency (Pizzolitto et al., 2012). The use of Lactobacillus delbrueckii and Pediococcus 2680 
acidilactici as probiotics ameliorated FB1-induced hepatorenal toxicity and genotoxicity in rats by 2681 
normalizing kidney function, restoring redox homeostasis and reducing DNA fragmentation (Khalil et 2682 
al., 2015, Abdellatef and Khalil, 2016). Antioxidant capabilities of probiotics against FB1 were also 2683 
demonstrated by Lactobacillus paracaeseu which upregulated antioxidant capacity, inhibited lipid 2684 
peroxidation, increased free radical scavenging and reduced DNA fragmentations. It also had protective 2685 
effects against immunotoxicity induced by FB1 (Abbès et al., 2016). The use of recombinant 2686 
carboxylesterase, FUMD, from yeast (Pichia pastoris) has been shown to degrade FB1 in the 2687 
gastrointestinal tract of pigs. FUMD is responsible for the removal of the tricarboxylic acid side chains 2688 
of FB1, forming HFB1 (Masching et al., 2016). As shown previously, HFB1 can undergo N-acylation 2689 
forming toxic derivatives, thus deamination is necessary for effective detoxification. FUMD along with 2690 
FUM1 were shown to be the genes responsible for the degradation of FB1 by the bacterium 2691 
Sphingopyxis sp. MTA144. FUMD, was responsible for the desertification; while FUM1, an 2692 
aminotransferase, deaminated FB1 and HFB1. HFB1 only has 1 amino group therefore, the product of 2693 
these reactions can no longer inhibit CS activity. The authors believe the product to be 2-keto-HFB1; 2694 
however, the products need to undergo characterization (Heinl et al., 2010).  2695 
Conclusion 2696 
Fumonisin contamination of global agricultural produce is unavoidable and unpredictable. This poses 2697 
a unique challenge to food quality and safety. The most potent and abundant class of fumonisins is FB1, 2698 
which is the cause of several species-specific toxicities and is involved in carcinogenesis. Therefore, it 2699 
is necessary to investigate the mode of action of FB1 as well as interventions that aide in detoxification. 2700 
As discussed above, the main mode of FB1 toxicity is via the disruption of sphingolipid metabolism. 2701 
This results in the accumulation of sphingoid bases in the ER, which disrupts signalling pathways and 2702 




cells and alters immune responses. Furthermore, FB1 induces epigenetic changes that affect cell cycle 2704 
regulation, DNA and protein synthesis as well as promotes cancer via the inhibition of tumour 2705 
suppressor genes and activation of procarcinogens. Considering only a handful of studies have 2706 
investigated the impact of FB1 on the epigenome, it is necessary that more accurate epigenetic 2707 
mechanisms of FB1-induced toxicity are explored. Through proper crop management and storage, FB1 2708 
levels in crops can be minimized. Dietary interventions that eliminate or detoxify FB1 in the gut, such 2709 
as the use of chemical adsorbents or probiotics may also be crucial in mitigating the unpleasant 2710 
consequences of FB1 (Figure 3.5). 2711 
 2712 
Figure 3.5. An overview of the toxic and carcinogenic modes of action by FB1 as well as strategies 2713 
involved in its detoxification 2714 
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Fumonisin B1 (FB1), a Fusarium-produced mycotoxin, is found in various foods and feeds. It is a well-3302 
known liver carcinogen in experimental animals; however, its role in genotoxicity is controversial. The 3303 
current study investigated FB1-triggered changes in the epigenetic regulation of PTEN and determined 3304 
its effect on DNA damage checkpoint regulation in human liver hepatoma G2 (HepG2) cells. Following 3305 
treatment with FB1 (IC50: 200 µM; 24 h), the expression of miR-30c, KDM5B, PTEN, H3K4me3, PI3K, 3306 
AKT, p-ser473-AKT, CHK1, and p-ser280-CHK1 was measured using qPCR and/or Western blot. 3307 
H3K4me3 enrichment at the PTEN promoter region was assayed via a ChIP assay and DNA damage 3308 
was determined using an ELISA. FB1 induced oxidative DNA damage. Total KDM5B expression was 3309 
reduced, which subsequently increased the total H3K4me3 and the enrichment of H3K4me3 at PTEN 3310 
promoters. Increased H3K4me3 induced an increase in PTEN transcript levels. However, miR-30c 3311 
inhibited PTEN translation. Thus, PI3K/AKT signaling was activated, inhibiting CHK1 activity via 3312 
phosphorylation of its serine 280 residue preventing the repair of damaged DNA. In conclusion, FB1 3313 
epigenetically modulates the PTEN/PI3K/AKT signaling cascade, preventing DNA damage checkpoint 3314 
regulation, and induces significant DNA damage. 3315 
Keywords: Fumonisin B1; DNA damage; epigenetics; PTEN; H3K4me3; Checkpoint Kinase 1 3316 
Key Contributions 3317 
Fumonisin B1 (FB1) induces oxidative damage to DNA and alters the epigenetic status of cells. This 3318 
study confirms the genotoxic potential of FB1 and provides novel insight into the impairment of DNA 3319 
damage responses by FB1 via the epigenetic downregulation of PTEN; which in turns inhibits DNA 3320 
damage checkpoint regulation via the PI3K/AKT/CHK1 axis. The diminished repair of FB1-induced 3321 
oxidative DNA lesions may contribute to the cytotoxic effects of FB1. 3322 
Introduction 3323 
Fumonisins are major food-borne mycotoxins produced by fungi belonging to the Fusarium genus [1,2]. 3324 
Presently, 28 fumonisin homologues have been characterized into the following groups: fumonisins A, 3325 
B, C, and P [2]. Over 70% of fumonisins produced are fumonisin B1 (FB1), making it the most prevalent 3326 
and toxicologically relevant homologue [3]. FB1 contamination is common in maize and cereal-related 3327 
products in several countries throughout the world, with concentrations reaching as high as 30,000 3328 
µg/kg [4]. Poor food processing, handling, and storage conditions aide FB1 contamination, thereby 3329 
increasing the risk of exposure for both animals and humans [5]. The effect of FB1 in animals is sex-3330 
dependent and has species-specific toxicity, with the liver, kidney, and nervous system being the most 3331 
common targets [6–11]. The International Agency for Research on Cancer (IARC) has classified FB1 3332 
as a class 2B carcinogen [12]. Studies on rodents have demonstrated that FB1 can initiate and promote 3333 
cancer [1,13], while the consumption of FB1-contaminated commodities has been associated with 3334 




dismissed FB1 as a mutagen and reported that FB1 is a weak genotoxin [16] or that it showed no signs 3336 
of genotoxicity [17,18]. Irrespective of these earlier studies, numerous studies have since observed that 3337 
a consequence of FB1 exposure is extensive DNA damage through strand breaks, micronuclei induction, 3338 
and fragmentation [19–21]. 3339 
Cells are equipped with a complex network of DNA damage responses (DDRs) that coordinate DNA 3340 
repair and consequently cell fate [22]. The tumor suppressor phosphatase and tensin homolog (PTEN) 3341 
controls multiple cellular processes including growth and differentiation by opposing the 3342 
phosphoinositide 3-kinases (PI3K)/protein kinase B (AKT) signaling cascade [23,24]. Emerging 3343 
evidence has demonstrated the unique role PTEN plays in maintaining genomic stability and DNA 3344 
repair [25,26]. PTEN responds to DNA damage by inhibiting the PI3K/AKT cascade and preventing 3345 
the inhibitory phosphorylation of checkpoint kinase 1 (CHK1). This activates checkpoint regulation 3346 
and induces cell cycle arrest, which allows for the repair of DNA [27,28]. Underlining the important 3347 
role of PTEN, poor expression of PTEN is a common risk factor in the occurrence of liver pathologies 3348 
[29,30]. Studies have elucidated that poor expression of PTEN may be due to epigenetic alterations 3349 
[31]. Small non-coding RNAs, known as microRNAs (miRNA), such as miR-19a and miR-21, reduce 3350 
PTEN gene expression by binding to the 3′ untranslated region (3′UTR) of PTEN mRNA and inhibits 3351 
its translation [32,33], while the trimethylation of lysine 4 residues of histone 3 (H3K4me3) on the 3352 
promoter region of PTEN is associated with active transcription [34].  3353 
While the role of PTEN in cellular functioning has been well established, further research should be 3354 
undertaken to determine the epigenetic mechanisms in which PTEN is regulated. Moreover, the 3355 
epigenetic effects of FB1 in humans have only recently begun to be uncovered and no study to date has 3356 
determined the effects FB1 has on PTEN [21,35]. Previously, Chuturgoon et al. [35] conducted miRNA 3357 
profile arrays in human hepatoma G2 (HepG2) cells following FB1 exposure and found miR-30c to be 3358 
one of the major miRNAs affected. Through computational prediction analysis, we found a possible 3359 
link between miR30c, PTEN, and the histone lysine demethylase 5B (KDM5B). KDM5B catalyzes the 3360 
removal of methyl groups from histone 3 lysine 4 (H3K4) [36]. H3K4me3 is predominantly found at 3361 
transcriptional start sites, where it promotes gene transcription [37]. Therefore, we proposed that 3362 
together miR-30c and KDM5B mediate the epigenetic regulation of PTEN. The current study 3363 
determined the consequences of FB1 exposure on DNA damage and DNA damage checkpoint 3364 
regulation via the PTEN/PI3K/AKT network. Further, we determined FB1 epigenetic regulation of 3365 
PTEN via miR-30c and H3K4me3 in human liver (HepG2) cells. 3366 
Method and Materials 3367 
 Materials 3368 
FB1 (Fusarium moniliforme, 62580) was purchased from Cayman Chemicals (Michigan, MI, USA). 3369 




Cell culture consumables were purchased from Whitehead Scientific (Johannesburg, South Africa). 3371 
Western blot reagents were obtained from Bio-Rad (California, CA, USA). All other reagents were 3372 
purchased from Merck (Massachusetts, MA, USA), unless otherwise stated. 3373 
 Cell Culture and Treatments 3374 
HepG2 cells (passage 3; 1.5 × 106) were cultured in complete culture media [CCM: Eagle’s Minimum 3375 
Essentials Medium (EMEM) supplemented with 10% fetal calf serum, 1% penicillin–streptomycin–3376 
fungizone, and 1% L-glutamine] at 37°C in a 5% CO2 humidified incubator until 80% confluent. 3377 
Thereafter, cells were treated with varying concentrations of FB1 (5, 100, and 200 µM) for 24 h. These 3378 
FB1 concentrations were obtained from the crystal violet assay (Supplementary Figure S4.1) and 3379 
represented 90%, 70%, and 50% cell viabilities, respectively. An untreated control was prepared along 3380 
with the FB1 treatments. Data obtained using 200 µM FB1 (IC50) are shown in the main text. The results 3381 
for all assays conducted using 5 and 100 µM FB1 are available in the Supplementary material 3382 
(Supplementary Figure S4.2–S4.7). Results were verified by performing two independent experiments 3383 
in triplicate. 3384 
DNA Damage 3385 
DNA was isolated using the FlexiGene DNA isolation kit (Qiagen, Hilden, Germany, 512608). 3386 
Extracted DNA was used to determine 8-OHdG levels using the DNA damage ELISA kit (Enzo Life 3387 
Sciences, New York, USA, ADI-EKS-350), as per the manufacturer’s instructions. 3388 
RNA Isolation and Quantitative Polymerase Chain Reaction (qPCR) 3389 
RNA was isolated according to the method described by Ghazi et al. (2019) [38]. For miRNA 3390 
expression, cDNA was synthesized using the miScript II RT Kit (Qiagen, Hilden, Germany, 218161), 3391 
as per the manufacturer’s instructions. The expression of miR-30c was analyzed using the miScript 3392 
SYBR Green PCR Kit (Qiagen, Hilden, Germany, 218073) and the miR-30c primer assay (Qiagen, 3393 
Hilden, Germany, MS00009366), as per the manufacturer’s instructions. Samples were amplified using 3394 
the CFX96 TouchTM Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA) with the 3395 
following cycling conditions: initial denaturation (95 °C, 15 min), followed by 40 cycles of denaturation 3396 
(94°C, 15 sec), annealing (55°C, 30 sec), and extension (70°C, 30 sec). 3397 
For mRNA expression, cDNA was prepared using the Maxima H Minus First Strand cDNA Synthesis 3398 
Kit (Thermo-Fisher Scientific, Waltham, MA, USA, K1652), as per the manufacturer’s instructions. 3399 
The expression of KDM5B, PTEN, AKT, and CHK1 was determined using the Powerup SYBR Green 3400 
Master Mix (Thermo-Fisher Scientific, Waltham, MA, USA, A25742), as per the manufacturer’s 3401 
instructions. Samples were amplified using the CFX96 TouchTM Real-Time PCR Detection System 3402 




min), followed by 40 cycles of denaturation (95°C, 15 sec), annealing (Temperatures: Table 4.1, 15 3404 
sec), and extension (72°C, 30 sec). 3405 




KDM5B 55 Sense 5′-CGA CAA AGC CAA GAG TCT CC-3′ 
Anti-
sense 
5′-CTG CCG TAG CAA GGC TATTC-3 
PTEN 56.6 Sense 5′-TTT GAA GAC CAT AAC CCA CCA C-3′ 
Anti-
sense 
5′-ATT ACA CCA GTT CGT CCC TTT C-3′ 
AKT1 55 Sense 5′-GCC TGG GTC AAA GAA GTC AA-3′ 
Anti-
sense 
5′-CAT CCC TCC AAG CTA TCG TC-3′ 




5′-TGT TCAACA AAC GCT CAC GAT TA-3′ 







Relative gene expression was determined using the method described by Livak and Schmittgen [39]. 2-3408 
ΔΔCt represents the fold change relative to the untreated control. miRNA and mRNA of interest were 3409 
normalized against the house-keeping genes, RNU6 (Qiagen, Hilden, Germany, Ms000033740) and 3410 
GAPDH, respectively. 3411 
Chromatin Immunoprecipitation Assay 3412 
H3K4me3 at the PTEN promoter region was determined using the chromatin immunoprecipitation 3413 
(ChIP) assay. Histones were crosslinked to DNA by incubating (37°C, 10 min) the cells in 37% 3414 
formaldehyde. Cells were washed in cold 0.1 M PBS (containing protease inhibitors), mechanically 3415 




sulphate (SDS)–lysis buffer (200 µl; 1% SDS, 10 mM ethylenediaminetetraacetic acid (EDTA), and 50 3417 
mM Tris; pH 8.1) and sheared by homogenization. Samples were centrifuged (13,000 rpm, 4°C, 10 3418 
min) and supernatants were diluted with ChIP dilution buffer [0.01% SDS, 1.1% Tritonx-100, 1.2 mM 3419 
EDTA, 16.7 mM Tris-HCl (pH 8.1), and 167 mM NaCl]. The diluted supernatants were split into equal 3420 
fractions. Anti-H3K4me3 (Abcam, Cambridge, UK, ab12209) was added to one fraction, while no 3421 
antibody was added to its counterpart. Both fractions were incubated overnight at 4°C. A 50% slurry of 3422 
Protein A agarose and salmon sperm DNA (Merck, Kenilworth, NJ, USA, 16-157) was added to all 3423 
samples and incubated (4°C, 1 h) with gentle rotation. Thereafter, samples were centrifuged (1000 rpm, 3424 
4 °C, 1 min), and pellets were washed once with the following buffers: low salt immune complex wash 3425 
buffer (0.1% SDS, 1% Tritonx-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1), and 150 Mm NaCl), high 3426 
salt immune complex wash buffer [0.1% SDS, 1% Tritonx-100, 2 mM EDTA, 20 mM Tris-HCl (pH 3427 
8.1), and 500 mM NaCl], Lithium chloride immune complex wash buffer (0.25 M LiCl, 1% IGEPAL, 3428 
1% deoxycholic acid, 1 mM EDTA, and 10 mM Tris; pH 8.1), and twice with TE buffer (10 mM Tris-3429 
HCl, 1 mM EDTA; pH 8.0). DNA was eluted using elution buffer (1% SDS, 0.1 M NaCHO3) for 15 3430 
min (gentle rotation, RT). Samples were centrifuged (1000 rpm, 4°C, 1 min) and elution was repeated 3431 
on the protein A agarose/ssDNA pellet. Eluates were combined and incubated in 5 M NaCl (65°C, 4 h) 3432 
to reverse crosslinks. DNA was further purified using a DNA Clean & Concentrator-5 kit, as per the 3433 
manufacturer’s instructions (Zymo research, Irvine, CA, USA, D4003). 3434 
H3K4me3 immunoprecipitated chromatin was used in a RT-qPCR reaction (as previously described) 3435 
to determine H3K4me3 at the PTEN promoter (Sense: 5′- CGC CCA GCT CCT TTT CCC-3′; Anti-3436 
sense: 5′- CTG CCG CCG ATT CTT AC-3′). The fold enrichment method was used to normalize data 3437 
obtained from the ChIP-qPCR. 3438 
Protein Isolation and Western Blotting 3439 
Protein was isolated using Cytobuster reagent (Merck, Kenilworth, NJ, USA, 71009-3) supplemented 3440 
with protease and phosphatase inhibitors (Roche, Basel, Switzerland, 05892791001 and 04906837001, 3441 
respectively). Cells were mechanically lysed, and centrifuged (13,000 rpm, 4°C, 10 min). Supernatants 3442 
were used to quantify protein concentration via the bicinchoninic acid assay (BCA). Proteins were 3443 
standardized to 1 mg/mL. The expression of KDM5B (Abcam, Cambridge, UK, ab19884), H3K4me3 3444 
(Abcam, Cambridge, UK, ab12209), PTEN (Cell Signalling Technologies, Danvers, MA, USA, 3445 
9552S), p-ser473-AKT (Cell Signaling Technologies, Danvers, MA, USA, 9271S), AKT (Cell 3446 
Signaling Technologies, Danvers, MA, USA 9272S), PI3K (Cell Signaling Technologies, Danvers, 3447 
MA, USA, 4249S), p-ser280-CHK1 (Cell Signaling Technologies, Danvers, MA, USA, 23475), and 3448 
CHK1 (Cell Signaling Technologies, Danvers, MA, USA, 2360S) were determined using Western 3449 
blotting as previously described [43]. The Image Lab Software version 5.0 (Bio-Rad, Hercules, CA, 3450 




relative band density and calculated by normalizing the protein of interest against the housekeeping 3452 
protein, β-actin. 3453 
 Statistical Analysis 3454 
All statistical analysis was performed using GraphPad Prism version 5.0 (GraphPad Software Inc., San 3455 
Diego CA, USA). The unpaired t test was used for all assays. One-way ANOVA with Dunnet’s post-3456 
test was used to evaluate the significant effect of FB1 in all Supplementary Figures. All results are 3457 
presented as the mean ± standard deviation, unless otherwise stated. A value of p < 0.05 was considered 3458 
to be statistically significant. 3459 
Results 3460 
FB1 Induces DNA Damage in HepG2 Cells 3461 
FB1 negatively impacts redox homeostasis, which results in oxidative damage to cellular structures. We 3462 
assessed FB1-mediated DNA damage by evaluating levels of the oxidative DNA damage biomarker— 3463 
8-hydroxy-2'-deoxyguanosine (8-OHdG). FB1 significantly increased the level of 8-OHdG (2.68-fold) 3464 
compared with the control (p = 0.0061; Control: 1.04 ± 0.0641 vs. FB1: 2.68 ± 0534; Figure 4.1.). 3465 
 3466 
Figure 4.1. Fumonisin B1 (FB1) significantly increased the oxidative DNA damage biomarker, 8-3467 
OHdG, in human hepatoma G2 (HepG2) cells (** p < 0.01). 3468 
FB1 Increases miR-30c Expression in HepG2 Cells 3469 
Since PTEN initiates DNA damage responses and miR-30c has been shown to disrupt DNA damage 3470 
responses, we investigated the epigenetic regulation of PTEN [26,40]. miR-30c is involved in regulating 3471 
cell cycle transition, proliferation, and lipid metabolism. FB1 (IC50; 200 µM) significantly upregulated 3472 




Target Scan version 7.2 (http://www.targetscan.org/vert_72/) was used to identify putative mRNA 3474 
targets of miR-30c. miR-30c has complimentary base pairs with PTEN (at positions 3957–3963, 5018–3475 
5029, and 5880–5886 in the 3′UTR) and KDM5B (at positions 432–438 in the 3′UTR) (Figure 4.2b) 3476 
 3477 
Figure 4.2. The effect of FB1 on miR-30c levels in HepG2 cells and potential miR-30c targets. (a) 3478 
FB1 significantly elevated miR-30c expression (** p ≤ 0.01). (b) Target Scan analysis of miR-30c 3479 
with the 3′ untranslated region (3′UTR) of KDM5B and PTEN. 3480 
FB1 Induces H3K4me3 by Downregulating KDM5B in HepG2 Cells 3481 
Since FB1 altered the expression of miR-30c (which has a complimentary sequence to KDM5B 3’ UTR), 3482 
we evaluated the gene and protein expression of KDM5B. FB1 decreased KDM5B transcript levels by 3483 
9.86-fold (p < 0.0001; Control: 1.04 ± 0.0642 vs. FB1: 9.86 ± 1.15; Figure 4.3a). KDM5B protein 3484 
expression (Figure 4.3b) was reduced slightly (p = 0.2966) by FB1 (1.47 ± 0.117 RBD) in comparison 3485 
with the control (1.70 ± 0.142 RBD). 3486 
KDM5B is a negative regulator of H3K4me3; hence, we determined the effect of FB1 on H3K4me3. 3487 
FB1 (3.00 ± 0.0589 RBD) induced a considerable increase (p < 0.0001) in total H3K4me3 compared 3488 







Figure 4.3. The effect of FB1 on KDM5B and H3K4me3 levels in HepG2 cells. FB1 reduced both 3493 
the transcript (a; *** p ≤ 0.0001) and protein (b; p > 0.05) expression of KDM5B. This may have 3494 
led to the subsequent increase in total H3K4me3 (c; *** p ≤ 0.0001). 3495 
 FB1 Alters PTEN Expression in HepG2 Cells 3496 
PTEN expression may be influenced by KDM5B and miR-30c. In addition to the total H3K4me3 levels, 3497 
FB1 also induced a significant 2.5-fold upregulation of H3K4me3 at PTEN promoter regions (p = 3498 
0.0052; Control: 1.04 ± 0.0641 vs. FB1: 2.15 ± 0.273; Figure 4.4a). 3499 
H3K4me3 at promoter regions is associated with active transcription. The FB1-induced increase in 3500 
H3K4me3 corresponded with active transcription of the PTEN gene with a 1.46-fold increase (p = 3501 
0.0039; Control: 1.04 ± 0.0641 vs. FB1: 1,46 ± 0,0354; Figure 4.4b). However, PTEN protein expression 3502 
was significantly downregulated (p = 0.0001) by FB1 (1.67 ± 0,0110 RBD) compared with the control 3503 





Figure 4.4. FB1-induced KDM5B and miR-30c modulates PTEN expression. PTEN expression is 3506 
influenced by both KDM5B and miR-30c. FB1 increased H3K4me3 at PTEN promoter regions (a; ** 3507 
p < 0.01), which resulted in significantly higher levels of PTEN transcripts (b; ** p < 0.01). However, 3508 
miR-30c negatively influenced PTEN translation/protein expression (c; *** p < 0.0001). 3509 
FB1 Affects PI3K/AKT Signaling in HepG2 Cells 3510 
Numerous biological processes are regulated by the PTEN/PI3K/AKT signaling network. PI3K protein 3511 
expression (p = 0.0014; Figure 4.5) was 2.44-fold greater in FB1-exposed cells (1.08 ± 0.126 RBD) 3512 
compared with the control (0.443 ± 0.0600 RBD). 3513 
Total AKT protein expression was slightly increased (p = 0.4200; Figure 4.5) by FB1 (Control 1.61 ± 3514 
0.0148 RBD vs. FB1 1.82 ± 0.396 RBD). AKT is activated by the phosphorylation of serine 473 within 3515 
the carboxy terminus. FB1 significantly increased the phosphorylation of AKT (p = 0.001, 0.973 ± 3516 







Figure 4.5. The effect of FB1 on the PI3K/AKT signaling cascade. The protein expression of PI3K, 3521 
AKT, and pAKT in HepG2 cells was evaluated using western blotting. FB1 increased PI3K (*** p < 3522 
0.0001), AKT (p > 0.05), and p-ser473-AKT (** p < 0.01) protein expression. PI3K and AKT 3523 
expression was normalized against β-actin, and p-ser473-AKT was normalized against AKT. 3524 
 FB1 Modulates CHK1 Expression and Activity in HepG2 Cells 3525 
CHK1 is critical in coordinating DDR and cell cycle checkpoints. FB1 elevated CHK1 transcript levels 3526 
by 1.79-fold (p = 0.0209; Figure 4.6a). Western blotting revealed an increase in total CHK1 protein 3527 
expression (p = 0.0008; Control 0.540 ± 0.105 RBD vs. FB1 1.18 ± 0.0614 RBD; Figure 4.6b). Active 3528 
PI3K/AKT signaling phosphorylates serine 280 of CHK1 and inactivates it. FB1 significantly elevated 3529 
(p = 0.0314; 1.54 ± 0.179 RBD) p-ser280-CHK1 expression in comparison with the control (1.09 ± 3530 








Figure 4.6. The effect of FB1 on CHK1 expression. FB1 significantly increased CHK1 transcript 3536 
levels (a; *p < 0.05), CHK1 protein expression (b; *** p < 0.0001), and p-ser280-CHK1 (c; * p < 3537 
0.05). CHK1 expression was normalized against β-actin and p-ser280-CHK1 was normalized 3538 
against CHK1. 3539 
Discussion 3540 
Considering that FB1 contamination of agricultural products is common throughout the world, it is 3541 
necessary to evaluate the health hazards FB1 poses to humans and animals. Several studies have 3542 
attributed oxidative stress as one of the mechanisms in which FB1 exerts its toxicity [41–45]. Excessive 3543 
production of reactive oxygen species (ROS) results in oxidative damage to cells and macromolecules 3544 
including DNA [44]. While some studies have disputed the genotoxic potential of FB1 [17,18], others 3545 
have reported chromosomal aberrations and oxidative DNA damage triggered by FB1 exposure 3546 
[16,41,47,48]. Apart from inducing DNA damage, FB1 may disrupt DDR network and repair processes. 3547 
One potential mechanism could be through the PTEN/PI3K/AKT/CHK1 axis. 3548 
To better understand the genotoxic potential of FB1, we set out to determine if FB1 induces DNA 3549 
damage and if it alters DNA damage checkpoint regulation via the PTEN/PI3K/AKT/CHK1 network. 3550 
Seeing that poor PTEN expression is common in toxicity, we further determined the effects of FB1 on 3551 
the epigenetic regulation of PTEN via miR-30c and H3K4me3 in human hepatoma G2 (HepG2) cells. 3552 
The liver is one of the primary organs in which FB1 is thought to accumulate, and is usually the initial 3553 
site for the metabolism and detoxification of food and food contaminants [49,50]. Due to the limitations 3554 
of primary hepatocytes such as poor availability, short life span, inter-donor variability, loss of hepatic 3555 
function, and early phenotypic changes, we opted to use the HepG2 cell line for this study [51,52]. The 3556 




Moreover, no mutations have been found in the PTEN gene of the HepG2 cell line, making it an apt 3558 
model for testing genotoxicity and epigenetic changes that may occur as a result of FB1 exposure [55]. 3559 
The effect of FB1 on HepG2 cell viability was conducted using a crystal violet assay in accordance with 3560 
Feoktistova et al. [56] (Supplementary Figure S4.1). FB1 reduced HepG2 cell viability in a dose-3561 
dependent manner (5, 50, 100, 200 µM). For subsequent assays, HepG2 cells were exposed to 5, 100, 3562 
and 200 µM FB1 as they represented 90%, 70%, and 50% cell viabilities, respectively. Results obtained 3563 
for 5 and 100 µM can be found in the supplementary materials (Supplementary Figures S4.2–S4.7). 3564 
We evaluated the genotoxic potential of FB1 by determining if FB1 inflicted damage on DNA. 3565 
Previously, we showed that at 200 µM FB1 enhanced ROS production, resulting in oxidative stress [45]. 3566 
Thus, in the present study we measured 8-OHdG levels as a marker of oxidative DNA damage. The low 3567 
redox potential of guanine makes it the most vulnerable base and its product (8-OHdG) the best 3568 
characterized oxidative lesion [57]. We found a significant 2.63-fold increase in 8-OHdG levels in the 3569 
DNA of FB1-exposed cells (Figure 4.1). The incorporation of 8-OHdG into DNA can generate double 3570 
strand breaks, making this a harmful lesion [58]. Several other in vivo and in vitro studies observed 3571 
DNA fragmentation as a consequence of FB1 exposure, proving that FB1 is genotoxic [19–21,42]. 3572 
While the impact FB1 has on DNA damage has been thoroughly researched, little is known on the impact 3573 
it may have on DNA damage responses. Hence, we investigated the effect of FB1 on the 3574 
PTEN/PI3K/AKT/CHK1 axis and further determined if FB1 effects the epigenetic regulation of PTEN. 3575 
Currently, only a few studies have demonstrated the effects of FB1 on epigenetic modifications in 3576 
humans. Previously, Chuturgoon et al. (2014) screened for alterations in the miRNA expression profile 3577 
of HepG2 cells exposed to 200 µM FB1. miR-30c was one of the miRNAs shown to be dysregulated 3578 
[35]. MiR-30c is an important regulator of hepatic liver metabolism, apoptosis, cell cycle transition, 3579 
proliferation, and differentiation [59–61]. We found that the expression of miR-30c was significantly 3580 
increased after exposure to 200 µM FB1 (Figure 4.2a). Using an online computational prediction 3581 
algorithm (TargetScan version 7.2), miR-30c was found to possibly target PTEN and KDM5B (Figure 3582 
4.2b). miRNAs silence their mRNA targets through mRNA cleavage or translational repression [62–3583 
64]. FB1 reduced KDM5B transcript and protein levels in HepG2 cells (Figure 4.3a, b). While FB1 3584 
reduced KDM5B mRNA levels by 9.86-fold, only a slight decrease in protein expression was observed. 3585 
A previous study did find a minor increase in KDM5B transcript levels at 200 µM FB1; however, these 3586 
results were not statistically significant [35]. Further studies using miR-30c inhibitors and mimics need 3587 
to be conducted to validate miR-30c regulation of KDM5B expression. 3588 
FB1 can also induce epigenetic changes through the post-translational modifications of histones, but no 3589 
study to date has investigated these changes in humans [65–67]. Here, we identified changes to H3K4 3590 
methylation. Although there was a slight decrease in KDM5B, we found a significant increase in global 3591 
H3K4me3 (Figure 4.3c). H3K4me3 is predominantly found at transcriptional start sites, where it 3592 




determined H3K4me3 levels at the PTEN promoter region using the ChIP assay; FB1 significantly 3594 
increased H3K4me3 at the PTEN promoter region (Figure 4.4a). These results correspond to the 3595 
substantial elevation in PTEN transcript levels; however, the protein expression of PTEN was decreased 3596 
(Figure 4.4b, c). PTEN may be post-transcriptionally regulated by miR-30c, as the decrease in PTEN 3597 
protein expression corresponded to the increased miR-30c levels. Hence, miR-30c may act as a possible 3598 
inhibitor of PTEN translation. 3599 
PTEN functions in regulating several cellular processes by antagonizing the PI3K/AKT signaling 3600 
cascade [70]. Emerging evidence has revealed that PTEN is central in maintaining the DNA integrity 3601 
by regulating DDR pathways via its interaction with CHK1 [27,28]. Additionally, PTEN regulates the 3602 
activity of CHK1 via the PI3K/AKT axis [71–74]. Briefly, PTEN dephosphorylates the primary product 3603 
of PI3K, phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 activates AKT via its phosphorylation at 3604 
serine residue 473 [71]. Downregulation of PTEN permitted PI3K/AKT signaling to proceed 3605 
undisturbed as PI3K and p-ser473-AKT expression was upregulated (Figure 4.5). FB1 inhibits ceramide 3606 
formation and promotes the formation of spingoid bases [75]. This may explain the activation of AKT 3607 
by FB1, as ceramide inhibits PI3K and promotes the dephosphorylation of AKT on serine 473 [76,77]. 3608 
Furthermore, sphingosine-1-phosphate activates PI3K/AKT signaling by binding to GI-coupled 3609 
receptors [78]. 3610 
AKT, in its activated form, inhibits CHK1 functioning by phosphorylating serine 280 of CHK1 3611 
[71,73,74]. Activated PI3K/AKT signaling impaired CHK1 function via increased p-ser-280-CHK1 3612 
after FB1 exposure (Figure 4.6). During DDR, CHK1 arrests cells at the G1/S, S, and G2/M phases by 3613 
phosphorylating the cdc25 family of phosphatases [79,80]. This allows for DNA repair to occur prior 3614 
to determining cell fate. Although we did not analyze changes in cell cycle, previous studies have shown 3615 
that FB1 disrupts G1/S blockade; however, increased G2/M arrest was observed [81–83]. Nonetheless, 3616 
the inhibitory phosphorylation of CHK1 coincided with DNA damage after FB1 exposure in HepG2 3617 
cells, as cell cycle checkpoints were disrupted, inhibiting repair. 3618 
In addition to 200 µM FB1, the effects of 5 and 100 µM FB1 were investigated (Supplementary Figures 3619 
S4.2–S4.7). While cells exposed to 5 and 200 µM FB1 responded in a similar manner, the effect at 200 3620 
µM FB1 was exacerbated. Additionally, we observed that 100 µM FB1 generally had the opposite effect 3621 
on 8-OHdG levels, H3K4 trimethylation on the PTEN promoter, and the expression of miR-30c, 3622 
KDM5B, PTEN, PI3K, p-ser423-AKT, CHK1, and p-ser-280-CHK1 in HepG2 cells in comparison 3623 
with the 5 and 200 µM FB1. As with many toxins, this suggests that FB1 is associated with a biphasic 3624 
dose response [84]. 3625 
Conclusions 3626 
This study further confirms the genotoxic potential of FB1, and that the inhibition of DNA damage 3627 




expression of PTEN via miR-30c. The downregulation of PTEN inhibits DNA damage checkpoint 3629 
regulation via the PI3K/AKT signaling network, preventing the repair of oxidative DNA lesions 3630 
induced by FB1 (Figure 4.7). Needless to say, further investigation should be conducted using miRNA 3631 
inhibitors and mimics, and on whether the outcome of FB1-induced DNA damage and impaired DNA 3632 
damage checkpoint regulation contributes to its cytotoxicity or carcinogenicity. 3633 
 3634 
Figure 4.7. FB1 induces oxidative DNA damage. It further impairs DNA damage checkpoint 3635 
regulation pathways via the PTEN/PI3K/AKT/CHK1 axis by epigenetically regulating PTEN. FB1 3636 
upregulates miR-30c, which inhibits PTEN translation, allowing for the phosphorylation of PIP2 3637 
to PIP3 by PI3K. This triggers the phosphorylation of AKT and subsequent phosphorylation of 3638 
ser-280-CHK1, inhibiting CHK1 activity. Inhibition of CHK1 inhibits DNA damage checkpoint 3639 
regulation. The resulted DNA damage may either contribute to FB1-mediated cytotoxicity or 3640 
carcinogenicity. 3641 
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Supplementary Information 3651 
 3652 
 3653 
Supplementary Figure S4.1. The cytotoxic effects of FB1 on HepG2 cells. HepG2 cells were treated 3654 
with 0, 5, 50, 100 and 200 µM FB1 for 24h. Cell viability was determined using the crystal violet assay 3655 
and expressed as a percentage of the untreated control. Control viability was taken as 100%.  FB1 3656 
significantly altered the cell viability of HepG2 cells. Data is represented as mean percentage cell 3657 






















Supplementary Figure 4.2. FB1 induced 8-OHdG levels in HepG2 cells.  8-OHdG levels were 3662 
measured as a marker of oxidative DNA damage. FB1 significantly altered 8-OHdG levels in HepG2 3663 
cells (***p = 0.0007). Data is represented as mean fold change ± SD (n=3) (*** p ≤0.001; one-way 3664 























Supplementary Figure S4.3: FB1 altered miR-30c expression in HepG2 cells.   qPCR analysis of 3668 
miR-30c showed that FB1 significantly altered miR-30c expression (***p < 0.0001). Results are 3669 
represented as mean fold-change ± SD (n=3) (*p < 0.05, ***p < 0.0001; one-way ANOVA with the 3670 
Dunnet: compare all columns to control post-test).  3671 
 3672 
 3673 
Supplementary Figure S4.4: The effect of FB1 on KDM5B and H3K4me3 expression in HepG2 3674 
cells. FB1 reduced both the transcript (a; ***p < 0.0001) and protein (b; *p= 0.0106) expression of 3675 
KDM5B. There was a dose-dependent increase in total H3K4me3 (c; *** p < 0.0001). Western blot 3676 
images of KDM5B and H3K4me3 (d). KDM5B and H3K4me3 expression was normalized against β-3677 
actin. Results are represented as mean fold-change ± SD (n=3) for gene expression and mean relative 3678 
band density ± SD (n=3) for protein expression (***p < 0.0001; one-way ANOVA with the Dunnet: 3679 






Supplementary Figure 4.5: FB1 induced KDM5B and miR-30c modulates PTEN expression.   3683 
PTEN expression is under the influence of both KDM5B and miR-30c. (a) Low levels of KDM5B 3684 
allowed for the increased H3K4me3 at PTEN promoter regions (*** p < 0.0001). (b) This resulted in 3685 
significantly higher levels of PTEN transcripts (*** p < 0.0001). (c) However, miR-30c inhibited PTEN 3686 
translation/protein expression at 5 µM FB1 but increased PTEN translation at 100 µM FB1 (*** p < 3687 
0.0001). (d) Western blot images of PTEN.  PTEN expression was normalized against β-actin. Results 3688 
are represented as mean fold-change ± SD (n=3) for gene expression and mean relative band density ± 3689 
SD (n=3) for protein expression (*p < 0.05, ***p < 0.0001; one-way ANOVA with the Dunnet: compare 3690 












Supplementary Figure 4.6: The effect of FB1 on the PI3K/AKT signalling cascade. (a) Western 3700 
blotting was used to determine the effect of FB1 on the PTEN/PI3K/AKT signalling network. FB1 3701 
significantly altered PI3K (*** p < 0.0001), AKT (*** p = 0.0004) and p-ser473-AKT (*p < 0.0174) 3702 
protein expression. (b) Western blot images of PI3K, AKT and pAKT. p-ser473-AKT expression was 3703 
normalized against AKT and PI3K and AKT expression was normalized against β-actin. Data is 3704 
represented as mean RBD ± SD (n=3), (* p ≤0.05, **p ≤0.01 and ***p ≤0.001; one-way ANOVA with 3705 
the Dunnet: compare all columns to control post-test).  3706 
 3707 
 3708 
Supplementary Figure 4.7: The influence of FB1 on CHK1 expression in HepG2 cells. FB1 3709 
significantly altered CHK1 gene expression (a; ***p = 0.0001), CHK1 protein expression (b; *** p 3710 
<0.0001) and p-ser280-CHK1 (c; ***p =0.0006). (d) Western blot images of CHK1 and p-ser280-3711 
CHK1. CHK1 expression was normalized against β-actin and p-ser280-CHK1 was normalized against 3712 
CHK1. Gene expression is represented as fold changes ± SD relative to the control and protein 3713 
expression is represented as mean RBD ± SD (*p ≤0.05, **p ≤0.01 and ***p ≤0.001; one-way ANOVA 3714 
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Fumonisin B1 (FB1) is a common contaminant of cereal grains that affects human and animal health. It 3991 
has become increasingly evident that epigenetic changes are implicated in FB1 toxicity. N6-3992 
methyladenosine (m6A) is the most abundant post-transcriptional RNA modification that is influenced 3993 
by fluctuations in redox status. Since oxidative stress is a characteristic of FB1 exposure, we determined 3994 
if there is cross talk between oxidative stress and m6A in FB1 exposed HepG2 cells. Briefly, HepG2 3995 
cells were treated with FB1 (0, 5, 50, 100, 200 µM; 24h) and ROS, LDH and m6A levels were quantified. 3996 
qPCR was used to determine expression of m6A modulators, Nrf2, Keap1 and miR-27b while western 3997 
blotting was used to quantify Keap1 and Nrf2 protein expression. Methylation status of Keap1 and Nrf2 3998 
promoters was assessed and RNA immunoprecipitation quantified m6a-Keap1 and m6A-Nrf2 levels.  3999 
FB1 induced an accumulation of intracellular ROS (p≤0.001) and LDH leakage (p≤0.001). Elevated 4000 
m6A levels (p≤0.05) were accompanied by an increase in m6A “writers” [METLL3 (p≤0.01) and 4001 
METLL14 (p≤0.01)], and “readers” [YTHDF1 (p≤0.01), YTHDF2 (p≤0.01), YTHDF3 (p≤0.001) and 4002 
YTHDC2 (p≤0.01)] and a decrease in m6A “erasers” [ALKBH5 (p≤0.001) and FTO (p≤0.001)]. 4003 
Hypermethylation and hypomethylation occurred at Keap1 (p≤0.001) and Nrf2 (p≤0.001) promoters, 4004 
respectively. MiR-27b was reduced (p≤0.001); however, m6A-Keap1 (p≤0.05) and m6A-Nrf2 (p≤0.01) 4005 
levels were upregulated. This resulted in the ultimate decrease in Keap1 (p≤0.001) and increase in Nrf2 4006 
(p≤0.001) expression. Our findings reveal that m6A RNA methylation can be modified by exposure to 4007 
FB1, and a cross talk between m6A and redox regulators does occur. 4008 
Keywords 4009 
Fumonisin B1, epigenetics, m6A RNA Methylation, Oxidative Stress, Keap1, Nrf2 4010 
Introduction 4011 
As one of the most toxic mycotoxins produced by the Fusarium fungal species, fumonisin B1 (FB1, 4012 
C34H59NO15) is a highly problematic agricultural contaminant in developing countries (Idahor, 2010, 4013 
Kamle et al., 2019). Not only does it affect food quality in regions that have already inadequate food 4014 
supplies but it also impinges on human and animal health. FB1 has been conjectured to be a major factor 4015 
is hepato-, nephro- and neuro-toxicity (Domijan, 2012, Müller et al., 2012, Singh and Kang, 2017, 4016 
Szabó et al., 2018). It has been implicated in carcinogenesis of the liver and kidney in animals and may 4017 
play a role in esophageal carcinogenesis in humans (Gelderblom et al., 2001, Alizadeh et al., 2012, 4018 
Müller et al., 2012). While it is universally acknowledged that inhibition of sphingolipid metabolism is 4019 
the major mechanism of FB1 toxicity (Riley and Merrill, 2019), mounting evidence suggests that 4020 
changes to the epigenetic landscape may also be critically involved in its toxicity. Although changes in 4021 
DNA methylation, microRNA (miRNA) profiles and histone modifications have already been linked to 4022 




et al., 2014b, Demirel et al., 2015, Arumugam et al., 2020); the link between RNA methylation and 4024 
FB1-induced hepatotoxicity remains uncharted territory.  4025 
RNA methylation accounts for over 60% of all RNA modifications and has been identified on all four 4026 
ribonucleic acid bases (Cantara et al., 2010, Roundtree et al., 2017). However, methylation to the sixth 4027 
nitrogen of adenosine, known as N6-methyladenosine (m6A), is the most prevalent modification that 4028 
occurs on mammalian messenger RNA (mRNA) and long non-coding RNA (lncRNA) (Desrosiers et 4029 
al., 1974, Pan, 2013).  It functions in various biological processes by controlling the fate of m6A 4030 
modified-RNA through splicing, export, translation, and degradation (Zaccara et al., 2019). 4031 
Transcriptome-wide analysis revealed that m6A sites are preferentially distributed within long exons, 4032 
in 3’ untranslated regions (3’UTR) and adjacent to stop codons of mRNA and non-coding RNAs in 4033 
various eukaryotes and some nuclear replicating viruses (Dominissini et al., 2012, Meyer et al., 2012, 4034 
Yue et al., 2015, Kennedy et al., 2016). 4035 
M6A “writers”, “erasers” and “readers” are responsible for this dynamic and reversable modification 4036 
(Zaccara et al., 2019). M6A sites are methylated by “writers” [which include methyltransferase-like 3 4037 
(METTL3), methyltransferase-like 14 (METTL14) and Wilm’s tumour 1-associated protein (WTAP)] 4038 
(Schwartz et al., 2014, Wang et al., 2016) whereas “erasers” [such as ALKB homolog 5 (ALKBH5) 4039 
and fat mass and obesity-associated protein (FTO)] are responsible for its demethylation (Jia et al., 4040 
2011, Zheng et al., 2013). Furthermore, m6A-modified transcripts are specifically  recognized by 4041 
“readers” namely, the YT521-B homology domain containing proteins 1 and 2 (YTHDC1 and 4042 
YTHDC2) and the YT521-B homology domain family proteins 1, 2, and 3 (YTHDF1, YTHDF2, and 4043 
YTHDF3) which bind to m6A within the consensus DRACH (where D = A/G/U, R= A/G, H=A/C/U) 4044 
sequence to regulate the expression and function of specific mRNAs and proteins (Dominissini et al., 4045 
2012, Zaccara et al., 2019). 4046 
Aberrant m6A patterns contribute to defective physiological processes, unusual immune responses, 4047 
abnormal metabolism, neurodegeneration and have been implicated in hepatic diseases, rheumatoid 4048 
arthritis, osteoporosis, type 2 diabetes mellitus, obesity, neurodegenerative complications, infectious 4049 
diseases and various cancers (Shen et al., 2015, Lan et al., 2019, Xu et al., 2019, Han et al., 2020, 4050 
Paramasivam et al., 2020). Of particular interest, studies have suggested that oxidative stress may be 4051 
prevalent in altering m6A methylation levels and that m6A modifications may in turn affect oxidative 4052 
stress through changes in the expression of redox regulating mRNA (Li et al., 2017, Zhao et al., 2019, 4053 
Wu et al., 2020, Zhao et al., 2020a). 4054 
We previously found that FB1 enhanced ROS production which led to liver cell injury. We further 4055 
observed activation of Kelch-like ECH associated protein 1 (Keap1)/ nuclear factor erythroid 2 (NF-4056 
E2)-related factor 2 (Nrf2) antioxidant signalling to counter the oxidative effects of FB1 (Arumugam et 4057 




ubiquitination, tagging it for proteasomal degradation. Changes in redox status triggers Nrf2 release 4059 
allowing it to translocate to the nucleus where it promotes the transcription of anti-oxidants and other 4060 
detoxifying enzymes (Kobayashi et al., 2006). However, whether FB1-mediated oxidative stress affects 4061 
m6A levels and if m6A modifications are a potential factor contributing to FB1-mediated oxidative 4062 
stress is unknown. Thus, the aim of this study was to investigate the effects of FB1 on m6A RNA 4063 
methylation and its crosstalk with oxidative stress responses in human hepatoma (HepG2) cells. We 4064 
further examined FB1-mediated alterations in the epigenetic regulation of Keap1/Nrf2 expression by 4065 
evaluating changes in promoter methylation, m6A-Nrf2, m6A-Keap1 and miRNA levels. 4066 
Method and Materials 4067 
Materials 4068 
The HepG2 cell line (HB-8065) was obtained from the American Type Culture Collection (ATCC) and 4069 
cell culture consumables were purchased from Whitehead Scientific (Johannesburg, South Africa). 4070 
MiR-27b-3p mimic (MSY0000419), miR-27b-3p inhibitor (MIN0000419), and attractene transfection 4071 
reagent (301005) were purchased from Qiagen (Hilden, Germany). Western blot reagents were 4072 
purchased from Bio-Rad (Hercules, CA, USA) while primary antibodies: anti-Nrf2 (#12721S), anti-4073 
Keap1 (#8047S); horse-radish peroxidase (HRP)-conjugated secondary antibody: goat anti-rabbit 4074 
(#7074S) were obtained from Cell Signalling Technologies (Danvers, MA, USA) and β-actin was 4075 
obtained from Sigma-Aldrich (A3854; St. Louis, MO, USA). All other reagents were purchased from 4076 
Merck (Boston, MA, USA), unless otherwise stated. 4077 
Cell Culture 4078 
HepG2 cells (1.5 X 106, passage 3) were seeded in 25 cm3 polystyrene tissue culture flasks containing 4079 
Eagle’s Minimum Essentials Medium (EMEM) supplemented with 10% heat-inactivated foetal calf 4080 
serum, 1% penicillin-streptomycin-fungizone, and 1% L-glutamine and maintained in a 5% carbon 4081 
dioxide (CO2) atmosphere at 37°C. At 80% confluency, cells were exposed to various concentrations 4082 
of FB1 (5, 50, 100 and 200 µM) for 24 hours (h) (Arumugam et al., 2020). An untreated control 4083 
(containing supplemented EMEM) was prepared along with FB1 treatments. All experiments were 4084 
repeated in two independent experiments and triplicate for reproducibility of results.  4085 
Detection of Intracellular Reactive Oxygen Species 4086 
Intracellular ROS was quantified using the 2,7-dichlorodihydrofluorescein-diacetate (H2DCF-DA) 4087 
assay, as previously described (Arumugam et al., 2019). 4088 
Measurement of Lactic Acid Dehydrogenase Leakage 4089 
Membrane damage to HepG2 cells were assessed through the measurement of lactic acid 4090 
dehydrogenase (LDH) leakage. Medium collected from control and FB1 treated cells were centrifuged 4091 




volume of LDH reagent (11644793001, Sigma Aldrich, St. Louis, MO, USA) was added to each well. 4093 
The plate was incubated for 30 min at room temperature (RT) in the dark. Absorbance was read with a 4094 
spectrophotometer (Bio-Tek μQuant, Winooski, VT, USA) at 500 nM. Results are represented as 4095 
relative fold change. 4096 
Transfection of HepG2 cells with MiR-27b Mimic and MiR-27b Inhibitor 4097 
MiR-27b is an oxidative stress responsive miRNA that targets Nrf2. To assess the effects of miR-27b 4098 
on Nrf2 mRNA and protein expression, cells were transfected with the mimic (Syn-hsa-miR-27b, 4099 
MYS0000419, Qiagen, Hilden, Germany) and inhibitor (Anti-hsa-miR-27b-3p, MIN0000419, Qiagen, 4100 
Hilden, Germany) to miR-27b. HepG2 cells were seeded in 25 cm3 polystyrene tissue culture flasks 4101 
until 80% confluent. Lyophilised miRNA mimic and inhibitor (5 nmol) was reconstituted to 20 µM in 4102 
nuclease-free water. For the transfection, miR-27b mimic or inhibitor (15 µl) was added to EMEM (72 4103 
µl) and attractene (3 µl) in microcentrifuge tubes. Samples were then incubated for 15 min at RT to 4104 
allow complex formation. Cells were rinsed with PBS and supplemented EMEM (2,940 µl) was added 4105 
to the flasks. The transfection complex was dispensed in a drop-wise fashion into the appropriate flask 4106 
with gentle swirling to ensure uniform distribution. All treatments were then incubated for 24 h (37°C, 4107 
5% CO2) and utilised for RNA and protein isolation. 4108 
RNA Isolation  4109 
RNA extraction from HepG2 cells was carried out using Qiazol reagent (79306, Qiagen, Hilden, 4110 
Germany). Once treatments were removed, HepG2 cells were rinsed thrice with PBS (0.1M) and 4111 
incubated with Qiazol and 0.1M PBS for 5 min. Cells were lysed with the cell scraper, and lysates were 4112 
incubated (-80°C, overnight). Thereafter, chloroform (100 µl) was dispensed into thawed samples and 4113 
centrifuged (12,000xg, 4°C, 15 min). Supernatants were transferred to sterile microcentrifuge tubes and 4114 
incubated with 500 µl isopropanol (-80°C, overnight). Subsequently, samples were centrifuged 4115 
(12,000xg, 4°C, 20 min), supernatants were discarded and residual salts from the RNA-containing 4116 
pellets were removed with 75% ice-cold ethanol and thereafter centrifuged (7,400xg, 4°C, 15 min). 4117 
RNA pellets were air-dried (30 min, RT) and resuspended in nuclease-free water (10 µl). RNA 4118 
concentration and purity were assessed using the Nanodrop2000 spectrophotometer (Thermo Scientific, 4119 
Waltham, USA). RNA with a 260:280 absorbance ratio between 1.8 and 2 was used for subsequent 4120 
assays and concentration was adjusted accordingly.  4121 
Quantification of Global m6A RNA Methylation  4122 
Global m6A RNA methylation was determined using the m6A RNA methylation quantification kit 4123 
(ab185912, Abcam, Cambridge, UK). Briefly, total RNA, together with m6A standards (0 – 0.1 ng/μl) 4124 
were bound to strip wells using a high-affinity RNA binding solution. Thereafter, m6A levels were 4125 
detected using an m6A capture and detection antibody. The detected signal was enhanced, and the 4126 




USA). The mean absorbance of the standards was used to construct a standard curve from which the 4128 
percentage m6A in each sample was determined. Results are presented as relative fold change.  4129 
Quantitative Polymerase Chain Reaction 4130 
qPCR was used to compare the changes in the expression of METLL3, METLL14, FTO, WTAP, 4131 
YTHDF1, YTHDF2, YTHDF3, YTHDC2, Nrf2, Keap1 and miR-27b. For mRNA expression, cDNA was 4132 
prepared from RNA (1000 ng/µl) using the Maxima H Minus First Strand cDNA Synthesis Kit 4133 
according to manufacturers’ protocol. qPCR was performed using the PowerUp™ SYBR™ Green 4134 
Master Mix (A25742, Thermo-Fisher Scientific, Waltham, MA, USA) and CFX96 TouchTM Real-Time 4135 
PCR Detection System (Bio-Rad, Hercules, CA, USA) with the following cycling conditions: initial 4136 
denaturation (95°C, 8 min), followed by 40 cycles of denaturation (95°C, 15 s), annealing 4137 
(Supplementary Table S5.1, 40 s), and extension (72°C, 30 s). Primer sequences and annealing 4138 
temperatures are listed in Supplementary Table S5.1.   4139 
For miRNA expression, cDNA synthesis was performed with 1000 ng/µl RNA, using the miScript II 4140 
RT Kit (218161, Qiagen, Hilden, Germany) according to the manufacturer’s instructions. RT-qPCR 4141 
was performed on the CFX96 TouchTM Real-Time PCR Detection System (Bio-Rad, Hercules, CA, 4142 
USA) using the miScript SYBR Green PCR Kit (218073, Qiagen, Hilden, Germany) and miR-27b 4143 
miScript primer assay (MS00009247, Qiagen, Hilden, Germany) according to the manufacturer’s 4144 
protocol with the following cycling conditions: initial denaturation (95°C, 15 min), followed by 40 4145 
cycles of denaturation (94°C, 15 s), annealing (55°C, 30 s), and extension (70°C, 30 s). 4146 
GAPDH and RNU6 were used as endogenous controls for mRNA and miRNA expression, respectively 4147 
and relative expression was calculated using the comparative threshold cycle (2ΔΔCt) method (Livak and 4148 
Schmittgen, 2001). 4149 
RNA Immunoprecipitation 4150 
Quantification of m6A-Nrf2 and m6A-Keap1 levels were determined using RNA immunoprecipitation. 4151 
Briefly, RNA (1000 ng/µl) were incubated with m6A-primary antibody (1:100; ab208577, Abcam, 4152 
Cambridge, UK) overnight at 4°C. Thereafter, the RNA-antibody complex was precipitated using 4153 
protein A beads [20 μl 50% bead slurry (Cell Signalling Technology, #9863), 4°C, 3 h]. Samples were 4154 
centrifuged (2,500xg, 4°C, 60s), washed twice in RNA immunoprecipitation buffer (150 mM KCl, 25 4155 
mM Tris-Cl (pH 7.4), 5mM EDTA, 0.5mM DTT, 0.5% IGEPAL, 100 U/ml SUPERase IN RNase 4156 
Inhibitor (Thermo-Fisher Scientific, AM2694), protease and phosphatase inhibitors (A32961, Thermo-4157 
Fisher Scientific)], washed once in nuclease free water and resuspended in nuclease free water (10 µl). 4158 
Immunoprecipitated RNA was standardised to 200 ng/μl, and reverse transcribed into cDNA as 4159 
described above. The expression of m6A-Nrf2 and m6A-Keap1 was then determined using qPCR as 4160 




DNA Isolation and Promoter Methylation Analysis 4162 
Genomic DNA was isolated from HepG2 cells as previously described (Ghazi et al., 2020b). Isolated 4163 
DNA was standardized to 4 ng/µl and used to determine methylation status at Nrf2 and Keap1 promoter 4164 
regions. This was done using the OneStep qMethyl Kit (5310, Zymo Research, 5310) as per 4165 
manufacturer’s instructions. Primer sequences and annealing temperatures are listed in Supplementary 4166 
Table 1. Cycling conditions were as follows: digestion by methyl sensitive restriction enzymes (37°C, 4167 
2 h), initial denaturation (95°C, 10 min), followed by 45 cycles of denaturation (95°C, 30s), annealing 4168 
(Supplementary Table S5.1, 60s), extension (72°C, 60s), final extension (72°C, 60s), and a hold at 4°C. 4169 
Results are represented as a fold-change relative to the control.   4170 
Protein Isolation and Western Blotting 4171 
The western blotting technique was used to determine protein expression of Nrf2 and Keap1. Protein 4172 
was isolated and quantified as previously described (Arumugam et al., 2019). The standardized protein 4173 
extracts (1 mg/ml) were separated using 10% sodium dodecyl sulphate-polyacrylamide gel 4174 
electrophoresis, and transferred to nitrocellulose membranes which were then blocked in 5% non-fat 4175 
dry milk (1 h) before incubation with the primary antibodies, anti-Nrf2 (1:1000; #12721S, Cell 4176 
Signalling Technologies, Danvers, MA, USA) and anti-Keap1 (1:1000; #8047S, Cell Signalling 4177 
Technologies, Danvers, MA, USA) overnight at 4°C. Membranes were washed thrice in Tween 20-Tris 4178 
buffer saline (TTBS: 150 mmol/l NaCl, 3 mmol/l KCl, 25 mmol/l Tris, 0.05% Tween 20, dH2O, pH 4179 
7.5) and thereafter incubated with horse-radish peroxidase-conjugated goat anti-rabbit (1:5000; #7074S, 4180 
Cell Signalling Technologies, Danvers, MA, USA) secondary antibody for 2 hours. Thereafter, 4181 
membranes were washed thrice with TTBS and protein expression was visualised using the Clarity 4182 
Western ECL Substrate Kit (1705060, Bio-Rad, Hercules, CA, USA) with the Chemidoc gel 4183 
documentation system (Bio-Rad, Hercules, CA, USA). β-actin served as a housekeeping control and 4184 
protein expression was determined using the Image Lab Software version 5.0 (Bio-Rad, Hercules, CA, 4185 
USA) which measured band densities of expressed proteins. Protein expression is represented as relative 4186 
band density and calculated by normalising the protein of interest against β-actin. 4187 
Statistical Analysis 4188 
Statistical analyses were performed using GraphPad Prism version 5.0 (GraphPad Software Inc., San 4189 
Diego, CA, USA). Data were expressed as the mean ± standard deviation and analysis of variance 4190 
(ANOVA) with Dunnet’s post-test was used to determine the statistical differences among the groups. 4191 








FB1 Enhanced ROS Production and Cell Membrane Damage 4197 
The effect of FB1 on ROS generation was evaluated using the H2DCF assay. FB1 altered the redox status 4198 
of HepG2 cells by inducing a significant dose-dependent increase in ROS levels (p= 0.0005; Figure. 4199 
5.1a). Excessive production of ROS leads to cellular injury and hepatoxicity. Upon damage to cellular 4200 
membranes, cells release the enzyme LDH. As depicted in Figure 5.1b, exposure to FB1 for 24 h 4201 
promoted LDH leakage in a significant dose-dependent manner (p < 0.0001) indicating severe cell 4202 
damage occurred.  4203 
 4204 
Figure 5.1. FB1-induced hepatotoxicity in HepG2 cells. HepG2 cells were cultured with varying 4205 
concentrations of FB1 for 24 h. Intracellular ROS generation was examined by an oxidation sensitive 4206 
fluorescent probe and ROS generation was significantly accelerated upon FB1 exposure (a; *** p ≤ 4207 
0.001). LDH leakage was used as an indicator of hepatic injury and was found to be significantly 4208 
increased at all FB1 concentrations tested (b; *** p ≤ 0.001).  4209 
FB1 Altered Global M6A Levels and Expression of M6A Regulatory Elements 4210 
To determine whether FB1-prompted oxidative stress has the potential to induce aberrant m6A 4211 
modifications, levels of total m6A-modified RNA in FB1-treated HepG2 cells were detected. In Figure 4212 
5.2a, the m6A levels of the FB1-treated groups increased, but only cells treated with 200 µM showed 4213 
significant changes in m6A compared to the control (p= 0,0132). 4214 
M6A modifications are regulated by methyltransferases and demethylases; therefore, we set out to 4215 
determine if changes in the expression of m6A-modifing enzymes were responsible for the changes in 4216 
m6A levels observed in FB1-exposed cells. There was a significant concentration-dependant increase 4217 
in the mRNA levels of m6A methyltransferase (Figure 5.2b) METTL3 (p = 0,0017), while METTL14 4218 
was reduced at 5 µM FB1 and upregulated at the higher (50-200 µM) concentration of FB1 tested (p = 4219 
0,0043). Conversely, a significant dose-dependent decrease in the m6A demethylases (Figure 5.2c), 4220 




Specific m6A readers recognize m6A-modified RNA and regulate gene expression through various 4222 
mechanisms. Thus, we determined if FB1 had any effects on the expression of the m6A readers (Figure 4223 
5.2d); and found that FB1 significantly increased the expression of YTHDF1 (p = 0,0038), YTHDF3 (p 4224 
= 0,0005) and YTHDC2 (p = 0,0064) in HepG2 cells in comparison to the untreated cells. YTHDF2 4225 
expression was reduced at 5 µM FB1 and elevated at the higher (50-200 µM) concentration of FB1 tested 4226 
(p = 0,0021). 4227 
Taken together, the data suggests that FB1-induced oxidative stress increased m6A methylation, 4228 
possibly, through mediating dysregulation of m6A regulatory genes. 4229 
 4230 
Figure 5.2. Aberrant m6A modifications induced by FB1 in HepG2 cells. FB1 increased global m6A 4231 
RNA modifications (a; *p  ≤ 0.05) and induced changes in m6A writers [b: METLL3 (** p ≤ 0.01) and 4232 
METLL14 (** p ≤ 0.01)], erasers [c: ALKBH5 (*** p ≤ 0.001) and FTO (*** p ≤ 0.001)] and readers 4233 
[d: YTHDF1 (** p ≤ 0.01), YTHDF2 (** p ≤ 0.01), YTHDF3 (*** p ≤ 0.001) and YTHDC2 (** p ≤ 4234 
0.01)].  4235 
FB1 Epigenetically Regulates Keap1 Expression 4236 
In response to xenobiotic stress, cells activate the Keap1/Nrf2 pathway. Inactivation of Keap1 is 4237 
required for Nrf2-mediated activation of the antioxidant response to oxidative stress (Kobayashi et al., 4238 
2006). Furthermore, it was recently observed that m6A modifications may also regulate Keap1/Nrf2 4239 
expression (Wang et al., 2019, Zhao et al., 2020a). Thus, we evaluated the epigenetic regulation of 4240 
Keap1 through both post-transcriptional (RNA methylation) and transcriptional (DNA methylation) 4241 




FB1 has previously been shown to induce changes in the methylation status of promoter regions in genes 4243 
(Demirel et al., 2015). We observed significant dose-dependent hypermethylation of CpG islands at the 4244 
Keap1 (p < 0.0001; Figure 5.3a), this led to a corresponding significant decrease in Keap1 mRNA 4245 
expression (p< 0.0001; Figure 5.3b).  4246 
Since FB1 altered global m6A RNA levels, we employed the m6A site predictor SRAMP to identify 4247 
m6A sites on Keap1 mRNA (Zhou et al., 2016). The results showed 29 possible m6A sites including 7 4248 
possible m6A sites with high confidence and 1 with very high confidence. Figure 5.3c represents the 4249 
m6A consensus sequence motif of Keap1 (AGACU or GGACU) depicted as sequence logo obtained 4250 
by the WebLogo 3 server (weblogo.threeplusone.com/create.cgi). The height of each stack indicates the 4251 
degree of conservation (bits). The height of the letters represents the relative frequency of the base.  4252 
Changes in m6A-Keap1 levels were then evaluated via RNA immunoprecipitation. In Figure 5.3d, 4253 
exposure to varying concentrations of FB1 lead to a significant dose-dependent increase in m6A-Keap1 4254 
levels (p= 0,0125). Furthermore, we assessed changes in Keap1 protein expression and found it to be 4255 
dose-dependently reduced by FB1 (p < 0.0001; Figure 5.3e). 4256 
 4257 
 4258 
Figure 5.3. The epigenetic effects of FB1 on Keap1 expression in HepG2 cells. FB1 induced hypermethylation at 4259 
Keap1 promoters (a; *** p ≤ 0.001) resulting in reduced Keap1 gene expression (b; *** p ≤ 0.001). A consensus 4260 
sequence for possible m6A modifications on Keap1 transcripts was constructed (c). RNA immunoprecipitation 4261 
with m6A antibodies revealed that FB1 upregulated m6A-Keap1 (d; * p ≤ 0.05) while western blotting found 4262 





FB1 Promoted Nrf2 Expression Through Epigenetic Modifications 4265 
DNA methylation, miR-27b and m6A-modifications are just a few of the epigenetic factors that play a 4266 
role in Nrf2 regulation, thus it was evaluated accordingly (Kang et al., 2014, Xu et al., 2017, Zhao et 4267 
al., 2020a). 4268 
First, methylation status of Nrf2 promoters was evaluated in control and FB1 treated HepG2 cells. FB1 4269 
induced a significant dose-dependent hypomethylation of Nrf2 promoters (Figure 5.4a; p< 0.0001). 4270 
Next, posttranscriptional regulation of Nrf2 was determined. MiR-27b was previously shown to directly 4271 
target Nrf2 (Xu et al., 2017). This was further confirmed using the bioinformatics prediction algorithm 4272 
software, TargetScan (version 7.1), where miR-27b was found to have complementary base pairs with 4273 
Nrf2 at positions 62-68 in humans (Agarwal et al., 2015). Thus, miR-27b expression was determined in 4274 
FB1 treated HepG2 cells using qPCR. The HepG2 cells were also treated with a miR-27b mimic and 4275 
inhibitor which acted as a positive and negative control, respectively. Here, miR-27b levels were 4276 
diminished at all concentrations of FB1 tested (Fig. 4b; p< 0.0001). The expression of miR-27b in 4277 
HepG2 cells treated with the mimic and inhibitor were increased and decreased, respectively (Figure 4278 
5.4b; p< 0.0001).  4279 
Nrf2 gene expression was also determined by qPCR. FB1 increased Nrf2 expression in HepG2 cells. 4280 
Treatment of HepG2 cells with the miR-27b mimic and inhibitor resulted in a decrease and increase, 4281 
respectively in Nrf2 levels (Figure 5.4c). 4282 
SRAMP was also used to predict m6A sites on Nrf2 transcripts. A total of 54 m6A sites were predicated 4283 
with 15 high confidence and 2 very high confidence sites. Figure 5.4d represents the consensus motif 4284 
of m6A modification on Nrf2 which is GGACU. We further tested m6A-Nrf2 levels and found that like 4285 
Keap1, FB1 significantly upregulated m6A-Nrf2 levels (p = 0,0018; Fig. 4e). Moreover, western blotting 4286 
analysis revealed that FB1 significantly increased Nrf2 protein expression in a dose-dependent manner 4287 
(p < 0.0001; Figure 5.4f). Treatment of HepG2 cells with the miR-27b mimic and inhibitor resulted in 4288 
a decrease and increase, respectively in Nrf2 protein levels (Figure 5.4f); further validating that Nrf2 is 4289 





Figure 5.4. FB1 epigenetically regulates Nrf2 expression in HepG2 cells. FB1 induced hypomethylation 4292 
at Nrf2 promoter regions (a; *** p ≤ 0.001) and reduced miR-27b (b; *** p ≤ 0.001) expression; which 4293 
led to the subsequent increase in Nrf2 mRNA levels (c; *** p ≤ 0.001). A consensus sequence for 4294 
possible m6A modifications on Nrf2 transcripts was constructed (d). m6A-Nrf2 (e; p ≤ 0.01) and Nrf2 4295 
protein expression (f; *** p ≤ 0.001) were significantly increased.  4296 
Discussion 4297 
FB1 is a well-known hepatotoxin and hepatocarcinogen (Gelderblom et al., 2001, Singh and Kang, 4298 
2017). It induces its toxicity via the disruption of sphingolipid metabolism, resulting in oxidative stress, 4299 
endoplasmic reticulum stress and autophagy (Liu et al., 2019). However, epigenetic changes also play 4300 
a critical role in its toxicity and carcinogenicity. For instance, miR-27b is an important regulator of 4301 
cholesterol and lipid metabolism, and prevents the bioactivation of procarcinogens via the suppression 4302 
of cytochrome 1b1 (Tsuchiya et al., 2006, Vickers et al., 2013). However, the downregulation of miR-4303 
27b by FB1 and concurrent increase in cytochrome 1b1 facilitates neoplastic transformation observed 4304 
in FB1 exposed liver cells (Chuturgoon et al., 2014b). Furthermore, FB1 specifically methylates CpG 4305 
islands found on the promoters of tumour suppressor genes and induces global hypomethylation which 4306 
are both common hallmarks of cancer (Chuturgoon et al., 2014a, Demirel et al., 2015). More recently, 4307 
FB1 prompted changes in miRNA-30c and histone methylation which led to the loss the tumour 4308 
suppressor, phosphatase and tensin homolog (PTEN) and diminished response and repair of oxidative 4309 
DNA lesions (Arumugam et al., 2020). While alterations in DNA methylation, histone modifications 4310 
and miRNA profiles have been shown to play a part in FB1-mediated hepatopathologies, little has been 4311 




With more than 100 identified RNA modifications, m6A remains the most prevalent epitranscriptomic 4313 
marker (Cantara et al., 2010). Changes in redox homeostasis have been shown to affect m6A levels and 4314 
m6A modifications in turn may affect oxidative stress through regulating redox-associated genes (Li et 4315 
al., 2017, Zhao et al., 2019, Wu et al., 2020, Zhao et al., 2020a). Therefore, in this study, we explored 4316 
the effects of m6A modifications to further analyse the mechanisms by which FB1 induces its toxicity. 4317 
We evaluated changes in ROS, global m6A RNA levels and expression of m6A regulatory genes in 4318 
HepG2 cells exposed to varying concentrations of FB1 for 24 h. We further examined the epigenetic 4319 
regulation of Keap1/Nrf2 signalling by assessing changes in promoter methylation, m6A-Nrf2, m6A-4320 
Keap1 and miR-27b levels. 4321 
In order to characterize oxidative stress induced by FB1, intracellular ROS production was quantified 4322 
using the fluorometric H2DCF assay. As presented in Figure 5.1a, exposure to FB1 for 24 h enhanced 4323 
intracellular ROS levels in a dose-dependent manner. Excessive levels of ROS inflict cellular injury. 4324 
We previously showed that FB1 (200µM, 24h) accelerated the production of ROS inducing severe 4325 
damage to lipids and proteins, contributing to its toxicity in HepG2 cells (Arumugam et al., 2019). Here, 4326 
we found that FB1-induced ROS inflicted severe cellular damage as LDH leakage was significantly 4327 
increased at all FB1 concentrations tested (Figure 5.1b). Taken together these results confirm that FB1 4328 
induces hepatotoxicity through an accumulation of intracellular ROS.  4329 
Environmental stimuli including heat shock and ultra-violet radiation have been shown to alter m6A 4330 
patterns in HepG2 cells (Dominissini et al., 2012). To determine whether FB1 may have an impact on 4331 
m6A patterns, we first determined whether FB1 altered global m6A levels. Analysis of total RNA 4332 
revealed that m6A levels were elevated in a dose-dependent manner by FB1; however, they were only 4333 
significantly elevated at the highest concentration of FB1 tested (200 µM; Figure 5.2a). Previous reports 4334 
have indicated that other Fusarium toxins that naturally co-occur with FB1 can alter m6A methylation 4335 
patterns. Deoxynivalenol (DON) differentially regulated genes related to the tumour necrosis factor 4336 
alpha inflammatory pathway through aberrant m6A patterns (Zhengchang et al., 2020), while fusaric 4337 
acid reduced p53 expression through the reduction of m6A-p53 levels (Ghazi et al., 2020a).  Of 4338 
particular interest, Wu et al. (2020) demonstrated that ROS-mediated increases in m6A RNA 4339 
methylation may be a potential mechanism of aflatoxin B1-induced hepatotoxicity. Although the 4340 
observed trends were different in these studies, the results suggest that m6A modifications are involved 4341 
in the toxic effects of these mycotoxins. In addition, m6A modifications promote hepatic growth and 4342 
aberrant m6A RNA levels in liver have been associated with liver pathologies such as hepatocellular 4343 
carcinogenesis, viral hepatitis and non-alcoholic fatty liver disease. Therefore, we speculate that 4344 
increases in m6A modification may be related to the toxic nature of FB1 in the liver. 4345 
Ideally, increased expression of m6A methyltransferases and reduced expression of m6A demethylases 4346 
should result in the elevated m6A levels that were observed. Thus, we determined if FB1 altered the 4347 




consisting of the catalytic unit METLL3 and structural components METTL14 and WTAP. FB1 dose-4349 
dependently increased the expression of METTL3 and METTL14 (Figure 5.2b); however, like global 4350 
m6A levels, results were only significant at the higher FB1 concentrations tested. M6A marks are 4351 
removed by the demethylases: FTO and ALKBH5. Exposure to FB1 resulted in the drastic decrease in 4352 
m6A-demethylases at all concentrations tested (Figure 5.2c). The extremely low levels of FTO may 4353 
also contribute to the toxic nature of FB1 as FTO knock down was shown to contribute to chromosomal 4354 
instability and cell cycle arrest (Huang et al., 2019). The results suggest that together m6A writers and 4355 
erasers are involved in regulating global m6A levels; however, METLL3 may play a more prominent 4356 
role as its expression pattern closely matched total m6A levels induced by FB1.The expression of m6A 4357 
readers were also determined as they recognize and govern the fate of m6A modified transcripts. For 4358 
instance, YTHDF1, YTHDF3 and YTHDC2 promote the translation of m6A marked transcripts; while 4359 
YTHDF2 accelerates the degradation of m6A-modified transcripts. FB1 increased the mRNA levels of 4360 
m6A “readers” in HepG2 cells; however, 200 µM FB1 was the only concentration to significantly 4361 
increase the expression of all m6A “readers” (Figure 5.2d). The differential expression in m6A 4362 
regulating enzymes may also contribute to abnormal lipid metabolism and immune profiles in the liver 4363 
(Zhao et al., 2020b). 4364 
FB1-induced increases in m6A levels may lead to the altered expression of important genes involved in 4365 
its toxicity. Since FB1 triggered abnormal ROS production, we decided to focus on Keap1 and Nrf2 as 4366 
the Keap1/Nrf2 signaling plays a critical role in responding to xenobiotic and electrophilic stress. Not 4367 
only did we set out to determine changes in m6A-Keap1 and m6A-Nrf2 but we also evaluated other 4368 
epigenetic changes that might affect their expression. 4369 
The most extensively studied epigenetic modification to eukaryotic genomes is DNA methylation which 4370 
occurs primarily at CpG sites. Methylation of CpG islands found in gene promoters prevents the binding 4371 
of transcription factors, silencing transcription. As seen in Figure 5.3a, FB1 induced significant 4372 
hypermethylation at the Keap1 promoter, inhibiting Keap1 transcription (Figure 5.3b). Before assessing 4373 
m6a-Keap1 levels, a sequence based m6A site predictor (SRAMP) was used to define potential m6A 4374 
sites on Keap1 mRNA (Zhou et al., 2016). 29 possible m6A sites were predicted on Keap1 transcripts 4375 
including 7 possible m6A sites with high confidence and 1 with very high confidence. Furthermore, the 4376 
consensus motifs (GGACU and AGACU) matched DRACH motif (Figure 5.3c). The results suggest 4377 
that m6A-modified Keap1 maybe be involved in its translation. Using RNA immunoprecipitation and 4378 
western blotting, we determined changes in m6A-Keap1 and Keap1 protein expression, respectively. 4379 
Although m6A modified Keap1 levels were increased (Figure 5.3d); there was a severe loss in Keap1 4380 
protein expression (Figure 5.3e). The m6A-reader YTHDF2 may be responsible for this. The aromatic 4381 
cage of YTHDF2 specifically targets m6A modified RNA to cytoplasmic decay sites and accelerates 4382 
the degradation of marked transcripts (Wang et al., 2014). The high levels of YTHDF2 observed post 4383 




was attenuated by the overexpression of METTL3 and diminished Keap1 levels. METLL3, enhanced 4385 
m6A modifications on pri-miR-873, promoted the generation of mature miR-873-5p which in turn 4386 
inhibited Keap1 expression (Wang et al., 2019). Cells may be responding to FB1-mediated oxidative 4387 
stress in a similar manner, however this needs to be further investigated. 4388 
Not only is Nrf2 expression regulated by DNA and RNA methylation but also by miRNA-27b (Kang 4389 
et al., 2014, Xu et al., 2017). As mentioned earlier, FB1 downregulated miR-27b expression 4390 
(Chuturgoon et al., 2014b). It was previously shown that miR-27b regulates Nrf2 expression (Xu et al., 4391 
2017) and this was further confirmed using TargetScan version 7.1 (Agarwal et al., 2015). 4392 
Hypomethylation of Nrf2 promoters (Figure 5.4a), coupled with the gross loss of miR-27b (Figure 5.4b) 4393 
resulted in elevated Nrf2 mRNA expression (Figure 5.4c). Moreover, 54 possible m6A sites with 15 4394 
high confidence and 2 very high confidence sites were predicted using SRAMP. The consensus motif 4395 
(GGACU) also matched the DRACH motif (Figure 5.4d).   FB1 significantly increased m6A-Nrf2 levels 4396 
(Figure 5.4e) and Nrf2 protein expression (Figure 5.4f). It is possible that the increase in YTHDF1, 4397 
YTHDF3 and/or YTHDC2 may be responsible for elevated Nrf2 protein expression as these readers 4398 
promote the translation of targeted transcripts (Wang et al., 2015). Oxidative stress was also shown to 4399 
elevate m6A-Nrf2 levels in di-(2-ethylhexyl) phthalate (DEHP) exposed rats, however, the fate of m6A-4400 
tagged Nrf2 transcripts were not further investigated. The authors speculated that Nrf2 protein 4401 
expression would be decreased, however, the opposite could be true; like our study YTHDC2 was also 4402 
elevated after DEHP exposure.  4403 
To our knowledge, this is the first study to identify that FB1 alters global and transcript-specific m6A 4404 
methylation levels. While several studies have noted the accumulation of ROS enhances m6A RNA 4405 
levels, we cannot say for certain that the observed changes were due to FB1 effect on ROS generation 4406 
(Li et al., 2017, Zhao et al., 2019, Wu et al., 2020, Zhao et al., 2020a). The use of positive and negative 4407 
controls such as hydrogen peroxide and an antioxidant such as N-acetylcysteine would have given a 4408 
more definitive answer. However, it is evident that FB1 does significantly alter the expression of m6A 4409 
modulator genes especially m6A demethylases. It would be interesting to further explore if the 4410 
differential expression of these m6A regulating genes may play a role in FB1 toxicity aside from m6A 4411 
regulation as these genes have been shown to regulate metabolism and immune profiles in the liver (Xu 4412 
et al., 2019).  Further, FB1 epigenetically regulates Keap1 and Nrf2 expression, through changes in 4413 
promoter methylation, RNA methylation and miR-27b levels. The downregulation of Keap1 and 4414 
upregulation of Nrf2 by FB1 suggests that antioxidant signalling pathways have been activated. An 4415 
increase in Nrf2 regulated anti-oxidants were previously observed in response to FB1-induced oxidative 4416 
stress (Arumugam et al., 2019). However, the activation of Nrf2 antioxidant signalling may not be 4417 
sufficient to counter the accumulation of ROS induced by FB1 as severe cellular injury occurred.  4418 
Furthermore, prolonged activation of Nrf2 signalling supports a cancerous phenotype through ROS 4419 




promoters, hypomethylation at Nrf2 promoters and altered miRNA profiles have shown to be involved 4421 
in deregulation of Keap1/Nrf2 in various cancers (Eades et al., 2011, Barbano et al., 2013, Kang et al., 4422 
2014, Fabrizio et al., 2018). We can only speculate that this may be a possible mechanism by which 4423 
FB1 promotes hepatocarcinogenesis. However, further studies should be conducted to test this 4424 
hypothesis. The use of longer exposure times and comparing differences in the epigenetic profiles 4425 
linked to Keap1/Nrf2 dysregulation in normal and cancerous cells may be key.  4426 
Conclusion 4427 
The results of this study revealed that FB1 induces hepatotoxicity as observed by ROS accumulation 4428 
and loss of cell membrane integrity. Global m6A levels were increased in response to changes in the 4429 
expression of m6A-modulating genes (Figure 5.5a). Further, we observed hypermethylation of Keap1 4430 
promoters, hypomethylation of Nrf2 promoters, reduction in miR-27b and increase in m6A-Keap1 and 4431 
m6A-Nrf2, which ultimately led to the activation of Keap1/Nrf2 signalling (Figure 5.5b-c). This study 4432 
provides new evidence that m6A modifications may play a pivotal role in FB1-induced oxidative stress 4433 
and hepatocarcinogenesis.    4434 
 4435 
Figure 5.5. FB1 alters global m6A RNA methylation and epigenetically regulates Keap1-Nrf2 signaling. (a) FB1 4436 
induced changes to global m6A RNA methylation by mediating changes in m6A “writers” (METLL3 and 4437 
METLL14) and m6A demethylases (FTO and ALKBH5). (b) FB1 epigenetically downregulates Keap1 through 4438 
hypomethylation of Keap1 gene promoters and degradation of m6A-Keap1 transcripts via YTHDF2. (c) Nrf2 is 4439 
epigenetically upregulated by FB1 via hypomethylation of Nrf2 promoters, reduced miR-27b and increased 4440 
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Supplementary Information 4456 
Supplementary Table S5.1: Primer sequences and annealing temperatures used in qPCRs 4457 
Gene Sense Primer 
5’→ 3’ 
Anti-sense Primer 





METTL3 TTGTCTCCAACCTTCCGTAGT CCAGATCAGAGAGGTGGTGTAG 56 
METTL14 GAACACAGAGCTTAAATCCCCA TGTCAGCTAAACCTACATCCCTG 56 
FTO GCTGCTTATTTCGGGACCTG AGCCTGGATTACCAATGAGGA 56 
ALKBH5 ATCCTCAGGAAGACAAGATTAG TTCTCTTCCTTGTCCATCTC 60 
YTHDF1 ATACCTCACCACCTACGGACA GTGCTGATAGATGTTGTTCCCC 56 
YTHDF2 CCTTAGGTGGAGCCATGATTG TCTGTGCTACCCAACTTCAGT 56 
YTHDF3 TCAGAGTAACAGCTATCCACCA GGTTGTCAGATATGGCATAGGCT 56 
YTHDC2 CAAAACATGCTGTTAGGAGCCT CCACTTGTCTTGCTCATTTCCC 60 
Keap1 CTGGAGGATCATACCAAGCAGG GGATACCCTCAATGGACACCAC 57 








Same as gene 
of interest 
Promoter Methylation 
Keap1 TTAGTTATTTAG-GAGGTTGT AACCCCCCTTCTCACTA 54 
Nrf2 TGAGATATTTTGCACATCCGATA ACTCTCAGGGTTCCTTTACACG 54 
RNA Immunoprecipitation 
Keap1 CTGGAGGATCATACCAAGCAGG GGATACCCTCAATGGACACCAC 57 




Supplementary Figure S5.1. TargetScan analyses of miR-27b to the 3’ UTR of NFE2L2 (Nrf2) in 4461 
humans. MiR-27b has complementary base pairs with the 3’ UTR of Nrf2 at positions 62-68 in humans. 4462 
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FB1 is a hazardous mycotoxin that induces toxic and carcinogenic effects in humans and animals.  FB1 4662 
induces changes to the epigenome which may provide insight into its toxic and carcinogenic nature. 4663 
The lncRNA, HOXA11-AS influences the epigenome by modulating DNA methylation functioning as 4664 
a competing endogenous RNA (ceRNA) or molecular scaffold. However, the role of HOXA11-AS in 4665 
FB1-toxicity is unknown. Therefore, we investigated the effect of FB1 on p53-dependent apoptosis via 4666 
the HOXA11-AS/miR-124/DNMT axis. HepG2 cells were treated with various concentrations of FB1 4667 
(0, 5, 50, 100 and 200 µM; 24 h). qPCR and/or western blotting was used to determine expression of 4668 
HOXA11-AS, miR-124, SP1, DNMT1, DNMT3A, DNMT3B and p53. Global DNA methylation and 4669 
p53 promoter methylation was assessed, whilst luminometry was used to measure caspase activity. FB1 4670 
upregulated HOXA11-AS (p≤0.05) leading to the subsequent decrease in miR-124 (p≤0.01) and 4671 
increase in SP1 (p≤0.001), DNMT1 (p≤0.001), DNMT3A (p≤0.001) and DNMT3B (p≤0.001). This 4672 
promoted global DNA methylation (p≤0.05) and hypermethylation of p53 promoters (p≤0.001) thereby 4673 
reducing p53 expression (p≤0.001) and caspase activity (p≤0.001). Taken together the data suggests 4674 
that FB1 inhibits p53-dependent apoptosis via HOXA11-AS/miR-124/DNMT axis in HepG2 cells.   4675 
Keywords 4676 
Fumonisin B1, Epigenetics, HOXA11-AS, miR-124, DNA Methylation, p53. 4677 
Introduction 4678 
Our life long development is not only dictated by our genetic code but also a dynamic network 4679 
regulating DNA methylation, covalent histone modifications, RNA modifications and non-coding RNA 4680 
(Kanherkar et al., 2014). This network is known as the epigenome. Together these modifications 4681 
regulate gene expression and bring about phenotypic variations without altering the genetic code 4682 
(Marczylo et al., 2016).  However, changes to the epigenome brought about by environmental factors 4683 
such as mycotoxins can lead to adverse health outcomes (Marczylo et al., 2016, Huang et al., 2019). 4684 
Mycotoxins are toxic secondary metabolites produced by various fungi (Bennett, 1987). They 4685 
chronically contaminate agricultural foods that are intended for human and animal consumption and 4686 
elicit a wide variety of detrimental effects (Bennett and Klich, 2003, Eskola et al., 2020). The 4687 
mechanisms by which mycotoxins induce their toxicity vary; however, over the past decade epigenetic 4688 
changes have been implicated in various mycotoxin-related diseases and toxicities in humans and 4689 
animals (Huang et al., 2019). The most toxicologically relevant mycotoxins include aflatoxins, 4690 
ochratoxins, trichothecenes and fumonisins (Fung and Clark, 2004). Fumonisins are naturally produced 4691 
by Fusarium verticillioides and Fusarium proliferatum (Ross et al., 1990, Ross et al., 1992). Due to 4692 
poor agricultural practices and storage conditions, fumonisins mainly contaminate cereals and cereal-4693 
based-products thereby, posing a serious threat to human and animal health (Mashinini and Dutton, 4694 




28 identified fumonisin analogues, fumonisin B1 (FB1) is regarded as the most relevant due to its potent 4696 
toxicity and widespread distribution (Rheeder et al., 2002).  4697 
Epigenetic changes have been linked to FB1 toxicity. For instance, FB1-induced changes in miRNA 4698 
profiles and covalent histone modifications have been linked to genetic instability, and may be potential 4699 
mechanisms for FB1-related carcinogenesis and neural tube defects (Chuturgoon et al., 2014b, Sancak 4700 
and Ozden, 2015, Gardner et al., 2016, Arumugam et al., 2020). Moreover, the effects of FB1 on global 4701 
DNA methylation have been thoroughly investigated by several research groups (Mobio et al., 2000, 4702 
Kouadio et al., 2007, Chuturgoon et al., 2014a), with Demirel et al. (2015) demonstrating that FB1 may 4703 
exert its carcinogenic effects by modulating the promoter methylation of specific tumour suppressor 4704 
genes. While the effects of FB1 on DNA methylation, histones modification and miRNA have been 4705 
explored, no study has evaluated the impact FB1 may have on long non-coding RNAs (lncRNAs). 4706 
LncRNAs were long considered irrelevant and thought of as merely “transcriptional noise” (Kung et 4707 
al., 2013). However, with recent advances in sensitive, high-throughput genomic technologies and next-4708 
generation sequencing, their true potential is finally being recognized (Atkinson et al., 2012, Zhu et al., 4709 
2016). LncRNAs influence chromatin structure and gene expression thereby, regulating several 4710 
biological processes such as  apoptosis, proliferation differentiation and cell cycle regulation (Hu et al., 4711 
2011, Han and Chang, 2015, Nötzold et al., 2017, Yang et al., 2018c, Li et al., 2019); thus, dysregulation 4712 
of lncRNAs have been associated with several pathological states such as, neurodegenerative disorders, 4713 
chronic liver diseases, renal failure and  numerous cancers (Prensner and Chinnaiyan, 2011, Sun et al., 4714 
2018a, Tang et al., 2019, Kim et al., 2020).  4715 
One such lncRNA is homeobox A11 antisense (HOXA11-AS), a highly conserved lncRNA located in 4716 
the HOXA gene cluster on chromosome 7p15 (Wei et al., 2020). By acting as a circulating endogenous 4717 
RNA (ceRNA) and molecular scaffold, HOXA11-AS contributes to the ever-changing epigenome (Wei 4718 
et al., 2020). As a ceRNA, HOXA11-AS sequesters miRNA with complementary binding sites such as 4719 
miR-148, miR-200 and miR-124 and blocks the regulatory interaction between the miRNA and its 4720 
target mRNA (Chen et al., 2017, Bai et al., 2019). By acting as a molecular scaffold, HOXA11-AS 4721 
modulates the transcription of target genes by recruiting proteins including DNA methyltransferases 4722 
(DNMTs) and transcription factors to the promoter regions of genes (Sun et al., 2016). Furthermore, 4723 
Yu et al. (2017b) demonstrated that HOXA11-AS “sponging” of miR-124 upregulates SP1, a DNMT1 4724 
transcription factor (Kishikawa et al., 2002). MiR-124 is also responsible for DNMT3B regulation 4725 
(Chen et al., 2015). Thus, it is possible that HOXA11-AS may play a role in FB1-mediated changes in 4726 
both global and gene-specific methylation by regulating DNMT expression. Using bioinformatic 4727 
prediction analysis and laboratory-based methods, this study evaluated the potential role of HOXA11-4728 
AS in FB1 toxicity and DNA methylation. We assessed the relationship between HOXA11-AS and miR-4729 
124 and how it may impact DNMT expression, global DNA methylation and promoter methylation via 4730 




suppressor and transcription factor that plays a pivotal role in facilitating stress responses (Shieh et al., 4732 
1999, Yin et al., 1999, Vousden and Prives, 2009). Such stresses include oxidative stress, DNA damage 4733 
and cell cycle abnormalities (Shieh et al., 1999, Yin et al., 1999). We recently found that FB1 induced 4734 
oxidative DNA damage and inhibited DNA damage checkpoint regulation (Arumugam et al., 2020). It 4735 
is possible that p53 may play a role in responding to FB1-mediated stress. Therefore, the aim of this 4736 
study was to determine the effects of FB1 on HOXA11-AS and the downstream effects it may have on 4737 
global and p53 promoter methylation via HOXA11-AS/miR-124/DNMT axis.  4738 
Method and Materials 4739 
Materials 4740 
FB1 (Fusarium moniliforme) was purchased from Cayman Chemicals (62580, Ann Arbor, MI, USA). 4741 
Silencing RNA (siRNA) against HOXA11-AS (SI03654588), siRNA negative control (0001027281), 4742 
miR-124 mimic (MSY0004591), miR-124 inhibitor (MIN0004591), and attractene transfection reagent 4743 
(301005) were purchased from Qiagen (Hilden, Germany). The DNA methylation inhibitor, 5-Aza-2-4744 
deoxycytidine (5-Aza-2-dc; A3653) was purchased from Sigma-Aldrich (A3854, St. Louis, MO, USA) 4745 
and the human heptoma (HepG2) cell line (HB-8065) was procured from the American Type Culture 4746 
Collection (ATCC). Cell culture consumables were obtained from Whitehead Scientific (Johannesburg, 4747 
South Africa). Western blot reagents were purchased from Bio-Rad (Hercules, CA, USA) while primary 4748 
and secondary antibodies were obtained from Cell Signalling Technologies (Danvers, MA, USA) and 4749 
β-actin was obtained from Sigma Aldrich (A3854, St. Louis, MO, USA). A detailed list of the antibodies 4750 
used in this study is included in Supplementary Table S6.1. All other reagents were purchased from 4751 
Merck (Boston, MA, USA), unless otherwise stated. 4752 
Cell culture  4753 
HepG2 cells were grown in complete culture medium [CCM: Eagle’s Minimum Essentials Medium 4754 
(EMEM) supplemented with 10% foetal calf serum, 1% penicillin-streptomycin fungizone, and 1% L-4755 
glutamine] under the following conditions: pH 7.4, 37°C, 5% CO2 and 95% relative humidity.  For 4756 
experiments, cells (1.5 X 106, passage 3) were seeded in 25 cm3 sterile tissue culture flasks. When 80% 4757 
confluency was achieved, cells were treated with a range of FB1 concentrations (5, 50, 100 and 200 4758 
µM) (Arumugam et al., 2020). 5-Aza-2-dc, an inhibitor of DNA methylation, was used as a negative 4759 
control. To induce DNA hypomethylation, cells were exposed to 10 µM of 5-Aza-2-dc (Ahn et al., 4760 
2013). An untreated control containing CCM only was also prepared. All treatments occurred for 24 4761 
hours (h) and experiments were repeated two independent times and in triplicate for reproducibility of 4762 
results.  4763 




To assess the effect of HOXA11-AS on miR-124 levels and DNMT1 scaffolding, HepG2 cells were 4765 
transfected with the siRNA-against HOXA11-AS (siR-HOXA11-AS) and a negative control siRNA 4766 
(siR-NC). HepG2 cells also underwent transfection with miR-124 mimic and miR-124 inhibitor in an 4767 
effort to assess the effects of miR-124 on DNMT3B and SP1 expression.  4768 
HepG2 cells were grown as described above to 80% confluency in 25 cm3 cell culture flasks. The 4769 
lyophilized siRNAs (20 nmol) and miR-124 mimic and inhibitor (1 nmol) were reconstituted in 4770 
nuclease-free water to a concentration of 20 μM. The transfection complex consisting of siRNA or 4771 
miRNA mimic or inhibitor (15 µl), CCM (72 µl) and attractene (3 µl) was prepared and incubated (15 4772 
min, RT). Thereafter, cells were washed with PBS and EMEM (2,910 µl) was added to yield a final 4773 
concentration of 100 nM of siRNAs, mimic and inhibitor. The transfection complex was added in a 4774 
dropwise manner with gentle swirling to allow even distribution. The cells were then incubated (37°C, 4775 
5% CO2, 24 h).  4776 
RNA isolation 4777 
Total RNA was isolated from control and treated HepG2 cells. Cells were washed with 0.1M PBS and 4778 
incubated (5 min, RT) with Qiazol reagent (79306, Qiagen, Hilden, Germany) and 0.1M PBS (1:1) 4779 
before being mechanically lysed. Cell lysates were stored at -80°C overnight. Chloroform (100 ul) was 4780 
added to the thawed lysates to promote phase separation, and samples were centrifuged (12,000xg, 4°C, 4781 
15 min). RNA in the aqueous phase was precipitated overnight (-80°C) using isopropanol (500 µl). 4782 
Once thawed, samples were centrifuged (12,000xg, 4°C, 20 min). The RNA-containing pellets were 4783 
washed with 75% ice-cold ethanol and centrifuged (7,400xg, 4°C, 15 min). RNA pellets were air dried 4784 
(30 min, RT) and resuspended in nuclease-free water (10 µl). Extracted RNA was quantified using the 4785 
Nanodrop2000 spectrophotometer (Thermo Scientific, Waltham, USA) and RNA purity was assessed 4786 
using the A260/A280 absorbance ratio. RNA was standardized to 1000 ng/µl in nucleus free water 4787 
unless otherwise stated. 4788 
Quantification of HOXA11-AS levels 4789 
HOXA11-AS expression was determined via real time quantitative polymerase chain reaction (RT-4790 
qPCR). cDNA was prepared from standardized RNA using the RT2 First Strand Kit (330404, Qiagen, 4791 
Hilden, Germany). Residual genomic DNA was removed from standardized RNA using the Genomic 4792 
DNA elimination mix for 5 min at 42°C prior to cDNA synthesis using the reverse transcriptase mix. 4793 
Thermocycler conditions for cDNA synthesis were as follows: 25°C for 5 min, 42°C for 30 min, 85°C 4794 
for 5 min and a final hold at 4°C. Thereafter, cDNA underwent preamplification using the RT2 PreAMP 4795 
cDNA Synthesis Kit (330451, Qiagen, Hilden, Germany) and RT2 lncRNA PreAMP Primer Mix 4796 
(330741, Qiagen, Hilden, Germany) as per manufacturer’s protocols. The expression of HOXA11-AS 4797 
was determined using the RT2 SYBR Green qPCR Master Mix (330503, Qiagen, Hilden, Germany) and 4798 




(LPH31725A-200, Qiagen, Hilden, Germany) was used as housekeeping control and run 4800 
simultaneously with HOXA11-AS. Relative changes in gene expression was determined using the 4801 
comparative threshold cycle (Ct) method as described by Livak and Schmittgen (2001). 4802 
Quantification of miR-124 expression 4803 
miR-124 expression was determined using RT-qPCR. The miScript II RT Kit (218161, Qiagen, Hilden, 4804 
Germany) was used to reverse transcribe standardized RNA to cDNA. miR-124 expression was 4805 
determined using the miScript SYBR Green PCR Kit (218073, Qiagen, Hilden, Germany) and Hs_miR-4806 
124*_1 10X miScript Primer Assay (MS00008547, Qiagen, Hilden, Germany), as per manufacturer’s 4807 
instructions. Human RNU6 (Qiagen, MS000033740, Qiagen, Hilden, Germany) was used as the 4808 
housekeeping gene to normalize miRNA expression. Amplification was conducted using the CFX96 4809 
Real Time PCR System (Bio-Rad, Hercules, CA, USA) and analysed using the Bio-Rad CFX Manager 4810 
Software version 3.1. Relative changes in gene expression was determined using the method described 4811 
by Livak and Schmittgen (2001). 4812 
Quantification of mRNA levels 4813 
cDNA was synthesized using standardized RNA and the Maxima H Minus First Strand cDNA Synthesis 4814 
Kit (K1652, Thermo-Fisher Scientific, Waltham, MA, USA) as per manufacturer’s instructions. The 4815 
gene expression of SP1, DNMT1, DNMT3A, DNMT3B and p53 was assessed using the PowerUp SYBR 4816 
Green Master Mix  (A25742, Thermo-Fisher Scientific, Waltham, MA, USA) and the CFX96 Real 4817 
Time PCR System (Bio-Rad, Hercules, CA, USA) with the following cycling conditions: initial 4818 
denaturation (95°C, 8 min), followed by 40 cycles of denaturation (95°C, 15 s), annealing 4819 
(Supplementary Table S6.2, 40 s), and extension (72°C, 30 s). Primer sequences and annealing 4820 
temperatures are listed in Supplementary Table S6.2. The housekeeping control, GAPDH was run 4821 
alongside the target and mRNA expression was normalized against GAPDH. Relative changes in gene 4822 
expression was determined using the Ct method as described by Livak and Schmittgen (2001).  4823 
RNA immunoprecipitation  4824 
RNA immunoprecipitation was performed to assess HOXA11-AS binding to DNMT1. DNMT1 4825 
antibody (1:100; 5032S, Cell Signalling Technologies, Danvers, MA, USA) was incubated with 4826 
standardized RNA (1000 ng/µl), overnight at 4°C. Protein A beads [20 μl, 50% bead slurry (#9863, Cell 4827 
Signalling Technology), 4°C, 3 h] were used to precipitate the RNA-DNMT1 complex. Samples were 4828 
centrifuged (2,500xg, 4°C, 60s) and washed twice in RNA immunoprecipitation buffer [150 mM KCl, 4829 
25 mM Tris-Cl (pH 7.4), 5mM EDTA, 0.5mM DTT, 0.5% IGEPAL, 100 U/ml SUPERase IN RNase 4830 
Inhibitor (AM2694, Thermo-Fisher Scientific), protease and phosphatase inhibitor (A32961, Thermo-4831 
Fisher Scientific)]. Samples were washed once in nuclease free water and resuspended in nuclease free 4832 
water (10 µl). Immunoprecipitated RNA was standardised to 200 ng/μl, and reverse transcribed into 4833 




as mentioned above. Primer sequences and annealing temperatures are listed in Supplementary Table 4835 
S6.2. 4836 
DNA isolation 4837 
Genomic DNA was isolated from HepG2 cells and used to assess global DNA methylation levels and 4838 
methylation status of p53 promoter region. Once treatments were removed, cells were washed thrice 4839 
with 0.1M PBS and incubated (RT, 15 min) in cell lysis buffer [0.5 M EDTA (pH 8.0), 1 M Tris-Cl (pH 4840 
7.6), and 0.1% SDS] before being mechanically lysed. Potassium acetate (5 M potassium acetate and 4841 
glacial acetic acid) was added to samples which were then invert mixed (8 min). Samples were 4842 
centrifuged (13,000 x g, 5 min, 24°C) and isopropanol was added to the aqueous phase to precipitate 4843 
DNA. Sample were then invert mixed (6 min) before being centrifuged (13,000 x g, 5 min, 24°C). 4844 
DNA-containing pellets were washed with 100% cold ethanol to remove residual salts. Samples were 4845 
centrifuged (13,000 x g, 5 min, 24°C), ethanol removed and pellets were left to air dry for 30 min. Once 4846 
dried, pellets were resuspended in TE buffer [10 mM EDTA (pH 8.0) and 100 mM Tris-Cl (pH 7.4)] 4847 
and heated (65°C, 15 min). DNA concentration was quantified using the Nanodrop2000 4848 
spectrophotometer and adjusted as required. 4849 
Quantification of global DNA methylation 4850 
Isolated DNA was standardized to 100 ng/µl and used to quantify global DNA methylation levels 4851 
through the Colorimetric Methylated DNA quantification Kit (ab117128, Abcam, Cambridge, UK) as 4852 
per manufacturers’ protocol. 4853 
p53 promoter methylation 4854 
Isolated genomic DNA was standardized to 4 ng/µl and used in the OneStep qMethyl Kit (5310, Zymo 4855 
Research, Irvine, CA, USA) to asses promoter methylation of p53. Primer sequences used were as 4856 
follows; p53 promoter sense: 5’- GTGGATATTACGGAAAGT-3’ and p53 promoter anti-sense: 5’-4857 
AAAATATCCCCGAAACC-3’. Cycling conditions were as follows: digestion by methyl sensitive 4858 
restriction enzymes (37°C, 2 h), initial denaturation (95°C, 10 min), followed by 45 cycles of 4859 
denaturation (95°C, 30s), annealing (54°C, 60s), extension (72°C, 60s), final extension (72°C, 60s), and 4860 
a hold at 4°C. Results are represented as a fold-change relative to the control.   4861 
Protein expression 4862 
HepG2 cells were lysed with Cytobuster reagent (71009-3, Merck, Kenilworth, NJ, USA) which 4863 
contained protease and phosphatase inhibitors (A32961, Thermo-Fisher Scientific). The protein 4864 
concentration was measured using the bicinchoninic acid assay (Walker, 1994) and standardized to 1 4865 
mg/ml. The protein expression of DNMT1, DNMT3A, DNMT3B, and p53 were determined using 4866 
western blotting as previously described (Arumugam et al., 2019). Protein expression is represented as 4867 




housekeeping protein, β-actin. A list of antibodies and dilutions used can be found in supplementary 4869 
table S6.1. 4870 
Caspase activity 4871 
The activity of caspases -3/7, -6, -8, and -9 were assessed using the Caspase-Glo luminometry assays 4872 
(G8090, G0970, G8200, and G8210, Promega,  Madison, WI, United States). Control and treated cells 4873 
(20,000 cells/well) were dispensed into an opaque 96-well microtiter plate in triplicate and incubated 4874 
with the respective Caspase-Glo reagent (20 µl) in the dark for 30 min at RT. Luminescence was 4875 
quantified using the Modulus microplate luminometer (Turner Biosystems) and the results were 4876 
expressed as relative light units (RLU). 4877 
Statistical analysis  4878 
Statistical analyses were performed using GraphPad Prism version 5.0 (GraphPad Prism Software Inc.). 4879 
Data was analysed using the one-way Analysis of Variance (ANOVA) with Dunnet’s post-test. The 4880 
results were represented as the mean ± standard deviation (SD) and a p value of less than 0.05 was 4881 
considered statistically significant. 4882 
Results 4883 
FB1-induced HOXA11-AS sponges miR-124, regulating SP1 and DNMT expression 4884 
The RT² lncRNA PCR Array Human IncFinder (LAHS-001Z, Qiagen, Hilden, Germany) was used to 4885 
identify differentially expressed lncRNA in HepG2 cells exposed to 200 µM FB1 [IC50 (Arumugam et 4886 
al., 2020)]. HOXA11-AS was identified as one of the most upregulated lncRNA (Supplementary Figure 4887 
S6.1). The expression of HOXA11-AS was then validated in HepG2 cells using a range of FB1 4888 
concentrations (5, 50, 100 and 200 µM) and the downstream effects of HOXA11-AS was determined. 4889 
HOXA11-AS expression was increased in response to increasing concentrations of FB1 (p ≤ 0.001; 4890 
Figure 6.1a). To validate the relationship between FB1 and HOXA11-AS, HepG2 cells were transfected 4891 
with siRNA against HOXA11-AS. Cells were transfected with silencing RNA against HOXA11-AS 4892 
which acted as a negative control and used to gain insight into potential downstream effects of 4893 
HOXA11-AS. Cells were also transfected with siR-NC to test the efficiency of transfection. HOXA11-4894 
AS expression was effectively knocked down in cells treated with siR-HOXA11-AS (p ≤ 0.05; Figure 4895 
6.1a); however, expression for the siR-NC treated cells was similar to the control, suggesting that 4896 
transfection was successful (Figure 6.1a). 4897 
It was previously shown that HOXA11-AS acts as a ceRNA for miR-124 (Lu et al., 2017). This was 4898 
confirmed using online bioinformatics prediction algorithm software, starBase v2.0 (Li et al., 2014). 4899 
MiR-124 was reduced at all FB1 concentrations, but significantly reduced at 100 µM and 200 µM FB1 4900 
(Figure 6.1b; p ≤ 0.01). Furthermore, we found miR-124 to be significantly upregulated in cells treated 4901 




6.1b). In addition to siRNA, HepG2 cells were transfected with a mimic and inhibitor against miR-124 4903 
which acted as a positive and negative control, respectively. The expression of miR-124 in HepG2 cells 4904 
treated with the mimic and inhibitor were increased and decreased, respectively (Figure 6.1b; p ≤ 0.001). 4905 
TargetScan (version 7.1), an online bioinformatics prediction software that predicts miRNA-mRNA 4906 
interactions was used to determine possible targets of miR-124 (Agarwal et al., 2015). MiR-124 was 4907 
shown to potentially regulate DNA methylation as it was found to have complementary base pairs with 4908 
the DNA methyltransferase, DNMT3B at positions 1363-1369 and the DNMT1 transcription factor, SP1 4909 
at positions 524-530, 4149-4155 and 4520-4526 (Figure 6.1c). 4910 
 Due to the decreased expression in miR-124 observed by FB1, we then evaluated the expression of SP1 4911 
and DNMT3B. FB1 significantly increased gene expression of SP1 (Figure 6.1d; p ≤ 0.001) and 4912 
DNMT3B (Figure 6.1d; p ≤ 0.001). DNMT3B protein expression (Figure 6.1e; p ≤ 0.001) was increased 4913 
in response to 50-200 µM FB1; yet, it was reduced at 5 µM FB1. SP1 gene and DNMT3B gene and 4914 
protein expression was also significantly increased in cells treated with miR-124 inhibitor and 4915 
significantly reduced in miR-124 mimic and siR-HOXA11-AS treated cells; confirming the relationship 4916 
between HOXA11-AS and miR-124 with SP1 and DNMT1. 4917 
 4918 
Figure 6.1. FB1 upregulated HOXA11-AS levels (a; ***p ≤ 0.001) which negatively regulated miR-4919 
124 (b; *** p ≤ 0.001). Bioinformatic prediction revealed that the 3’ UTR of SP1 and DNMT3B contains 4920 
binding sites for miR-124 (c). SP1 gene (d; ***p ≤ 0.001) and DNMT3B gene (d; ***p ≤ 0.001) and 4921 






  FB1 elevates DNMT1 expression and promotes HOXA11-AS-DNMT1 binding 4925 
SP1 activates the transcription of DNMT1 (Kishikawa et al., 2002), thus, DNMT1 expression was 4926 
assessed. qPCR and western blotting analysis revealed a significant increase in DNMT1 mRNA (Figure 4927 
6.2a; p ≤ 0.001) and protein expression (Figure 6.2b; ≤ 0.001), respectively.  4928 
In addition to its function as a ceRNA, HOXA11-AS acts as a scaffold for DNMT1 by recruiting it to 4929 
gene promoters (Sun et al., 2016), therefore, HOXA11-AS-DNMT1 binding was evaluated by 4930 
performing RNA immunoprecipitation. There was a slight reduction in the interaction at 5 µM FB1, 4931 
however, increased at the all other concentrations tested (Figure 6.2c; p ≤ 0.001). HOXA11-AS-4932 
DNMT1 interactions were significantly reduced in siR-HOXA11AS treated cells (p≤ 0.01; Figure 6.2c). 4933 
 4934 
Figure 6.2. FB1 significantly upregulated DNMT1 mRNA (a; ***p ≤ 0.001) and DNMT1 protein (b; 4935 
***p ≤ 0.001) expression and altered HOXA11-AS-DNMT1 binding (c; ***p ≤ 0.001) in HepG2 cells. 4936 
FB1 altered DNMT3A expression and global DNA methylation status of HepG2 cells 4937 
Although DNMT3A is not regulated by HOXA-11AS or miR-124, it does play an important role in 4938 
DNA methylation., FB1 significantly increased DNMT3A gene (Figure 6.3a, p ≤ 0.001) and protein 4939 
(Figure 6.3b; p ≤ 0.001) expression at all concentrations investigated.  4940 
Since FB1 differentially regulated DNMT expression, we next determined whether FB1 affected global 4941 
DNA methylation levels (Figure 6.3c). Along with FB1 treatments, cells were treated with 5-Aza-2-dc, 4942 
a known DNA methylation inhibitor. Naturally, 5-Aza-2-dc treatment significantly reduced total 4943 
methylation levels in HepG2 cells (p ≤ 0.05; Figure 6.3c). In contrast, FB1 increased total methylation 4944 






Figure 6.3. qPCR and western blot quantification revealed that DNMT3A gene (a; ***p ≤ 0.001) and 4948 
DNMT3A protein (b; *** p ≤ 0.001) expression was significantly elevated in FB1-exposed HepG2 cells. 4949 
Methylation of cytosine in the DNA of HepG2 cells were also increased following FB1 treatment (c; * 4950 
p ≤ 0.05). 4951 
FB1 reduced p53 expression via hypermethylation of gene promoter 4952 
In addition to global methylation levels, we evaluated gene-specific methylation in HepG2 cells. 4953 
Methylation of specific CpG islands on gene promoters silences their transcription. We assessed 4954 
promoter methylation of the tumour suppressor, p53. p53 promoters of HepG2 cells were significantly 4955 
hypermethylated in response to FB1 (Figure 6.4a; p ≤ 0.001). This led to significant decreases in p53 4956 








Figure 6.4. Increasing doses of FB1 led to increasing hypermethylation at p53 promoter regions (a; *** 4962 
p ≤ 0.001) in HepG2 cells. This led to a significant dose-dependent decrease in p53 gene (b; *** p ≤ 4963 
0.001) and p53 protein (c; *** p ≤ 0.001) expression.  4964 
FB1 inhibits caspase dependent apoptosis 4965 
The p53 tumour suppressor protein plays a major role in apoptosis. One of the mechanisms by which it 4966 
does this is through caspase activation (Schuler et al., 2000).  There was a significant dose-dependent 4967 
decline in the activity of caspases -3/7 (Figure 6.5a; p ≤ 0.001), -6 (Figure 6.5b; p ≤ 0.001), -8 (Figure 4968 
6.5c; p ≤ 0.001) and -9 (Figure 6.5d; p ≤ 0.001) in the presence of FB1. 4969 
 4970 
Figure 6.5. The activity of caspases -3/7 (a; *** p ≤ 0.001), -6 (b; *** p ≤ 0.001), -8 (c; *** p ≤ 0.001) 4971 





The epigenetic landscape is critical in modulating functional pathways such as apoptosis, proliferation 4974 
and differentiation; however, it is continuously changing in response to external stimuli such as 4975 
mycotoxin insult (Marczylo et al., 2016, Huang et al., 2019). FB1 is regarded as one of the most 4976 
important mycotoxins as it abundantly contaminates agricultural staples and adversely affects human 4977 
and animal health (Idahor, 2010, Kamle et al., 2019). FB1 impacts the epigenetic landscape of humans 4978 
and animals which may play a role in its toxicity (Mobio et al., 2000, Chuturgoon et al., 2014a, 4979 
Chuturgoon et al., 2014b, Demirel et al., 2015, Sancak and Ozden, 2015, Gardner et al., 2016, 4980 
Arumugam et al., 2020). One mechanism studied is the alteration of DNA methylation patterns which 4981 
contributes to genomic instability as well as effects the expression of genes regulating protein and DNA 4982 
synthesis, cell cycle, proliferation and apoptosis (Mobio et al., 2000, Kouadio et al., 2007, Chuturgoon 4983 
et al., 2014a, Demirel et al., 2015). Thus, in this study we evaluated the anti-apoptotic effects of FB1 by 4984 
assessing the epigenetic regulation of p53 via the HOXA11-AS/miR-124/DNMT axis. 4985 
Once considered irrelevant, lncRNAs are gaining increasing advertence due to our new understanding 4986 
of the functional role they play (Kung et al., 2013). Although over 146,000 lncRNAs have been 4987 
documented to date; most have only been predicted and studied via computational analysis (Volders et 4988 
al., 2015). To determine if FB1 affected lncRNA profiles of HepG2 cells, we used a lncRNA array and 4989 
evaluated changes in the expression of 84 lncRNA using an untreated control and IC50 [200 µM FB1; 4990 
(Arumugam et al., 2020)]. We found that FB1 significantly dysregulated the lncRNA profiles of HepG2 4991 
cells and HOXA11-AS was amongst the most upregulated lncRNA (Supplementary Figure S6.1). Thus, 4992 
we validated HOXA11-AS expression and further investigated its downstream effects following FB1 4993 
exposure. 4994 
HOXA11-AS has mainly oncogenic functions, influencing the proliferation, invasion and migration of 4995 
various cancers such as hepatocellular carcinomas, oesophageal cancer, renal cancer and melanomas 4996 
(Lu et al., 2017, Yu et al., 2017a, Sun et al., 2018b, Yang et al., 2018a, Liu et al., 2019, Zhang et al., 4997 
2019). Conversely, it has tumour suppressor capabilities in epithelial ovarian cancer (Richards et al., 4998 
2015). In addition to its carcinogenic effects, HOXA11-AS influences gene expression by modulating 4999 
epigenetic modifications by functioning as a ceRNA and molecular scaffold (Sun et al., 2016, Wang et 5000 
al., 2017).  5001 
As a ceRNA or RNA “sponge”, HOXA11-AS is able to bind to certain miRNAs blocking the interaction 5002 
between the miRNA and its target mRNA. This reduces the negative regulatory impact that miRNAs 5003 
have on their target mRNA. For instance, Lu et al. (2017) demonstrated that HOXA11-AS positively 5004 
regulated enhancer of zeste homolog 2 (EZH2) expression by sequestering miR-124 and preventing 5005 
miRNA-124 degradation of EZH2 mRNA. We confirmed the relationship between HOXA11-AS and 5006 




(Supplementary Figure S6.2) (Li et al., 2014). We further validated the ceRNA capabilities of 5008 
HOXA11-AS by determining the expression of HOXA11-AS and miR-124 in HepG2 cells treated with 5009 
various concentrations of FB1 (0, 5, 50, 100 and 200 µM).  HOXA11-AS was significantly upregulated 5010 
in the presence of FB1 which resulted in the concurrent decrease in miRNA-124 levels (Figure 6.1a, b). 5011 
This relationship was confirmed using relevant controls as miR-124 expression was significantly 5012 
elevated in cells where HOXA11-AS was knocked down. 5013 
To explore the downstream targets of miR-124, the online bioinformatics tool Targetscan (version 7.2) 5014 
was employed (Agarwal et al., 2015). We found that miR-124 may influence DNA methylation as we 5015 
uncovered complementary binding sites between miR-124 and the 3’UTR of SP1 at positions 524-530, 5016 
4149-4155 and 4520-4526 and the 3’UTR of DNMT3B at positions 1363-1369 (Figure 6.1c). 5017 
DNMT3B directly regulates DNA methylation (Okano et al., 1998, Hervouet et al., 2018); while SP1 5018 
indirectly influences DNA methylation as it binds to the cis-element of DNMT1 gene promoter, 5019 
activating its transcription (Kishikawa et al., 2002). FB1-induced HOXA11-AS prevented the 5020 
degradation of miR-124 targets as DNMT3B gene and protein expression (Figure 6.1d, e) as well as 5021 
SP1 gene expression (Figure 6.1d) were significantly upregulated. The use of appropriate controls 5022 
confirmed this relationship as miR-124 knockdown resulted in a significant increase of its targets; while 5023 
the use of miR-124 mimic and siR-HOXA11-AS independently downregulated DNMT3B and SP1 5024 
expression. Furthermore, several other studies confirmed that HOXA11-AS sequesters miR-124 with 5025 
one study revealing that HOXA11-AS positively regulates SP1 by sponging miRNA-124 (Cui et al., 5026 
2017, Xu et al., 2017, Yu et al., 2017b, Yang et al., 2018b, Jin et al., 2019, Zhang et al., 2019). Since 5027 
FB1 altered the expression of SP1, we determined if DNMT1 expression was also altered. In agreement 5028 
with the upregulation of SP1, DNMT1 expression was also elevated both at the gene and protein levels 5029 
(Figure 6.2a, b). Apart from its ceRNA capability, HOXA11-AS can also serve as a molecular scaffold 5030 
that recruits chromatin modifying proteins such as EZH2, LSD1 and DNMT1 to the promoter region of 5031 
genes thus modulating their transcription (Wei et al., 2020). For example, HOXA11‑AS interacts with 5032 
DNMT1 and EZH2, recruiting these proteins to the promoter regions of miR‑200b and mediating 5033 
methylation silencing of miR‑200b in non-small cell lung cancer cells (Chen et al., 2017). Using RNA 5034 
immunoprecipitation, we determined if FB1 influences HOXA11-AS-DNMT1 binding and found that 5035 
HOXA11-AS-DNMT1 interactions were significantly higher in the presence of FB1 and reduced with 5036 
HOXA11-AS knockdown (Figure 6.2c). However, this interaction should be further investigated at 5037 
specific gene promoters.  5038 
Four members make up the DNMT family with DNMT1, -3A and -3B having catalytic capabilities 5039 
(Hervouet et al., 2018). Seeing as FB1 altered the expression of DNMT1 and DNMT3B, we determined 5040 
if FB1 affects DNMT3A and found the mRNA and protein expression to be significantly upregulated 5041 
(Figure 6.3a, b). DNMTs are responsible for the transferring methyl groups from S-adenosyl-5042 




the increase in DNMT expression corresponded with an increase in total DNA methylation levels 5044 
(Figure 6.3c); however, our results were not significant and opposed the results of another study which 5045 
investigated in the effects of 200 µM FB1 in HepG2 cells (Chuturgoon et al., 2014a). Chuturgoon et al. 5046 
(2014a) found that FB1 reduced the expression of DNMTs which resulted in global hypomethylation, 5047 
however similar to our study, DNA hypermethylation occurred in human intestinal Caco-2 cells and rat 5048 
C6 glioma cells after 24 hours (Mobio et al., 2000, Kouadio et al., 2007). 5049 
While several studies have investigated the effects of FB1 on global DNA methylation only one other 5050 
study has looked at its effects on gene-specific methylation (Demirel et al., 2015).  Demirel et al. (2015) 5051 
assessed CpG promoter methylation of tumour suppressor genes in rat liver (clone 9) cells and kidney 5052 
epithelial (NRK-52E) cells. CpG islands of VHL and e-cadherin promoters were methylated in both 5053 
cell lines; while, the c-Myc promoter was methylated exclusively in Clone 9 cells and methylation of 5054 
the p16 gene occurred in NRK-52E cells. Thus, we investigated the role of DNA methylation on the 5055 
tumour suppressor p53.  5056 
p53 responds to cellular stress such as DNA damage, oxidative stress and cell cycle abnormalities by 5057 
inducing cell cycle arrest, apoptosis or autophagy (Shieh et al., 1999, Yin et al., 1999, Vousden and 5058 
Prives, 2009). FB1 is a known inducer of oxidative stress, DNA damage and altered cell cycle 5059 
checkpoint regulation (Mobio et al., 2000, Galvano et al., 2002, Stockmann-Juvala et al., 2004, Domijan 5060 
et al., 2007, Kim et al., 2018, Arumugam et al., 2019, Arumugam et al., 2020). Furthermore, HOXA11-5061 
AS is known to repress p53 expression; however, the mechanism is unknown (Connell et al., 2009). 5062 
Therefore, we evaluated CpG island methylation at p53 promoters and subsequently p53 expression. 5063 
We found that the promoter region of p53 was significantly hypermethylated (Figure 6.4a), leading to 5064 
the subsequent decrease in p53 transcription and translation (Fig. 4b, c). It is possible that p53 activity 5065 
may be also be disrupted by FB1. p53 is activated via a host of post-translational modifications, 5066 
including phosphorylation (Sakaguchi et al., 1998). FB1 was shown to inhibit checkpoint kinase 1 5067 
(Arumugam et al., 2020), a kinase responsible for p53 phosphorylation and activation (Ou et al., 2005).  5068 
One mechanism by which p53 initiates apoptosis is through the activation of the caspase cascade. p53 5069 
activates initiator caspases (caspase- 8 and -9) and subsequently downstream effector caspases (caspase-5070 
3/7) (Ding et al., 1998, Schuler et al., 2000). p53 is also responsible for the transactivation of effector 5071 
caspase-6 (Ehrnhoefer et al., 2014). We found a significant decrease in the activity of all 4 of the above-5072 
mentioned caspases (Figure 6.5). Taken together, our results suggest that FB1 inhibits p53-dependent 5073 
cell death. FB1 was also found to inhibit apoptosis in HepG2 cells through the upregulation of anti-5074 
apoptotic Birc-8/ILP-2 and decrease in apoptotic Smac/DIABLO (Chuturgoon et al., 2015). Together 5075 
the inhibition of p53 and activation of Birc-8 prevents caspase-dependent apoptosis in the presence of 5076 
FB1. However, several other studies have observed stress-induced apoptosis in response to FB1 exposure 5077 
(Tolleson et al., 1996, Tolleson et al., 1999, Seefelder et al., 2003). The difference could be due to the 5078 




mechanisms. It is possible that inhibition of p53-dependent apoptosis via the HOXA11-AS/miR-5080 
124/DNMT axis may be responsible for promoting FB1-induced carcinogenesis. However, further 5081 
studies using cancerous and primary liver cell lines should be conducted to test this hypothesis. 5082 
Nevertheless, this study provides novel insight into the relationship between HOXA11-As, DNA 5083 
methylation and p53 expression, which was previously unknown and adds to our understanding on the 5084 
impact of FB1 on the human epigenome. 5085 
Conclusion 5086 
This study revealed that FB1 upregulated the lncRNA, HOXA11-AS, which in turn sequesters and 5087 
inhibits miR-124, leading to an increase in SP1, DNMT1, DNMT3A and DNMT3B expression. The 5088 
increase in DNMTs not only elevated global methylation of FB1 exposed HepG2 cells but also 5089 
hypermethylation of p53 promoters. This led to a decrease in p53 expression and ultimately diminished 5090 
caspase activity. Therefore, FB1 inhibits p53-dependent cell death via the HOXA11-AS/miR-5091 
124/DNMT axis (Figure 6.6).  5092 
 5093 
Figure 6.6. FB1 inhibits p53 via HOXA11-AS/miR-124/DNMT axis. FB1 enhances HOXA11-AS levels. 5094 
HOXA11-AS inhibits miR-124, thus preventing the interaction between miR-124 and its target mRNAs (SP1 and 5095 
DNMT3B). The resulting upregulation of SP1 promotes DNMT1 expression. Moreover, FB1 enhances DNMT3A 5096 
levels. The increase in DNMT expression facilitates promoter hypermethylation of p53, reducing p53 transcription 5097 
and expression. 5098 
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Supplementary Table S6.1: Antibodies with dilutions used for western blotting 5116 
Antibody Dilution Catalogue number  
(Cell Signaling Technologies) 
Primary Antibodies 
Rabbit-Anti-DNMT1 1:250 5032S 
Rabbit-Anti-DNMT3A 1:250 3598S 
Rabbit-Anti-DNMT3B 1:250 57868S 
Mouse-Anti-p53 1:500 2524S 
Secondary Antibodies 
Goat-Anti- Rabbit 1:5000 #7074S 









Supplementary Table S6.2: Primer sequences and annealing temperatures used in qPCRs 5122 
Gene Sense Primer 
5’→ 3’ 
Anti-sense Primer 





DNMT1 ACCGCTTCTACTTCCTCGAGGCCTA  GTTGCAGTCCTCTGTGAACACTGTGG  60 
DNMT3A GGGGACGTCCGCAGCGTCACAC CAGGGTTGGACTCGAGAAATCGC  58 
DNMT3B CCTGCTGAATTACTCACGCCCC  GTCTGTGTAGTGCACAGGAAAGCC  58 
SP1 CTTGGTATCATCACAAGCCAGTT  TCCCTGATGATCCACTGGTAGTA  56 
p53 ACTTGTCGCTCTTGAAGCTAC  GATGCGGAGAATCTTTGGAACA  58 
GAPDH TCCACCACCCTGTTGCTGTA ACCACAGTCCATGCCATCAC Same as gene 
of interest 
Promoter Methylation 











Supplementary Figure S6.1. FB1 alters lncRNA profiles in HepG2 cells. A: Scatter plot showing 5126 
normalized expression of lncRNA in FB1 treated HepG2 cells. Yellow dots represent upregulated 5127 
lncRNA, blue dots represent downregulated lncRNA and black dots represent unchanged lncRNA in 5128 
FB1 treated cells compared to the control. B: Heatmap showing expression profile of all lncRNA 5129 
assessed using the array. C: Normalized expression of HOXA11-AS using the lncRNA array. 5130 
 5131 
 5132 





Supplementary Figure S6.3. TargetScan analyses of miR-124 to the 3’ UTR of SP1 and DNMT3B in 5135 
humans. MiR-124 has complementary base pairs with the 3’ UTR of SP1 at positions 524-530, 4149-5136 
4155 and 4520-4526 and DNMT3B at positions 1363-1369 in humans. 5137 
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CHAPTER 7 5350 
CONCLUSION 5351 
7.1. General conclusions 5352 
Epigenetic modifications are necessary for normal development and health; however, environmental 5353 
factors such as mycotoxin exposure disrupts the epigenome of cells often leading to toxicity (Huang et 5354 
al., 2019). Many studies have focused on the health implications of FB1 as well as molecular 5355 
mechanisms involved in its toxicity (Wang et al., 1991, Yin et al., 2016, Kouzi et al., 2018, Arumugam 5356 
et al., 2019, Arumugam et al., 2020, Liu et al., 2020). Furthermore, some studies have evaluated 5357 
epigenetic changes that occur due to FB1 exposure but these studies mainly focused on DNA 5358 
methylation and histone modifications and most failed to assess the downstream implications of these 5359 
epigenetic changes (Mobio et al., 2000, Kouadio et al., 2007, Pellanda et al., 2012, Chuturgoon et al., 5360 
2014a, Chuturgoon et al., 2014b, Demirel et al., 2015, Sancak and Ozden, 2015, Gardner et al., 2016).  5361 
This study, for the first time, demonstrates that FB1 not only alters the epigenetic landscape in HepG2 5362 
cells; but that these epigenetic modifications affect cellular responses to FB1 mediated stress. 5363 
Furthermore, it is the first study to evaluate the effect of FB1 on the m6A epitranscriptome and lncRNAs.  5364 
FB1 induced oxidative damage to DNA of HepG2 cells. PTEN is vital in maintaining genomic stability 5365 
and DNA repair, while its inactivation or downregulation promotes DNA instability and damage (Ming 5366 
and He, 2012, Bassi et al., 2013). Downregulation of PTEN activates PI3K/AKT signaling which 5367 
inhibits CHK1 activity and DNA damage checkpoint signaling (Puc et al., 2005, Puc and Parsons, 5368 
2005). Therefore, epigenetic modifications that affect PTEN expression were evaluated in the presence 5369 
of FB1. FB1 reduced the expression of histone demethylase, KDM5B which in turn resulted in the 5370 
significant increase in global H3K4me3. H3K4me3 was also elevated at the promoter region of PTEN, 5371 
where it activated PTEN transcription. While there was a significant increase in PTEN mRNA levels, 5372 
FB1 reduced the protein expression of PTEN. PTEN is post-transcriptionally regulated by miR-30c (Hu 5373 
et al., 2019). FB1 upregulated miR-30c, which inhibited the translation of PTEN, resulting in reduced 5374 
PTEN protein expression. PTEN is a negative regulator of PI3K/AKT signaling (Cantley and Neel, 5375 
1999). The downregulation of PTEN permitted PI3K/AKT signaling to proceed undisturbed, resulting 5376 
in the inhibitory phosphorylation of serine-280-CHK1. Inhibition of CHK1 prevents DNA repair and 5377 
promotes genomic instability. This may contribute to the toxicity and carcinogenicity of FB1.  5378 
Alterations to the m6A epitranscriptome have been linked to the toxic effects of some Fusarium 5379 
mycotoxins (Ghazi et al., 2020, Zhengchang et al., 2020). Furthermore, m6A is influenced by cellular 5380 
stresses such as oxidative stress and may in turn regulate responses to oxidative stress (Zhao et al., 5381 
2020). Intracellular ROS and global m6A levels were both elevated in HepG2 cells exposed to FB1. 5382 
Furthermore, FB1 upregulated m6A methyltransferases (METTL3 and METTL14) and downregulated 5383 




FB1-induced increases in m6A levels may lead to the altered expression of important genes involved in 5385 
its toxicity. Considering that there was an accumulation of intracellular ROS, the effect of m6A on 5386 
Keap1/Nrf2 signaling was determined. Additional epigenetic changes to Keap1/Nrf2 were also 5387 
evaluated. FB1 induced hypermethylation of the Keap1 promoter region, which inhibited Keap1 5388 
transcription; 29 possible m6A sites with the consensus motifs: GGACU and AGACU, were predicted 5389 
on Keap1 transcripts. M6A-Keap1 levels were upregulated; however, Keap1 protein expression was 5390 
reduced. FB1 increased the m6A reader YTHDF2, which may be responsible for inhibiting Keap1 5391 
translation. Hypomethylation of Nrf2 promoters together with decreased miR-27b upregulated Nrf2 5392 
mRNA levels in HepG2 cells exposed to FB1; 54 possible m6A sites with the consensus motif GAACU 5393 
were predicated on Nrf2 transcripts. FB1 elevated m6A-Nrf2 and Nrf2 protein expression. The increase 5394 
in m6A readers YTHDF1, YTHDF3 and YTHDC2 may be responsible for promoting Nrf2 translation. 5395 
The downregulation of Keap1 and upregulation of Nrf2 activates antioxidant responses, which was 5396 
previously observed (Arumugam et al., 2019). However, severe cellular injury occurred in cells exposed 5397 
to FB1, suggesting that the activation of Nrf2 antioxidant signaling may not be sufficient to counter the 5398 
accumulation of ROS.  Furthermore, prolonged activation of Nrf2 by epigenetic changes may support 5399 
the cancerous phenotype observed in some models exposed to FB1. 5400 
The tumor suppressor, p53 is activated by cellular stress such as genotoxic and oxidative stress. When 5401 
activated, p53 regulates several stress responses such as cell cycle arrest, DNA repair and apoptosis 5402 
(Fridman and Lowe, 2003). However, p53 inactivation by epigenetic modifications inhibits its response 5403 
to stress and promotes carcinogenesis (Saldaña-Meyer and Recillas-Targa, 2011, Chmelarova et al., 5404 
2013). FB1 elevated the expression of the lncRNA, HOXA11-AS. HOXA11-AS sequestered miR-124, 5405 
inhibiting its regulation of DNMT3B and SP1. Therefore, FB1 upregulated the expression of DNMT3B 5406 
and the DNMT1 transcription factor, SP1 as well as the expression of DNMT1 and DNMT3A. The 5407 
increase in DNMT expression facilitated global DNA hypermethylation and p53 promoter 5408 
hypermethylation. This led to the decrease in both p53 gene and protein expression. p53 is known to 5409 
activate caspase-dependent apoptosis during cellular stress. The decrease in p53 inhibited caspase-5410 
mediated apoptosis as observed by the decrease in the activity of initiator caspases-8 and -9 as well as 5411 
executioner caspases-3/7 and -6. It is possible that the inhibition of p53-dependent apoptosis via the 5412 
HOXA11-AS/miR-124/DNMT axis may be responsible for promoting FB1-induced carcinogenesis. 5413 
Taken together, this study suggests that FB1 induces hepatoxicity in the form of DNA damage and 5414 
oxidative stress. FB1 also alters the epigenome of liver cells by affecting DNA methylation, m6A RNA 5415 
methylation, H3K4me3, miRNA (miR-30c, miR-27b and miR-124) and lncRNA (HOXA11-AS). 5416 
These epigenetic changes in turn disrupt the DNA damage and anti-oxidant response mechanisms 5417 
further exacerbating FB1-induced hepatotoxicity. Furthermore, the epigenetic downregulation of the 5418 




and dysregulation of apoptosis, provides a potential mode of action by which FB1 may induce or 5420 
promote hepatocellular carcinomas. 5421 
7.2. Limitations, shortcomings and recommendations 5422 
 This study provides novel mechanisms for FB1-induced hepatotoxicity at the epigenetic level using an 5423 
in vitro model that was acutely exposed (24 hours) to FB1. However, the following limitations and 5424 
shortcomings were found: 5425 
• In vitro models usually consist of a single cell type (in this study, HepG2 cells) grown in 5426 
monolayer and are therefore not exact dissociated replicates of their in vivo counterparts. This 5427 
limits our interpretations of epigenetic patterns and interactions between the various cell types 5428 
found in a multicellular organism. The use of in vivo models may express different patterns of 5429 
epigenetic changes with different outcomes on stress response signaling that may be more 5430 
accurate than the use of an in vitro model. 5431 
• Maize is considered a staple in many developing countries and thus may be consumed on a daily 5432 
basis. Humans and animals that are heavily reliant on maize are recurrently exposed to FB1. The 5433 
use of an acute model such as the one used in this study (24 hours) may not provide realistic 5434 
epigenetic patterns. Additionally, while HepG2 cells were exposed to a range of FB1 5435 
concentrations (0-200 µM) which included an IC50, it may not provide realistic results that are 5436 
pertinent to humans.  5437 
• While we can conclude that hepatoxicity induced by FB1 may be a result of its epigenetic 5438 
properties, we cannot say with confidence that epigenetic mechanisms identified in this study also 5439 
contribute to the carcinogenic nature of FB1. This is because a cancerous cell line was used in this 5440 
study. The use of a primary cell line along with a cancerous cell line should be used to evaluate 5441 
whether these FB1-induced epigenetic alterations to stress responses contributes to its 5442 
carcinogenicity. 5443 
Taking the limitations of this study into consideration, chronic exposure (greater than 24 h) to FB1 or 5444 
the use of an in vivo model may exhibit different patterns of epigenetic changes with different outcomes 5445 
on stress response signaling.  The outcomes observed may provide more realistic results than the ones 5446 
found in the current study. Furthermore, the concentration of FB1 used in experiments should be 5447 
calculated based on the average daily intake of FB1 and not a range based on the IC50. Hence this study 5448 
provides insight for future epigenetic studies using longer exposure times to FB1, more accurate 5449 
concentrations or in vivo models.  5450 
7.3. Final remarks 5451 
Collectively, this study suggests that FB1 possesses epigenetic properties which dysregulate cellular 5452 
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